女性化激素疗法 (Chinese Wikipedia)

Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000-10, 62 (8): 1839–46, 1849–50 [2022-01-14]. PMID 11057840. （原始内容存档于2022-04-21）.

archive.org (Global: 6^th place; Chinese: 4^th place)

Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Lauritzen C. Clinical use of oestrogens and progestogens. Maturitas. 1990-09, 12 (3): 199–214. PMID 2215269. doi:10.1016/0378-5122(90)90004-P.
Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer--forward to the past?. J. Urol. 2003-05, 169 (5): 1735–7. PMID 12686820. doi:10.1097/01.ju.0000061024.75334.40.
de Lignières B, Silberstein S. Pharmacodynamics of oestrogens and progestogens. Cephalalgia. 2000-04, 20 (3): 200–7. PMID 10997774. S2CID 40392817. doi:10.1046/j.1468-2982.2000.00042.x.
Koch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, Lübke K, Mehring M, Römmler A, Schwartz U, Hammerstein J. Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers. Contraception. 1976, 14 (2): 117–35. PMID 949890. doi:10.1016/0010-7824(76)90081-0.
Wang C, Yeung KK. Use of low-dosage oral cyproterone acetate as a male contraceptive. Contraception. 1980, 21 (3): 245–72. PMID 6771091. doi:10.1016/0010-7824(80)90005-0.
Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Contraception. 1980-04, 21 (4): 393–413. PMID 6771095. doi:10.1016/s0010-7824(80)80017-5.
Wenderoth, U. K.; Jacobi, G. H. Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. World Journal of Urology. 1983, 1 (1): 40–48. ISSN 0724-4983. S2CID 23447326. doi:10.1007/BF00326861.
Schröder, Fritz H.; Radlmaier, Albert. Steroidal Antiandrogens. V. Craig Jordan; Barrington J. A. Furr (编). Hormone Therapy in Breast and Prostate Cancer. Humana Press. 2009: 325–346. ISBN 978-1-60761-471-5. doi:10.1007/978-1-59259-152-7_15. 如前所述，CPA会导致血浆睾酮水平的不完全抑制，降低约70%并保持在去势值的三倍左右。[Rennie等人]发现CPA与极低剂量（0.1 mg/d）的DES联合使用可以非常有效地去除血浆睾酮和组织中的双氢睾酮雄激素。[...]该方案结合了两种化合物的睾酮降低作用，因此只需少量雌激素即可将血浆睾酮降低至接近去势水平。（CPA, as mentioned earlier, leads to an incomplete suppression of plasma testosterone levels, which decrease by about 70% and remain at about three times castration values. [Rennie et al.] found that the combination of CPA with an extremely low dose (0.1 mg/d) of DES led to a very effective withdrawal of androgens in terms of plasma testosterone and tissue dihydrotestosterone. [...] this regimen combines the testosterone-reducing effects of two compounds, therefore, only small amounts of estrogen are required to bring down plasma testosterone to approximately castrate levels.）
Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997-01, 49 (1): 71–8. PMID 9000189. doi:10.1016/S0090-4295(96)00325-1.
Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International. 2001-01, 87 (1): 47–56. PMID 11121992. S2CID 28215804. doi:10.1046/j.1464-410x.2001.00988.x .
Reilly DR, Delva NJ, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Can J Psychiatry. 2000-08, 45 (6): 559–63. PMID 10986575. S2CID 27710792. doi:10.1177/070674370004500608 . [...]在第一次注射亮丙瑞林之前进行雌激素或抗雄激素治疗可能会降低[治疗开始时由睾酮“爆发”引起的症状风险]（16）。（[...] estrogen or antiandrogen treatment prior to the first leuprolide injection may reduce [the risk of symptoms caused by the testosterone "flare" at the initiation of treatment] (16).）
Horton R. Dihydrotestosterone is a peripheral paracrine hormone. J. Androl. 1992, 13 (1): 23–7. PMID 1551803. doi:10.1002/j.1939-4640.1992.tb01621.x.
Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010-06, 44 (6): 1090–7. PMID 20442354. S2CID 207263793. doi:10.1345/aph.1M591.
Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012-01, 32 (1): 54–66. PMID 22392828. S2CID 12853220. doi:10.1002/PHAR.1006.
Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Cox DB, Kent JC, Casey TM, Owens RA, Hartmann PE. Breast growth and the urinary excretion of lactose during human pregnancy and early lactation: endocrine relationships. Exp. Physiol. 1999-03, 84 (2): 421–34. PMID 10226182. doi:10.1017/S0958067099018072 .
Meyer WJ, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Archives of Sexual Behavior. 1986-04, 15 (2): 121–38. PMID 3013122. S2CID 42786642. doi:10.1007/bf01542220.
Morris JM. The syndrome of testicular feminization in male pseudohermaphrodites. Am. J. Obstet. Gynecol. 1953-06, 65 (6): 1192–1211. PMID 13057950. doi:10.1016/0002-9378(53)90359-7.
Foss GL. Disturbances of lactation. Clin Obstet Gynecol. 1958-03, 1 (1): 245–54. PMID 13573669. S2CID 42825519. doi:10.1097/00003081-195803000-00021. 在实验上，我已经能够诱导一名男性异装癖者的泌乳，该男性异装癖者的睾丸在几年前已被切除，其乳房在很长一段时间内使用芪雌酚和乙炔雌酮，发育已良好[9]。1955年7月9日，皮下植入600 mg雌二醇，每周注射50 mg孕酮，持续四个月。下个月每天注射10 mg二丙酸雌二醇和50 mg孕酮。这些注射又持续了一个月，将孕酮增加到每天100 mg。然后停用两种激素，逐日增加剂量注射催乳素和生长激素，持续四天；同时，患者每天使用吸乳器四次，每次5分钟。在此期间，乳腺静脉明显增大，在第六天和第七天收集到了1到2 mg乳状液体。（Experimentally I have been able to induce lactogenesis in a male transvestite whose testes had been removed some years before and whose breasts had been well developed over a long period with stilbestrol and ethisterone.9 In July, 1955, 600 mg. of estradiol was implanted subcutaneously and weekly injections of 50 mg. of progesterone were given for four months. For the next month daily injections of 10 mg. estradiol dipropionate and 50 mg. progesterone were given. These injections were continued for another month, increasing progesterone to 100 mg. daily. Both hormones were then withdrawn, and daily injections of increasing doses of prolactin and somatotropin were given for four days; at the same time, the patient used a breast bump four times daily for 5 minutes on both sides. During this time the mammary veins were visibly enlarged and on the sixth and seventh days 1 to 2 cc. of milky fluid was collected.）
Kanhai RC, Hage JJ, van Diest PJ, Bloemena E, Mulder JW. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. The American Journal of Surgical Pathology. 2000-01, 24 (1): 74–80. PMID 10632490. doi:10.1097/00000478-200001000-00009.
Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML, Bertino JS. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J Clin Pharmacol. 2005, 45 (6): 614–9. PMID 15901742. S2CID 28399314. doi:10.1177/0091270005276621.
Brady BM, Anderson RA, Kinniburgh D, Baird DT. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. Clin. Endocrinol. (Oxf). 2003, 58 (4): 506–12. PMID 12641635. S2CID 12567639. doi:10.1046/j.1365-2265.2003.01751.x.
Fisher, Alessandra Daphne; Maggi, Mario. Endocrine Treatment of Transsexual Male-to-Female Persons. Management of Gender Dysphoria. 2015: 83–91. ISBN 978-88-470-5695-4. doi:10.1007/978-88-470-5696-1_10.
Kirk, Sheila. Feminizing Hormonal Therapy For The Transgendered. Pittsburgh, PA: Together Lifeworks. 1999: 38. ISBN 1887796045.
Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology. 2000-03, 55 (3): 328–33. PMID 10699602. doi:10.1016/S0090-4295(99)00580-4.
Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2006-07, 26 (7): 1660–6. PMID 16645152. S2CID 12778600. doi:10.1161/01.ATV.0000224325.96659.53 .
Bullough VL. Transsexualism in history. Arch Sex Behav. 1975-09, 4 (5): 561–71. PMID 1103789. S2CID 36577490. doi:10.1007/bf01542134.
Benjamin, Harry. Transvestism and Transsexualism in the male and female1. Journal of Sex Research. 1967, 3 (2): 107–127. ISSN 0022-4499. doi:10.1080/00224496709550519.
Schaefer LC, Wheeler CC. Harry Benjamin's first ten cases (1938-1953): a clinical historical note. Arch Sex Behav. 1995-02, 24 (1): 73–93. PMID 7733806. S2CID 31571764. doi:10.1007/bf01541990.
Edgerton MT, Knorr NJ, Callison JR. The surgical treatment of transsexual patients. Limitations and indications. Plast. Reconstr. Surg. 1970-01, 45 (1): 38–46. PMID 4902840. S2CID 27318408. doi:10.1097/00006534-197001000-00006.

bedfordshire.nhs.uk (Global: low place; Chinese: low place)

gpref.bedfordshire.nhs.uk

Sunderland Clinical Commissioning Group. SHARED CARE PRESCRIBING GUIDANCE FOR Treatment of Gender Dysphoria in Transwomen (Male to Female Transsexuals) (PDF) (报告). NHS. 14 March 2017 [2022-01-15]. （原始内容 (PDF)存档于2019-03-28）.

books.google.com (Global: 3^rd place; Chinese: 8^th place)

James Barrett. Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management. CRC Press. 2017-09-29: 216– [2021-10-15]. ISBN 978-1-315-34513-0. （原始内容存档于2021-02-08）.
Carlo Trombetta; Giovanni Liguori; Michele Bertolotto. Management of Gender Dysphoria: A Multidisciplinary Approach. Springer. 2015-03-03: 85– [2021-10-15]. ISBN 978-88-470-5696-1. （原始内容存档于2022-04-25）.
Kristen Eckstrand; Jesse M. Ehrenfeld. Lesbian, Gay, Bisexual, and Transgender Healthcare: A Clinical Guide to Preventive, Primary, and Specialist Care. Springer. 2016-02-17: 357– [2021-10-15]. ISBN 978-3-319-19752-4. （原始内容存档于2022-04-25）.
Vincenzo Mirone. Clinical Uro-Andrology. Springer. 2015-02-12: 17– [2021-10-15]. ISBN 978-3-662-45018-5. （原始内容存档于2022-04-21）.
Gianna E. Israel. Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. 2001-03: 56– [2021-10-15]. ISBN 978-1-56639-852-7. （原始内容存档于2022-04-21）.
William B. Shore. Adolescent Medicine, An Issue of Primary Care: Clinics in Office Practice, E-Book. Elsevier Health Sciences. 2014-08-21: 663– [2022-01-07]. ISBN 978-0-323-32340-6. （原始内容存档于2022-04-21）.
Ivy M. Alexander; Versie Johnson-Mallard; Elizabeth Kostas-Polston; Catherine Ingram Fogel, Nancy Fugate Woods. Women's Health Care in Advanced Practice Nursing, Second Edition. Springer Publishing Company. 2017-06-28: 468– [2022-01-07]. ISBN 978-0-8261-9004-8. （原始内容存档于2022-04-25）.
Alfred S. Wolf; H.P.G. Schneider. Östrogene in Diagnostik und Therapie. Springer-Verlag. 2013-03-12: 79, 81 [2022-01-14]. ISBN 978-3-642-75101-1. （原始内容存档于2022-04-21）.
Carlo Trombetta; Giovanni Liguori; Michele Bertolotto. Management of Gender Dysphoria: A Multidisciplinary Approach. Springer. 2015-03-03: 85– [2021-10-15]. ISBN 978-88-470-5696-1. （原始内容存档于2022-04-25）.
Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg. Williams Textbook of Endocrinology. Elsevier Health Sciences. 2015-11-11: 714, 934 [2022-01-14]. ISBN 978-0-323-34157-8. （原始内容存档于2022-05-23）.
Sarah Boslaugh. Transgender Health Issues. ABC-CLIO. 2018-08-03: 37– [2022-01-14]. ISBN 978-1-4408-5888-8. （原始内容存档于2022-04-25）.
Jerome F. Strauss; Robert L. Barbieri; Antonio R. Gargiulo. Yen & Jaffe's Reproductive Endocrinology E-Book: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. 2017-12-23: 250– [2022-01-14]. ISBN 978-0-323-58232-2. （原始内容存档于2022-04-22）.
Loren S Schechter. Surgical Management of the Transgender Patient. Elsevier Health Sciences. 2016-09-22: 26– [2022-01-14]. ISBN 978-0-323-48408-4. （原始内容存档于2022-04-25）.
Lynne Carroll; Lauren Mizock. Clinical Issues and Affirmative Treatment with Transgender Clients, An Issue of Psychiatric Clinics of North America, E-Book. Elsevier Health Sciences. 2017-02-07: 107– [2022-01-14]. ISBN 978-0-323-51004-2. （原始内容存档于2022-04-21）.
Laura Erickson-Schroth. Trans Bodies, Trans Selves: A Resource for the Transgender Community. Oxford University Press. 2014-05-12: 258– [2022-01-14]. ISBN 978-0-19-932536-8. （原始内容存档于2022-04-25）.
J. Larry Jameson; Leslie J. De Groot. Endocrinology - E-Book: Adult and Pediatric. Elsevier Health Sciences. 2010-05-18: 2282– [2022-01-14]. ISBN 978-1-4557-1126-0. （原始内容存档于2022-04-21）.
Randi Ettner; Stan Monstrey; Eli Coleman. Principles of Transgender Medicine and Surgery. Routledge. 2016-05-20: 169–170, 216, 251 [2022-01-14]. ISBN 978-1-317-51460-2. （原始内容存档于2022-04-25）.
Jashin J. Wu. Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. 2012-10-18: 364– [2022-01-14]. ISBN 978-1-4557-3801-4. （原始内容存档于2020-08-19）. Spironolactone is an aldosterone antagonist and a relatively weak antiandrogen that blocks the AR and inhibits androgen biosynthesis.
H.J.T. Coelingh Benni; H.M. Vemer. Chronic Hyperandrogenic Anovulation. CRC Press. 1990-12-15: 152– [2022-01-14]. ISBN 978-1-85070-322-8. （原始内容存档于2020-08-19）.
Jeffrey K. Aronson. Meyler's Side Effects of Cardiovascular Drugs. Elsevier. 2009-03-02: 253–258 [2022-01-14]. ISBN 978-0-08-093289-7. （原始内容存档于2020-08-19）.
Pharmacology of the Skin II: Methods, Absorption, Metabolism and Toxicity, Drugs and Diseases. Springer Science & Business Media. 2012-12-06: 474, 489 [2022-01-14]. ISBN 978-3-642-74054-1. （原始内容存档于2022-04-30）.
Dangerous Sex Offenders: A Task Force Report of the American Psychiatric Association. American Psychiatric Pub. 1999: 112–144 [2022-01-14]. ISBN 978-0-89042-280-9. （原始内容存档于2020-08-01）.
Hinman, Frank, Jr. Benign Prostatic Hypertrophy. Springer Science & Business Media. 1983: 259, 266, 272 [2022-01-14]. ISBN 978-1-4612-5476-8. （原始内容存档于2022-04-21）.
Wein, Alan J.; Kavoussi, Louis R.; Novick, Andrew C.; Partin, Alan W.; Peters, Craig A. Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. 2011-08-25: 2938– [2022-01-14]. ISBN 978-1-4160-6911-9. （原始内容存档于2020-12-22）.
A. Hughes; S. H. Hasan; G. W. Oertel; H. E. Voss, F. Bahner, F. Neumann, H. Steinbeck, K.-J. Gräf, J. Brotherton, H. J. Horn, R. K. Wagner. Androgens II and Antiandrogens / Androgene II und Antiandrogene. Springer Science & Business Media. 2013-11-27: 490–491 [2022-01-14]. ISBN 978-3-642-80859-3. （原始内容存档于2022-04-25）.
Thomas L. Lemke; David A. Williams. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 2008: 1286–1288 [2022-01-14]. ISBN 978-0-7817-6879-5. （原始内容存档于2017-09-08）.
William D. Figg; Cindy H. Chau; Eric J. Small. Drug Management of Prostate Cancer. Springer Science & Business Media. 2010-09-14: 71–72 [2022-01-14]. ISBN 978-1-60327-829-4. （原始内容存档于2022-04-21）.
Bruce A. Chabner; Dan L. Longo. Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. 2010-11-08: 680– [2022-01-14]. ISBN 978-1-60547-431-1. （原始内容存档于2020-07-27）.
Lutz Moser. Controversies in the Treatment of Prostate Cancer. Karger Medical and Scientific Publishers. 2008-01-01: 41– [2022-01-14]. ISBN 978-3-8055-8524-8. （原始内容存档于2020-07-27）.
Prostate Cancer. Demos Medical Publishing. 2011-12-20: 460, 504 [2022-01-14]. ISBN 978-1-935281-91-7. （原始内容存档于2022-04-25）.
J. Ramon; L.J. Denis. Prostate Cancer. Springer Science & Business Media. 2007-06-05: 256– [2022-01-14]. ISBN 978-3-540-40901-4. （原始内容存档于2020-07-27）.
Payne, Anita H.; Hardy, Matthew P. The Leydig Cell in Health and Disease. Springer Science & Business Media. 2007-10-28: 422–431 [2022-01-14]. ISBN 978-1-59745-453-7. （原始内容存档于2020-07-27）. 雌激素是下丘脑-垂体-睾丸轴的高效抑制剂（212-214）。除了它们在下丘脑和垂体水平的负反馈作用外，还可能对睾丸产生直接抑制作用（215，216）。[...][用雌激素治疗的]睾丸组织学显示曲细精管紊乱、空泡化和管腔缺失，以及精子发生的区室化。（Estrogens are highly efficient inhibitors of the hypothalamic-hypophyseal-testicular axis (212–214). Aside from their negative feedback action at the level of the hypothalamus and pituitary, direct inhibitory effects on the testis are likely (215,216). [...] The histology of the testes [with estrogen treatment] showed disorganization of the seminiferous tubules, vacuolization and absence of lumen, and compartmentalization of spermatogenesis.）
Salam, Muhammad A. Principles & Practice of Urology: A Comprehensive Text. Universal-Publishers. 2003: 684– [2022-01-14]. ISBN 978-1-58112-412-5. （原始内容存档于2020-07-27）. 雌激素主要通过下丘脑-垂体水平的负反馈来减少LH分泌和睾丸雄激素合成。[...]有趣的是，如果不间断地暴露，3年后停止雌激素治疗，血清睾酮可能会保持在去势水平长达3年。这种长期抑制被认为是雌激素对睾丸间质细胞的直接影响所致。（Estrogens act primarily through negative feedback at the hypothalamic-pituitary level to reduce LH secretion and testicular androgen synthesis. [...] Interestingly, if the treatment with estrogens is discontinued after 3 yr. of uninterrupted exposure, serum testosterone may remain at castration levels for up to another 3 yr. This prolonged suppression is thought to result from a direct effect of estrogens on the Leydig cells.）
Shlomo Melmed. Williams Textbook of Endocrinology. Elsevier Health Sciences. 2016-01-01: 154, 621, 711 [2022-01-14]. ISBN 978-0-323-29738-7. （原始内容存档于2022-04-21）.
Timothy L. Ratliff; William J. Catalona. Genitourinary Cancer: Basic and Clinical Aspects. Springer Science & Business Media. 2012-12-06: 158– [2022-01-14]. ISBN 978-1-4613-2033-3. （原始内容存档于2022-04-21）.
Jerome F. Strauss; Jerome F. Strauss, III; Robert L. Barbieri. Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. 2013-09-13: 272– [2022-01-14]. ISBN 978-1-4557-2758-2. （原始内容存档于2022-04-25）.
J. Larry Jameson; Leslie J. De Groot. Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. 2015-02-25: 2009, 2207, 2479 [2022-01-14]. ISBN 978-0-323-32195-2. （原始内容存档于2022-04-21）.
Louis J Denis; Keith Griffiths; Amir V Kaisary; Gerald P Murphy. Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. CRC Press. 1999-03-01: 308– [2022-01-14]. ISBN 978-1-85317-422-3. （原始内容存档于2021-02-08）.
Loren S Schechter; Bauback Safa. Gender Confirmation Surgery, An Issue of Clinics in Plastic Surgery, E-Book. Elsevier Health Sciences. 2018-06-23: 314– [2022-01-14]. ISBN 978-0-323-61075-9. （原始内容存档于2022-04-26）.
Emans, S. Jean; Laufer, Marc R. Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology. Lippincott Williams & Wilkins. 2012-01-05: 365–. ISBN 978-1-4511-5406-1. （原始内容存档于2016-05-16）. Therapy with GnRH analogs is expensive and requires intramuscular injections of depot formulations, the insert of a subcutaneous implant yearly, or, much less commonly, daily subcutaneous injections.
Hillard, Paula J. Adams. Practical Pediatric and Adolescent Gynecology. John Wiley & Sons. 2013-03-29: 182– [2022-01-14]. ISBN 978-1-118-53857-9. （原始内容存档于2020-07-27）. Treatment is expensive, with costs typically in the range of $10,000–$15,000 per year.
Everett E. Vokes; Harvey M. Golomb. Oncologic Therapies. Springer Science & Business Media. 2011-06-28: 493– [2022-01-14]. ISBN 978-3-642-55780-4. （原始内容存档于2022-04-21）.
Mozayani, Ashraf; Raymon title = Handbook of Drug Interactions: A Clinical and Forensic Guide, Lionel. Springer Science & Business Media https://books.google.com/books?id=NhBJ6kg_uP0C&pg=PA656. 2011-09-18: 656–. ISBN 978-1-61779-222-9. 缺少或|title=为空 (帮助)
Bhasin, Shalender. Pharmacology, Biology, and Clinical Applications of Androgens: Current Status and Future Prospects. John Wiley & Sons. 1996-02-13: 72–. ISBN 978-0-471-13320-9.
Ulrike Blume-Peytavi; David A. Whiting; Ralph M. Trüeb. Hair Growth and Disorders. Springer Science & Business Media. 2008-06-26: 182, 369 [2022-01-14]. ISBN 978-3-540-46911-7. （原始内容存档于2020-01-11）.
Jerry Shapiro; Nina Otberg. Hair Loss and Restoration, Second Edition. CRC Press. 2015-04-17: 39–40 [2022-01-14]. ISBN 978-1-4822-3199-1. （原始内容存档于2020-01-11）.
Ralph M. Trüeb; Won-Soo Lee. Male Alopecia: Guide to Successful Management. Springer Science & Business Media. 2014-02-13: 91– [2022-01-14]. ISBN 978-3-319-03233-7. （原始内容存档于2021-08-29）.
Thomas L. Lemke; David A. Williams. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 2012-01-24: 1397–1399 [2022-01-14]. ISBN 978-1-60913-345-0. （原始内容存档于2021-04-15）.
Mary C. Brucker; Tekoa L. King. Pharmacology for Women's Health. Jones & Bartlett Publishers. 2015-09-08: 368– [2022-01-14]. ISBN 978-1-284-05748-5. （原始内容存档于2022-04-26）.
Ilan H. Meyer; Mary E. Northridge. The Health of Sexual Minorities: Public Health Perspectives on Lesbian, Gay, Bisexual and Transgender Populations. Springer. 2007-03-12: 476– [2022-01-14]. ISBN 978-0-387-31334-4. （原始内容存档于2022-05-06）.
Gianna E. Israel; Donald E. Tarver; Joy Diane Shaffer. Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. 2001-03-01: 58– [2022-01-14]. ISBN 978-1-56639-852-7. （原始内容存档于2022-04-25）.
Richard Ekins; Dave King. The Transgender Phenomenon. SAGE Publications. 2006-10-23: 48– [2022-01-14]. ISBN 978-1-84787-726-0. （原始内容存档于2022-04-21）.
Daniel R. Mishell; Val Davajan. Reproductive endocrinology, infertility, and contraception. F. A. Davis Co. 1979: 224 [2022-01-14]. ISBN 978-0-8036-6235-3. （原始内容存档于2022-05-02）. 有人建议在每个雌激素治疗周期的最后一周添加孕激素，以形成更圆润的乳房，而不是这些患者中出现的锥形乳房，但我们无法检测到乳房轮廓在有没有孕激素情况下的差异。（It has been suggested that progestins be added during the last week of each cycle of estrogen therapy in order to develop more rounded breasts rather than the conical breasts many of these patients develop, but we have been unable to detect any difference in breast contour with or without progestins.）
Sperling, Mark A. Pediatric Endocrinology. Elsevier Health Sciences. 2014-04-10: 598– [2022-01-14]. ISBN 978-1-4557-5973-6. （原始内容存档于2022-04-30）. 雌激素刺激乳头生长，乳腺终末导管分支发展到形成导管的阶段，脂肪基质生长至构成乳房质量的约85%。[...]初潮前后，当末端导管分支形成多个盲囊芽时，乳腺小叶出现。这些效果是由于有孕酮存在。[...]完整的小泡发育通常仅在怀孕期间，在额外的孕酮和催乳素的影响下发生。（Estrogen stimulates the nipples to grow, mammary terminal duct branching to progress to the stage at which ductules are formed, and fatty stromal growth to increase until it constitutes about 85% of the mass of the breast. [...] Lobulation appears around menarche, when multiple blind saccular buds form by branching of the terminal ducts. These effects are due to the presence of progesterone. [...] Full alveolar development normally only occurs during pregnancy under the influence of additional progesterone and prolactin.）
Lee-Ellen C. Copstead-Kirkhorn; Jacquelyn L. Banasik. Pathophysiology - E-Book. Elsevier Health Sciences. 2014-06-25: 660– [2022-01-14]. ISBN 978-0-323-29317-4. （原始内容存档于2021-04-14）. 在整个生育期，一些女性在月经开始前的每个月经周期后期都会注意到乳房肿胀。在月经周期的这个阶段，乳房组织的保水和随后的肿胀被认为是由于高水平的循环孕酮刺激了乳房的分泌细胞。（Throughout the reproductive years, some women note swelling of the breast around the latter part of each menstrual cycle before the onset of menstruation. The water retention and subsequent swelling of breast tissue during this phase of the menstrual cycle are thought to be due to high levels of circulating progesterone stimulating the secretory cells of the breast.12）
Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 889– [2022-01-14]. ISBN 978-0-7817-1750-2. （原始内容存档于2022-04-21）.
Sanjay Rajagopalan; Debabrata Mukherjee; Emile R. Mohler. Manual of Vascular Diseases. Lippincott Williams & Wilkins. 2005: 1– [2022-01-14]. ISBN 978-0-7817-4499-7. （原始内容存档于2022-04-21）.
Paul Peter Rosen. Rosen's Breast Pathology. Lippincott Williams & Wilkins. 2009: 31– [2022-01-14]. ISBN 978-0-7817-7137-5. （原始内容存档于2020-07-27）.
A. Wayne Meikle. Hormone Replacement Therapy. Springer Science & Business Media. 1999-06-01: 383, 389 [2022-01-14]. ISBN 978-1-59259-700-0. （原始内容存档于2020-08-01）.
Harold Gardiner-Hill. Modern Trends in Endocrinology. Butterworth. 1958: 192 [2022-01-14]. （原始内容存档于2022-04-21）. 最近，Foss(1956)尝试在一名被阉割的男性异装癖者中开始哺乳。给他植入了500 mg的雌二醇，10个月后，又植入了600 mg的雌二醇，随后每天注射二丙酸雌二醇和黄体酮，持续6周。停药后立即每天注射22·9 mg催乳素，连续3天，但没有效果。在每天用雌二醇和黄体酮治疗的第二个月后，他被给予催乳素和生长激素联合注射4天，每天使用吸乳器抽吸4次。在第四天和第五天，从右侧乳头挤出几滴初乳。这是现代激素知识在男性中的一个可能应用，值得进一步试验。（Recently, an attempt has been made by Foss (1956) to initiate lactation in a castrated male transvestist. He was given an implant of 500 milligrams of oestradiol, and 10 months later, a further 600 milligrams of oestradiol, followed by daily injections of oestradiol dipropionate and progesterone for 6 weeks. Immediately after withdrawal of this treatment, 22·9 milligrams of prolactin were injected daily for 3 days but without effect. After a second month of treatment with oestradiol and progesterone daily, he was given combined injections of prolactin and somatotrophin for 4 days, suction with a breast-pump being employed 4 times daily. On the fourth and fifth days a few drops of colostrum were expressed from the right nipple. There is a possible application here of modern hormone knowledge to man, and further trials would be of interest.）
Edward Flückiger; Emilio Del Pozo; Klaus von Werder. Prolactin: Physiology, Pharmacology, and Clinical Findings. Springer-Verlag. 1982: 13 [2022-01-14]. ISBN 978-3-540-11071-2. （原始内容存档于2022-04-28）. [...]对男性变性者的观察（Wyss和DelPozo未发表）表明，在人类男性中也可以类似地实现泌乳诱导。[...]（[...] An observation (Wyss and Del Pozo unpublished) in a male transsexual showed that induction of lactation can be similarly achieved in the human male. [...]）
Carla A. Pfeffer. Queering Families: The Postmodern Partnerships of Cisgender Women and Transgender Men. Oxford University Press. 2017: 19– [2022-01-14]. ISBN 978-0-19-990805-9. （原始内容存档于2022-04-21）. 仅仅2年后，温弗瑞进行的另一次采访，引发了许多观众相同的反应。在2010年的这一集中，女同性恋伙伴克里斯汀·麦金博士和丽莎·博茨抱着他们的双胞胎婴儿时喜极而泣。再一次，当人们发现美丽的克里斯汀是一位男到女变性人，曾经是一位英俊的军官克里斯时，观众的下巴都掉了下来，而丽莎使用克里斯汀在性别确认手术之前储存的精子生下了她们的亲生孩子[10]。当温弗瑞观看克里斯汀母乳喂养她们孩子的视频时，温弗瑞的下巴差点撞到地板上（这一集在网上称为“成为自己孩子父亲的妈妈”）。[...]（Just 2 years later, Winfrey would feature another interview that elicited many of the same audience reactions. In this 2010 episode, lesbian partners Dr. Christine McGinn and Lisa Bortz beamed with joy as they held their infant twins. Again, audience members' jaws dropped when it was revealed that beautiful Christine was a male-to-female transsexual who used to be a handsome military officer Chris, and that Lisa had given birth to the couple's biological children using sperm Chris banked prior to gender confirmation surgeries.10 And it was Winfrey's chin that nearly hit the floor as she watched video of Christine breastfeeding the couples' children (the episode is referred to online as "The Mom Who Fathered Her Own Children"). [...]）
Eberhard Nieschlag; Hermann Behre. Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. 2013-06-29: 54–. ISBN 978-3-662-04491-9.
Michael S. Baggish; Mickey M. Karram. Atlas of Pelvic Anatomy and Gynecologic Surgery. Elsevier Health Sciences. 2011-08-18: 1200– [2022-01-14]. ISBN 978-1-4557-1068-3. （原始内容存档于2022-04-19）.
Peterson's Principles of Oral and Maxillofacial Surgery. PMPH-USA. 2012: 1209– [2022-01-14]. ISBN 978-1-60795-111-7. （原始内容存档于2022-04-30）.
Marc A. Fritz; Leon Speroff. Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. 2012-03-28: 753– [2022-01-15]. ISBN 978-1-4511-4847-3. （原始内容存档于2022-04-21）.
Christopher Li. Breast Cancer Epidemiology. Springer Science & Business Media. 2009-11-11: 266– [2022-01-15]. ISBN 978-1-4419-0685-4. （原始内容存档于2022-04-21）.
Stella Pelengaris; Michael Khan. The Molecular Biology of Cancer: A Bridge from Bench to Bedside. John Wiley & Sons. 2013-03-13: 586– [2022-01-15]. ISBN 978-1-118-43085-9. （原始内容存档于2022-04-21）.
Gilda Cardenosa. Breast Imaging. Lippincott Williams & Wilkins. 2004: 1– [2022-01-15]. ISBN 978-0-7817-4685-4. （原始内容存档于2022-04-21）.
Jerome F. Strauss, III; Robert L. Barbieri. Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. 2013-09-13: 236– [2022-01-15]. ISBN 978-1-4557-2758-2. （原始内容存档于2020-07-27）.
Elizabeth Siegel Watkins. The Estrogen Elixir: A History of Hormone Replacement Therapy in America. JHU Press. 2007-04-16: 10– [2022-01-14]. ISBN 978-0-8018-8602-7. （原始内容存档于2022-04-19）.
Institute of Medicine; Board on the Health of Select Populations; Committee on Lesbian, Gay, Bisexual, and Transgender Health Issues and Research Gaps and Opportunities. The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. National Academies Press. 2011-06-24: 70– [2022-01-14]. ISBN 978-0-309-21065-2. （原始内容存档于2022-04-25）.
Dallas Denny. Current Concepts in Transgender Identity. Routledge. 2013-05-13: 15– [2022-01-14]. ISBN 978-1-134-82110-5. （原始内容存档于2022-04-25）.
Susan Stryker; Associate Professor of Gender and Women's Studies Susan Stryker; Stephen Whittle. The Transgender Studies Reader. Taylor & Francis. 2006: 363– [2022-01-14]. ISBN 978-0-415-94709-1. （原始内容存档于2022-04-21）.
Baudewijntje P.C. Kreukels; Thomas D. Steensma; Annelou L.C. de Vries. Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge. Springer Science & Business Media. 2013-07-01: 279– [2022-01-14]. ISBN 978-1-4614-7441-8. （原始内容存档于2022-04-25）.
Harry Benjamin; Gobind Behari Lal; Richard Green; Robert E. L. Masters. The Transsexual Phenomenon. Ace Publishing Company. 1966 [2022-01-14]. （原始内容存档于2022-04-21）.
Hamburger, Christian; Benjamin, Harry. Endocrine Treatment of Male and Female Transsexualism / Appendix for the Practicing Physician: Suggestions and Guidelines for the Management of Transsexuals. Money, John; Green, Richard (编). Transsexualism and Sex Reassignment. Johns Hopkins Press. 1969: 291–307 [2022-01-14]. ISBN 9780801810381. OCLC 6866559. （原始内容存档于2022-04-21）.
Abbie E. Goldberg. The SAGE Encyclopedia of LGBTQ Studies. SAGE Publications. 2016-04-13: 1211– [2022-01-14]. ISBN 978-1-4833-7132-0. （原始内容存档于2022-04-25）.
Susan Stryker; Stephen Whittle. The Transgender Studies Reader. Routledge. 2013-10-18: 45– [2022-01-14]. ISBN 978-1-135-39884-2. （原始内容存档于2022-04-21）.
Green, R., & Money, J. (1969). Transsexualism and Sex Reassignment. Johns Hopkins University Press. https://scholar.google.com/scholar?cluster=8048451400842332421 （页面存档备份，存于互联网档案馆） https://books.google.com/books?id=pdBrAAAAMAAJ （页面存档备份，存于互联网档案馆）

confex.com (Global: 6,094^th place; Chinese: 4,939^th place)

endo.confex.com

Leinung, MC. Variable Response to Oral Estradiol Therapy in Male to Female Transgender Patients. Endocrine Reviews. 2014-06, 35 (Supplement) [2022-01-07]. doi:10.1210/endo-meetings.2014.RE.2.OR42-1 (不活跃 2021-10-31). （原始内容存档于2022-04-21）.

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Wesp LM, Deutsch MB. Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons. Psychiatr. Clin. North Am. 2017-03, 40 (1): 99–111. PMID 28159148. doi:10.1016/j.psc.2016.10.006.
Murad, Mohammad Hassan; Elamin, Mohamed B.; Garcia, Magaly Zumaeta; Mullan, Rebecca J.; Murad, Ayman; Erwin, Patricia J.; Montori, Victor M. Hormonal therapy and sex reassignment: A systematic review and meta-analysis of quality of life and psychosocial outcomes. Clinical Endocrinology. 2010, 72 (2): 214–231. PMID 19473181. S2CID 19590739. doi:10.1111/j.1365-2265.2009.03625.x.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Wylie, Kevan; Barrett, James; Besser, Mike; Bouman, Walter Pierre; Bridgman, Michelle; Clayton, Angela; Green, Richard; Hamilton, Mark; Hines, Melissa; Ivbijaro, Gabriel; Khoosal, Deenesh; Lawrence, Alex; Lenihan, Penny; Loewenthal, Del; Ralph, David; Reed, Terry; Stevens, John; Terry, Tim; Thom, Ben; Thornton, Jane; Walsh, Dominic; Ward, David; Coleman, Eli; Di Ceglie, Domenico; Martin, Emma; McGarry, Philip; Messenger, Andrew; Reid, Russell; Sethi, Su; Sutcliffe, Paul; Wilson, Daniel; Carr, Susan; Davies, Dai; Dean, Tracey; Ellis, Michelle; Ferguson, Brian; Skinner, Darren; Williams, Vicky; Brechin, Susan; Lucey, Jim; Rathbone, Maxine. Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria (PDF). Sexual and Relationship Therapy. 2014, 29 (2): 154–214 [2021-10-15]. ISSN 1468-1994. S2CID 144632597. doi:10.1080/14681994.2014.883353. （原始内容 (PDF)存档于2018-09-02）.
Wesp LM, Deutsch MB. Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons. Psychiatr. Clin. North Am. 2017-03, 40 (1): 99–111. PMID 28159148. doi:10.1016/j.psc.2016.10.006.
Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016-12, 5 (6): 877–884. PMC 5182227 . PMID 28078219. doi:10.21037/tau.2016.09.04.
Randolph JF. Gender-Affirming Hormone Therapy for Transgender Females. Clin Obstet Gynecol. 2018-12, 61 (4): 705–721. PMID 30256230. doi:10.1097/GRF.0000000000000396.
Nakatsuka M. Endocrine treatment of transsexuals: assessment of cardiovascular risk factors. Expert Rev Endocrinol Metab. 2010-05, 5 (3): 319–322. PMID 30861686. S2CID 73253356. doi:10.1586/eem.10.18.
Fishman, Sarah L.; Paliou, Maria; Poretsky, Leonid; Hembree, Wylie C. Endocrine Care of Transgender Adults. Transgender Medicine. Contemporary Endocrinology. 2019: 143–163. ISBN 978-3-030-05682-7. ISSN 2523-3785. doi:10.1007/978-3-030-05683-4_8.
Winkler-Crepaz, K.; Müller, A.; Böttcher, B.; Wildt, L. Hormonbehandlung bei Transgenderpatienten [Hormone treatment of transgender patients]. Gynäkologische Endokrinologie. 2017, 15 (1): 39–42. ISSN 1610-2894. S2CID 12270365. doi:10.1007/s10304-016-0116-9.
Urdl, W. Behandlungsgrundsätze bei Transsexualität [Therapeutic principles in transsexualism]. Gynäkologische Endokrinologie. 2009, 7 (3): 153–160. ISSN 1610-2894. S2CID 8001811. doi:10.1007/s10304-009-0314-9.
Gooren LJ. Clinical practice. Care of transsexual persons. N. Engl. J. Med. 2011-03, 364 (13): 1251–7. PMID 21449788. doi:10.1056/NEJMcp1008161.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017-04, 5 (4): 291–300. PMC 5366074 . PMID 27916515. doi:10.1016/S2213-8587(16)30319-9.
Coxon, Jonny; Seal, Leighton. Hormone management of trans women. Trends in Urology & Men's Health. 2018, 9 (6): 10–14. ISSN 2044-3730. S2CID 222189278. doi:10.1002/tre.663.
Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J. Clin. Endocrinol. Metab. 2008-01, 93 (1): 19–25. PMID 17986639. doi:10.1210/jc.2007-1809.
Athanasoulia-Kaspar, Anastasia P.; Stalla, Günter K. Endokrinologische Betreuung von Patienten mit Transsexualität [Endocrinological care of patients with transsexuality]. Geburtshilfe und Frauenheilkunde. 2019, 79 (7): 672–675. ISSN 0016-5751. doi:10.1055/a-0801-3319.
Meriggiola MC, Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin. Endocrinol. (Oxf). 2015-11, 83 (5): 607–15. PMID 25692882. S2CID 39706760. doi:10.1111/cen.12754.
Costa EM, Mendonca BB. Clinical management of transsexual subjects. Arq Bras Endocrinol Metabol. 2014-03, 58 (2): 188–96. PMID 24830596. doi:10.1590/0004-2730000003091.
Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. The Journal of Clinical Endocrinology and Metabolism. 2003-08, 88 (8): 3467–73. PMID 12915619. doi:10.1210/jc.2002-021967.
Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations. J. Clin. Endocrinol. Metab. 2014-12, 99 (12): 4379–89. PMID 25140398. doi:10.1210/jc.2014-1919.
Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance. Ann. Endocrinol. (Paris). 2016-02, 77 (1): 14–21. PMID 26830952. doi:10.1016/j.ando.2015.12.001.
Asscheman, Henk; Gooren, Louis J.G. Hormone Treatment in Transsexuals. Journal of Psychology & Human Sexuality. 1993, 5 (4): 39–54. ISSN 0890-7064. doi:10.1300/J056v05n04_03.
Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Lim HH, Jang YH, Choi GY, Lee JJ, Lee ES. Gender affirmative care of transgender people: a single center's experience in Korea. Obstet Gynecol Sci. 2019-01, 62 (1): 46–55. PMC 6333764 . PMID 30671393. doi:10.5468/ogs.2019.62.1.46. When we prescribed estradiol, we preferred sublingual estradiol valerate instead of the oral form for feminizing HT since prior researchers have reported the effectiveness of sublingual administration in maintaining high blood estradiol concentration and low E1/E2 ratio [13].
Majumder, Anirban; Chatterjee, Sudip; Maji, Debasis; Roychaudhuri, Soumyabrata; Ghosh, Sujoy; Selvan, Chitra; George, Belinda; Kalra, Pramila; Maisnam, Indira; Sanyal, Debmalya. IDEA group consensus statement on medical management of adult gender incongruent individuals seeking gender reaffirmation as female. Indian Journal of Endocrinology and Metabolism. 2020, 24 (2): 128. ISSN 2230-8210. PMID 32699777. S2CID 218596936. doi:10.4103/ijem.IJEM_593_19.
Reisman T, Goldstein Z. Case Report: Induced Lactation in a Transgender Woman. Transgend Health. 2018, 3 (1): 24–26. PMC 5779241 . PMID 29372185. doi:10.1089/trgh.2017.0044.
Henderson A. Domperidone. Discovering new choices for lactating mothers. Awhonn Lifelines. 2003, 7 (1): 54–60. PMID 12674062. doi:10.1177/1091592303251726.
Stege R, Gunnarsson PO, Johansson CJ, Olsson P, Pousette A, Carlström K. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients. Prostate. 1996, 28 (5): 307–10. PMID 8610057. doi:10.1002/(SICI)1097-0045(199605)28:5<307::AID-PROS6>3.0.CO;2-8.
Leinung MC, Feustel PJ, Joseph J. Hormonal Treatment of Transgender Women with Oral Estradiol. Transgend Health. 2018, 3 (1): 74–81. PMC 5944393 . PMID 29756046. doi:10.1089/trgh.2017.0035.
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2022-01-07]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始内容 (PDF)存档于2016-08-22）.
Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016-12, 5 (6): 877–884. PMC 5182227 . PMID 28078219. doi:10.21037/tau.2016.09.04.
Lauritzen C. Clinical use of oestrogens and progestogens. Maturitas. 1990-09, 12 (3): 199–214. PMID 2215269. doi:10.1016/0378-5122(90)90004-P.
Irwig MS. Cardiovascular health in transgender people. Rev Endocr Metab Disord. 2018-09, 19 (3): 243–251. PMID 30073551. S2CID 51908458. doi:10.1007/s11154-018-9454-3.
Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, Hunkeler E, Lash TL, Millman A, Quinn VP, Robinson B, Roblin D, Silverberg MJ, Safer J, Slovis J, Tangpricha V, Goodman M. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Ann. Intern. Med. 2018-08, 169 (4): 205–213. PMC 6636681 . PMID 29987313. doi:10.7326/M17-2785.
Ockrim J, Lalani EN, Abel P. Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nat Clin Pract Oncol. 2006-10, 3 (10): 552–63. PMID 17019433. S2CID 6847203. doi:10.1038/ncponc0602.
Lycette JL, Bland LB, Garzotto M, Beer TM. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?. Clin Genitourin Cancer. 2006-12, 5 (3): 198–205. PMID 17239273. doi:10.3816/CGC.2006.n.037.
Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017-04, 5 (4): 291–300. PMC 5366074 . PMID 27916515. doi:10.1016/S2213-8587(16)30319-9.
Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A. Single drug polyestradiol phosphate therapy in prostatic cancer. Am. J. Clin. Oncol. 1988,. 11 Suppl 2: S101–3. PMID 3242384. S2CID 32650111. doi:10.1097/00000421-198801102-00024.
Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer--forward to the past?. J. Urol. 2003-05, 169 (5): 1735–7. PMID 12686820. doi:10.1097/01.ju.0000061024.75334.40.
Leinung, MC. Variable Response to Oral Estradiol Therapy in Male to Female Transgender Patients. Endocrine Reviews. 2014-06, 35 (Supplement) [2022-01-07]. doi:10.1210/endo-meetings.2014.RE.2.OR42-1 (不活跃 2021-10-31). （原始内容存档于2022-04-21）.
Liang JJ, Jolly D, Chan KJ, Safer JD. Testosterone Levels Achieved by Medically Treated Transgender Women in a United States Endocrinology Clinic Cohort. Endocr Pract. 2018-02, 24 (2): 135–142. PMID 29144822. doi:10.4158/EP-2017-0116.
Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J. Clin. Endocrinol. Metab. 2008-01, 93 (1): 19–25. PMID 17986639. doi:10.1210/jc.2007-1809 .
Wylie, Kevan Richard; Fung, Robert; Boshier, Claudia; Rotchell, Margaret. Recommendations of endocrine treatment for patients with gender dysphoria. Sexual and Relationship Therapy. 2009, 24 (2): 175–187. ISSN 1468-1994. S2CID 20471537. doi:10.1080/14681990903023306.
Haupt, Claudia; Henke, Miriam; Kutschmar, Alexia; Hauser, Birgit; Baldinger, Sandra; Schreiber, Gerhard. Antiandrogens or estradiol treatments or both during hormone replacement therapy in transitioning transgender women. Cochrane Database of Systematic Reviews. 2018, 2018 (10): CD013138. ISSN 1465-1858. PMC 6517060 . doi:10.1002/14651858.CD013138.
Vermeulen A. Longacting steroid preparations. Acta Clin Belg. 1975, 30 (1): 48–55. PMID 1231448. doi:10.1080/17843286.1975.11716973.
Rauramo L, Punnonen R, Kaihola LH, Grönroos M. Serum oestrone, oestradiol and oestriol concentrations in castrated women during intramuscular oestradiol valerate and oestradiolbenzoate-oestradiolphenylpropionate therapy. Maturitas. 1980-01, 2 (1): 53–8. PMID 7402086. doi:10.1016/0378-5122(80)90060-2.
Gava, Giulia; Seracchioli, Renato; Meriggiola, Maria Cristina. Therapy with Antiandrogens in Gender Dysphoric Natal Males. Endocrinology of the Testis and Male Reproduction. Endocrinology. 2017: 1199–1209. ISBN 978-3-319-44440-6. ISSN 2510-1927. doi:10.1007/978-3-319-44441-3_42.
Lieberman R. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology. 2001, 58 (2 Suppl 1): 83–90. PMID 11502457. doi:10.1016/s0090-4295(01)01247-x. There are several classes of antiandrogens including (1) antigonadotropins (eg, LHRH agonists/antagonists, synthetic estrogens [diethylstilbestrol]); (2) nonsteroidal androgen-receptor antagonists (eg, flutamide, bicalutamide, nilutamide); (3) steroidal agents with mixed actions (eg, cyproterone acetate); (4) adrenal androgen inhibitors (eg, ketoconazole, hydrocortisone); (5) steroidal agents that inhibit androgen biosynthesis (eg, 5α-reductase inhibitors (type II) and dual-acting 5α-reductase inhibitors); [...]
Dimitrakakis C. Androgens and breast cancer in men and women (PDF). Endocrinol. Metab. Clin. North Am. 2011-09, 40 (3): 533–47, viii [2022-01-14]. PMID 21889719. doi:10.1016/j.ecl.2011.05.007. （原始内容 (PDF)存档于2022-04-21）.
Schneider HP. Androgens and antiandrogens. Ann. N. Y. Acad. Sci. 2003-11, 997 (1): 292–306. Bibcode:2003NYASA.997..292S. PMID 14644837. S2CID 8400556. doi:10.1196/annals.1290.033.
Tiefenbacher K, Daxenbichler G. The Role of Androgens in Normal and Malignant Breast Tissue. Breast Care (Basel). 2008, 3 (5): 325–331. PMC 2931104 . PMID 20824027. doi:10.1159/000158055.
Gibson DA, Saunders PK, McEwan IJ. Androgens and androgen receptor: Above and beyond. Mol. Cell. Endocrinol. 2018-04, 465: 1–3. PMID 29481861. S2CID 3702165. doi:10.1016/j.mce.2018.02.013.
Brueggemeier, Robert W. Sex Hormones (Male): Analogs and Antagonists. Encyclopedia of Molecular Cell Biology and Molecular Medicine. 2006. ISBN 978-3527600908. doi:10.1002/3527600906.mcb.200500066.
de Lignières B, Silberstein S. Pharmacodynamics of oestrogens and progestogens. Cephalalgia. 2000-04, 20 (3): 200–7. PMID 10997774. S2CID 40392817. doi:10.1046/j.1468-2982.2000.00042.x.
Lotti, Francesco; Maggi, Mario. Hormonal Treatment for Skin Androgen-Related Disorders. European Handbook of Dermatological Treatments. 2015: 1451–1464. ISBN 978-3-662-45138-0. doi:10.1007/978-3-662-45139-7_142.
Schmidt TH, Shinkai K. Evidence-based approach to cutaneous hyperandrogenism in women. J. Am. Acad. Dermatol. 2015-10, 73 (4): 672–90. PMID 26138647. doi:10.1016/j.jaad.2015.05.026.
Clapauch, Ruth; Weiss, Rita Vasconcellos; Rech, Ciciliana Maila Zilio. Testosterone and Women. Testosterone. 2017: 319–351. ISBN 978-3-319-46084-0. doi:10.1007/978-3-319-46086-4_17.
Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem. 2000, 7 (2): 211–47. PMID 10637363. doi:10.2174/0929867003375371.
Angus L, Leemaqz S, Ooi O, Cundill P, Silberstein N, Locke P, Zajac JD, Cheung AS. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocr Connect. 2019-07, 8 (7): 935–940. PMC 6612061 . PMID 31234145. doi:10.1530/EC-19-0272.
Kolkhof P, Bärfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 2017-07, 234 (1): T125–T140. PMC 5488394 . PMID 28634268. doi:10.1530/JOE-16-0600.
McMullen GR, Van Herle AJ. Hirsutism and the effectiveness of spironolactone in its management. J. Endocrinol. Invest. 1993-12, 16 (11): 925–32. PMID 8144871. S2CID 42231952. doi:10.1007/BF03348960.
Loriaux, D. Lynn. Spironolactone and endocrine dysfunction. Annals of Internal Medicine. 1976-11, 85 (5): 630–6. PMID 984618. doi:10.7326/0003-4819-85-5-630.
Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993, 13 (1): 37–45. PMID 8094898. doi:10.1002/j.1875-9114.1993.tb02688.x (不活跃 2021-10-31).
Shaw JC. Spironolactone in dermatologic therapy. J. Am. Acad. Dermatol. 1991-02, 24 (2 Pt 1): 236–43. PMID 1826112. doi:10.1016/0190-9622(91)70034-Y.
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. Am J Clin Dermatol. 2017, 18 (2): 169–191. PMC 5360829 . PMID 28155090. doi:10.1007/s40257-016-0245-x.
Doggrell SA, Brown L. The spironolactone renaissance. Expert Opin Investig Drugs. 2001-05, 10 (5): 943–54. PMID 11322868. S2CID 39820875. doi:10.1517/13543784.10.5.943.
Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J. Urol. 1986-09, 136 (3): 624–31. PMID 2942707. doi:10.1016/S0022-5347(17)44996-2.
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int. J. Cardiol. 2015, 200: 25–9. PMID 26404748. doi:10.1016/j.ijcard.2015.05.127.
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004, 351 (6): 543–51. PMID 15295047. doi:10.1056/NEJMoa040135.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 2016, 74 (5): 945–73.e33. PMID 26897386. doi:10.1016/j.jaad.2015.12.037 .
Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol. 2015, 151 (9): 941–4. PMID 25796182. doi:10.1001/jamadermatol.2015.34 .
Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp. Clin. Endocrinol. 1994, 102 (1): 1–32. PMID 8005205. doi:10.1055/s-0029-1211261.
Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003, 63 (5): 463–92. PMID 12600226. S2CID 28436828. doi:10.2165/00003495-200363050-00003.
Koch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, Lübke K, Mehring M, Römmler A, Schwartz U, Hammerstein J. Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers. Contraception. 1976, 14 (2): 117–35. PMID 949890. doi:10.1016/0010-7824(76)90081-0.
Moltz, L.; Römmler, A.; Schwartz, U.; Hammerstein, J. Effects of Cyproterone Acetate (CPA) on Pituitary Gonadotrophin Release and on Androgen Secretion Before and After LH-RH Double Stimulation Tests in Men. International Journal of Andrology. 1978, 1 (s2b): 713–719. ISSN 0105-6263. doi:10.1111/j.1365-2605.1978.tb00518.x .
Wang C, Yeung KK. Use of low-dosage oral cyproterone acetate as a male contraceptive. Contraception. 1980, 21 (3): 245–72. PMID 6771091. doi:10.1016/0010-7824(80)90005-0.
Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Contraception. 1980-04, 21 (4): 393–413. PMID 6771095. doi:10.1016/s0010-7824(80)80017-5.
Knuth UA, Hano R, Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J. Clin. Endocrinol. Metab. 1984, 59 (5): 963–9. PMID 6237116. doi:10.1210/jcem-59-5-963.
Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol. 1980, 52 (3): 208–15. PMID 7000222. doi:10.1111/j.1464-410x.1980.tb02961.x.
Fung, Raymond; Hellstern-Layefsky, Miriam; Lega, Iliana. Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?. International Journal of Transgenderism. 2017, 18 (2): 123–128. ISSN 1553-2739. S2CID 79095497. doi:10.1080/15532739.2017.1290566.
Meyer G, Mayer M, Mondorf A, Fluegel AK, Herrmann E, Bojunga J. Safety and rapid efficacy of guideline-based gender affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. Eur. J. Endocrinol. 2019-11, 182 (2): 149–156. PMID 31751300. S2CID 208229129. doi:10.1530/EJE-19-0463.
Pucci E, Petraglia F. Treatment of androgen excess in females: yesterday, today and tomorrow. Gynecol. Endocrinol. 1997-12, 11 (6): 411–33. PMID 9476091. doi:10.3109/09513599709152569.
Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol. Int. 2004, 73 (4): 289–95. PMID 15604569. S2CID 24799765. doi:10.1159/000081585.
Hammerstein, J. Antiandrogens: Clinical Aspects. Hair and Hair Diseases. 1990: 827–886. ISBN 978-3-642-74614-7. doi:10.1007/978-3-642-74612-3_35.
Lothstein, Leslie M. Antiandrogen treatment for sexual disorders: Guidelines for establishing a standard of care. Sexual Addiction & Compulsivity. 1996, 3 (4): 313–331. ISSN 1072-0162. doi:10.1080/10720169608400122.
Novak E, Hendrix JW, Chen TT, Seckman CE, Royer GL, Pochi PE. Sebum production and plasma testosterone levels in man after high-dose medroxyprogesterone acetate treatment and androgen administration. Acta Endocrinol. 1980-10, 95 (2): 265–70. PMID 6449127. doi:10.1530/acta.0.0950265.
Kirschner MA, Schneider G. Suppression of the pituitary-Leydig cell axis and sebum production in normal men by medroxyprogesterone acetate (provera). Acta Endocrinol. 1972-02, 69 (2): 385–93. PMID 5066846. doi:10.1530/acta.0.0690385.
Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol. Endocrinol. 1999-03, 13 (3): 440–54. PMID 10077001. doi:10.1210/mend.13.3.0255 .
Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003-08, 68 (2): 75–87. PMID 12954518. doi:10.1016/S0010-7824(03)00136-7.
Nieschlag E. Clinical trials in male hormonal contraception (PDF). Contraception. 2010-11, 82 (5): 457–70 [2022-01-14]. PMID 20933120. doi:10.1016/j.contraception.2010.03.020. （原始内容 (PDF)存档于2020-12-05）.
Nieschlag E, Zitzmann M, Kamischke A. Use of progestins in male contraception. Steroids. 2003-11, 68 (10–13): 965–72. PMID 14667989. S2CID 22458746. doi:10.1016/S0039-128X(03)00135-1.
Wu FC, Balasubramanian R, Mulders TM, Coelingh-Bennink HJ. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J. Clin. Endocrinol. Metab. 1999-01, 84 (1): 112–22. PMID 9920070. doi:10.1210/jcem.84.1.5412 .
Geller J, Albert J, Geller S. Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue. The Prostate. 1982, 3 (1): 11–5. PMID 6176985. S2CID 23541558. doi:10.1002/pros.2990030103.
Sander S, Nissen-Meyer R, Aakvaag A. On gestagen treatment of advanced prostatic carcinoma. Scand. J. Urol. Nephrol. 1978, 12 (2): 119–21. PMID 694436. doi:10.3109/00365597809179977.
Wenderoth, U. K.; Jacobi, G. H. Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. World Journal of Urology. 1983, 1 (1): 40–48. ISSN 0724-4983. S2CID 23447326. doi:10.1007/BF00326861.
Schröder, Fritz H.; Radlmaier, Albert. Steroidal Antiandrogens. V. Craig Jordan; Barrington J. A. Furr (编). Hormone Therapy in Breast and Prostate Cancer. Humana Press. 2009: 325–346. ISBN 978-1-60761-471-5. doi:10.1007/978-1-59259-152-7_15. 如前所述，CPA会导致血浆睾酮水平的不完全抑制，降低约70%并保持在去势值的三倍左右。[Rennie等人]发现CPA与极低剂量（0.1 mg/d）的DES联合使用可以非常有效地去除血浆睾酮和组织中的双氢睾酮雄激素。[...]该方案结合了两种化合物的睾酮降低作用，因此只需少量雌激素即可将血浆睾酮降低至接近去势水平。（CPA, as mentioned earlier, leads to an incomplete suppression of plasma testosterone levels, which decrease by about 70% and remain at about three times castration values. [Rennie et al.] found that the combination of CPA with an extremely low dose (0.1 mg/d) of DES led to a very effective withdrawal of androgens in terms of plasma testosterone and tissue dihydrotestosterone. [...] this regimen combines the testosterone-reducing effects of two compounds, therefore, only small amounts of estrogen are required to bring down plasma testosterone to approximately castrate levels.）
Melamed AJ. Current concepts in the treatment of prostate cancer. Drug Intell Clin Pharm. 1987-03, 21 (3): 247–54. PMID 3552544. S2CID 7482144. doi:10.1177/106002808702100302. [醋酸甲羟孕酮]使血浆睾酮水平暂时降低至略高于去势男性的水平。当以40 mg tid的剂量使用时，与0.5–1.5 mg/d的雌二醇联合使用，可协同抑制垂体促性腺激素，并将血浆睾酮维持在去势水平长达一年。（[Megestrol acetate] produces a transient reduction in plasma testosterone to levels somewhat higher than those in castrated men. When used in a dose of 40 mg tid, in combination with estradiol 0.5–1.5 mg/d, it acts synergistically to suppress pituitary gonadotropins and maintain plasma testosterone at castration levels for periods up to one year.）
Erem C. Update on idiopathic hirsutism: diagnosis and treatment. Acta Clin Belg. 2013, 68 (4): 268–74. PMID 24455796. S2CID 39120534. doi:10.2143/ACB.3267.
Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 2018-03, 103 (3): 824–838. PMID 29211888. S2CID 3784055. doi:10.1210/jc.2017-01186 .
Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997-01, 49 (1): 71–8. PMID 9000189. doi:10.1016/S0090-4295(96)00325-1.
Neyman, A; Fuqua, JS; Eugster, EA. Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents. Hormone Research in Paediatrics. 2017-12, 88: 1–628 [2022-01-14]. PMID 28968603. doi:10.1159/000481424 . （原始内容存档于2022-04-21）.
Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens. J. Urol. 2018-05, 200 (5): 956–966. PMID 29730201. S2CID 19162538. doi:10.1016/j.juro.2018.04.083.
Ito Y, Sadar MD. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Res Rep Urol. 2018, 10: 23–32. PMC 5818862 . PMID 29497605. doi:10.2147/RRU.S157116.
Ricci F, Buzzatti G, Rubagotti A, Boccardo F. Safety of antiandrogen therapy for treating prostate cancer. Expert Opin Drug Saf. 2014-11, 13 (11): 1483–99. PMID 25270521. S2CID 207488100. doi:10.1517/14740338.2014.966686.
Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology. 1996-01, 47 (1A Suppl): 70–9; discussion 80–4. PMID 8560681. doi:10.1016/S0090-4295(96)80012-4.
Vogelzang NJ. Enzalutamide--a major advance in the treatment of metastatic prostate cancer. N. Engl. J. Med. 2012-09, 367 (13): 1256–7. PMID 23013078. doi:10.1056/NEJMe1209041.
Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect. Case Reports in Gastroenterology. 2018, 12 (2): 266–270. ISSN 1662-0631. S2CID 81661015. doi:10.1159/000485175 .
Gao Y, Maurer T, Mirmirani P. Understanding and Addressing Hair Disorders in Transgender Individuals. Am J Clin Dermatol. 2018-01, 19 (4): 517–527. PMID 29352423. S2CID 6467968. doi:10.1007/s40257-018-0343-z. 非甾体抗雄激素包括氟他胺、尼鲁米特和比卡鲁胺，它们不会降低雄激素水平，可能对想要保持性欲和生育能力的个体有利[9]。（Non-steroidal antiandrogens include flutamide, nilutamide, and bicalutamide, which do not lower androgen levels and may be favorable for individuals who want to preserve sex drive and fertility [9].）
Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International. 2001-01, 87 (1): 47–56. PMID 11121992. S2CID 28215804. doi:10.1046/j.1464-410x.2001.00988.x .
Morgante, E; Gradini, R; Realacci, M; Sale, P; D'eramo, G; Perrone, G A; Cardillo, M R; Petrangeli, E; Russo, Ma; Di Silverio, F. Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study. Histopathology. 2001, 38 (3): 195–201. ISSN 0309-0167. PMID 11260298. S2CID 36892099. doi:10.1046/j.1365-2559.2001.01077.x.
Jones, C. A.; Reiter, L.; Greenblatt, E. Fertility preservation in transgender patients. International Journal of Transgenderism. 2016, 17 (2): 76–82. ISSN 1553-2739. S2CID 58849546. doi:10.1080/15532739.2016.1153992. 传统上，建议患者在开始异性激素治疗之前冷冻保存精子，因为随着时间的推移，高剂量雌激素治疗可能会降低精子活力（Lubbert等，1992）。然而，由于研究有限，雌激素治疗导致的生育力下降仍有争议。（Traditionally, patients have been advised to cryopreserve sperm prior to starting cross-sex hormone therapy as there is a potential for a decline in sperm motility with high-dose estrogen therapy over time (Lubbert et al., 1992). However, this decline in fertility due to estrogen therapy is controversial due to limited studies.）
Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J. Urol. 1995-12, 154 (6): 1991–8. PMID 7500443. doi:10.1016/S0022-5347(01)66670-9.
Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007-02, 3 (2): 157–67. PMID 17237842. S2CID 19745821. doi:10.1038/ncpendmet0399.
Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015-01, 11 (1): 19–28. PMID 25581052. S2CID 7516507. doi:10.2217/whe.14.68 .
Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogues. N. Engl. J. Med. 1991-01, 324 (2): 93–103. PMID 1984190. doi:10.1056/NEJM199101103240205.
Krakowsky Y, Morgentaler A. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. Eur Urol Focus. 2017-07, 5 (1): 81–89. PMID 28753828. S2CID 10011200. doi:10.1016/j.euf.2017.06.008.
Scaletscky R, Smith JA. Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?. Drug Saf. 1993-04, 8 (4): 265–70. PMID 8481213. S2CID 36964191. doi:10.2165/00002018-199308040-00001.
Reilly DR, Delva NJ, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Can J Psychiatry. 2000-08, 45 (6): 559–63. PMID 10986575. S2CID 27710792. doi:10.1177/070674370004500608 . [...]在第一次注射亮丙瑞林之前进行雌激素或抗雄激素治疗可能会降低[治疗开始时由睾酮“爆发”引起的症状风险]（16）。（[...] estrogen or antiandrogen treatment prior to the first leuprolide injection may reduce [the risk of symptoms caused by the testosterone "flare" at the initiation of treatment] (16).）
Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp. Clin. Endocrinol. Diabetes. 2005-12, 113 (10): 586–92. PMID 16320157. doi:10.1055/s-2005-865900.
T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of Transgender Medicine. Endocrine Reviews. 2018-10, 40 (1): 97–117 [2022-01-14]. PMID 30307546. doi:10.1210/er.2018-00011 . （原始内容存档于2022-04-21）.
Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocr. Rev. 2017-06, 38 (3): 220–254. PMC 6459338 . PMID 28472278. doi:10.1210/er.2016-1067.
Marchetti PM, Barth JH. Clinical biochemistry of dihydrotestosterone. Ann. Clin. Biochem. 2013-03, 50 (Pt 2): 95–107. PMID 23431485. S2CID 8325257. doi:10.1258/acb.2012.012159.
Jin Y, Penning TM. Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract. Res. Clin. Endocrinol. Metab. 2001, 15 (1): 79–94. PMID 11469812. doi:10.1053/beem.2001.0120.
Horton R. Dihydrotestosterone is a peripheral paracrine hormone. J. Androl. 1992, 13 (1): 23–7. PMID 1551803. doi:10.1002/j.1939-4640.1992.tb01621.x.
Wilson JD. Role of dihydrotestosterone in androgen action. Prostate Suppl. 1996, 6 (S6): 88–92. PMID 8630237. doi:10.1002/(SICI)1097-0045(1996)6+<88::AID-PROS17>3.0.CO;2-N.
Okeigwe I, Kuohung W. 5-Alpha reductase deficiency: a 40-year retrospective review. Curr Opin Endocrinol Diabetes Obes. 2014-12, 21 (6): 483–7. PMID 25321150. S2CID 1093345. doi:10.1097/MED.0000000000000116.
Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol. Cell. Endocrinol. 2002-12, 198 (1–2): 51–9. PMID 12573814. S2CID 54356569. doi:10.1016/S0303-7207(02)00368-4.
Liang, Jennifer J.; Rasmusson, Ann M. Overview of the Molecular Steps in Steroidogenesis of the GABAergic Neurosteroids Allopregnanolone and Pregnanolone. Chronic Stress. 2018, 2: 247054701881855. ISSN 2470-5470. PMC 7219929 . PMID 32440589. doi:10.1177/2470547018818555.
Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014-06, 55 (6): 367–79. PMC 4064044 . PMID 24955220. doi:10.4111/kju.2014.55.6.367.
Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 2000-04, 37 (4): 367–80. PMID 10765065. S2CID 25793400. doi:10.1159/000020181.
Yamana K, Labrie F, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010-08, 2 (3): 293–9. PMID 25961201. S2CID 28841145. doi:10.1515/HMBCI.2010.035.
Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2018-08, 7 (1): 95–114. PMID 30098986. S2CID 51968365. doi:10.1016/j.sxmr.2018.06.002.
Azzouni F, Mohler J. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis. 2012-09, 15 (3): 222–30. PMID 22333687. S2CID 205537645. doi:10.1038/pcan.2012.1 .
Yim E, Nole KL, Tosti A. 5α-Reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2014-12, 21 (6): 493–8. PMID 25268732. S2CID 30008068. doi:10.1097/MED.0000000000000112.
Arif T, Dorjay K, Adil M, Sami M. Dutasteride in Androgenetic Alopecia: An Update. Curr Clin Pharmacol. 2017, 12 (1): 31–35. PMID 28294070. doi:10.2174/1574884712666170310111125.
Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010-06, 44 (6): 1090–7. PMID 20442354. S2CID 207263793. doi:10.1345/aph.1M591.
Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014-07, 15 (3): 217–30. PMID 24848508. S2CID 31245042. doi:10.1007/s40257-014-0077-5.
Reddy DS, Estes WA. Clinical Potential of Neurosteroids for CNS Disorders. Trends Pharmacol. Sci. 2016-07, 37 (7): 543–561. PMC 5310676 . PMID 27156439. doi:10.1016/j.tips.2016.04.003.
Martinez PE, Rubinow DR, Nieman LK, Koziol DE, Morrow AL, Schiller CE, Cintron D, Thompson KD, Khine KK, Schmidt PJ. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. Neuropsychopharmacology. 2016-03, 41 (4): 1093–102. PMC 4748434 . PMID 26272051. doi:10.1038/npp.2015.246.
Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012-01, 32 (1): 54–66. PMID 22392828. S2CID 12853220. doi:10.1002/PHAR.1006.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Trost L, Saitz TR, Hellstrom WJ. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. Sex Med Rev. 2013-05, 1 (1): 24–41. PMID 27784557. doi:10.1002/smrj.3.
Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. J Sex Med. 2016-09, 13 (9): 1297–1310. PMID 27475241. doi:10.1016/j.jsxm.2016.07.006.
Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018-05, 28 (3): 288–293 [2022-01-14]. PMID 29528971. S2CID 4587434. doi:10.1097/MOU.0000000000000497. （原始内容存档于2022-04-21）.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011-03, 8 (3): 872–84. PMID 21176115. doi:10.1111/j.1743-6109.2010.02157.x.
Traish, Abdulmaged M. The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. Current Sexual Health Reports. 2018, 10 (3): 88–103. ISSN 1548-3584. S2CID 81560714. doi:10.1007/s11930-018-0161-6.
Malde S, Cartwright R, Tikkinen KA. What's New in Epidemiology?. Eur Urol Focus. 2018-01, 4 (1): 11–13. PMID 29449167. doi:10.1016/j.euf.2018.02.003.
Kuhl, Herbert; Wiegratz, Inka. Das Post-Finasterid-Syndrom [The Post-Finasteride Syndrome]. Gynäkologische Endokrinologie. 2017, 15 (2): 153–163. ISSN 1610-2894. S2CID 207071180. doi:10.1007/s10304-017-0126-2.
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?. Rev Endocr Metab Disord. 2015-09, 16 (3): 177–98. PMID 26296373. S2CID 25002351. doi:10.1007/s11154-015-9319-y.
Trüeb RM. Discriminating in favour of or against men with increased risk of finasteride-related side effects?. Exp. Dermatol. 2017-06, 26 (6): 527–528. PMID 27489125. S2CID 36236057. doi:10.1111/exd.13155 . [...]建议在为男性到女性的跨性别者开具口服非那雄胺的处方时要谨慎，因为该药物与诱发抑郁、焦虑和自杀意念有关，这些症状在性别不安患者中尤为常见，他们已经处于高风险中[9]。（[...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.[9]）
Macias, Hector; Hinck, Lindsay. Mammary gland development. Wiley Interdisciplinary Reviews: Developmental Biology. 2012, 1 (4): 533–557. ISSN 1759-7684. PMC 3404495 . PMID 22844349. doi:10.1002/wdev.35.
Sun, Susie X.; Bostanci, Zeynep; Kass, Rena B.; Mancino, Anne T.; Rosenbloom, Arlan L.; Klimberg, V. Suzanne; Bland, Kirby I. Breast Physiology. The Breast. 2018: 37–56.e6. ISBN 9780323359559. doi:10.1016/B978-0-323-35955-9.00003-9.
Wierckx K, Gooren L, T'Sjoen G. Clinical review: Breast development in trans women receiving cross-sex hormones. J Sex Med. 2014, 11 (5): 1240–7. PMID 24618412. doi:10.1111/jsm.12487.
Cox DB, Kent JC, Casey TM, Owens RA, Hartmann PE. Breast growth and the urinary excretion of lactose during human pregnancy and early lactation: endocrine relationships. Exp. Physiol. 1999-03, 84 (2): 421–34. PMID 10226182. doi:10.1017/S0958067099018072 .
Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects?. Trends Endocrinol. Metab. 2004-08, 15 (6): 277–85. PMID 15358281. S2CID 35891204. doi:10.1016/j.tem.2004.06.006.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Kronawitter D, Gooren LJ, Zollver H, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. Eur. J. Endocrinol. 2009-08, 161 (2): 363–8. PMID 19497984. doi:10.1530/EJE-09-0265 .
Majumder A, Sanyal D. Outcome and preferences in male-to-female subjects with gender dysphoria: Experience from Eastern India. Indian J Endocrinol Metab. 2017, 21 (1): 21–25. PMC 5240066 . PMID 28217493. doi:10.4103/2230-8210.196000.
Meyer WJ, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Archives of Sexual Behavior. 1986-04, 15 (2): 121–38. PMID 3013122. S2CID 42786642. doi:10.1007/bf01542220.
Morris JM. The syndrome of testicular feminization in male pseudohermaphrodites. Am. J. Obstet. Gynecol. 1953-06, 65 (6): 1192–1211. PMID 13057950. doi:10.1016/0002-9378(53)90359-7.
Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocrine-Related Cancer. 2006, 13 (2): 279–92. PMID 16728564. doi:10.1677/erc.1.00729 . 脂肪细胞占人体乳房的大部分，而上皮细胞仅占人体乳房体积的约10%。（Adipocytes make up the bulk of the human breast, with epithelial cells accounting for only approximately 10% of human breast volume.）
Howard BA, Gusterson BA. Human breast development. Journal of Mammary Gland Biology and Neoplasia. 2000, 5 (2): 119–37. PMID 11149569. S2CID 10819224. doi:10.1023/A:1026487120779. 在基质中，纤维和脂肪组织的数量增加，成人非哺乳期乳房由80%或更多的基质组成。（In the stroma, there is an increase in the amount of fibrous and fatty tissue, with the adult nonlactating breast consisting of 80% or more of stroma.）
Hagisawa S, Shimura N, Arisaka O. Effect of excess estrogen on breast and external genitalia development in growth hormone deficiency. Journal of Pediatric and Adolescent Gynecology. 2012, 25 (3): e61–3. PMID 22206682. doi:10.1016/j.jpag.2011.11.005. 雌激素刺激乳头的发育，从乳腺导管分叉到小管形成阶段的过程，及脂肪基质生长至构成乳房质量的约85%。（Estrogen stimulates growth of the nipples, progression of mammary duct branching to the stage at which ductiles are formed, and fatty stromal growth until it constitutes about 85% of the mass of the breast.）
Farage MA, Neill S, MacLean AB. Physiological changes associated with the menstrual cycle: a review. Obstet Gynecol Surv. 2009, 64 (1): 58–72. PMID 19099613. S2CID 22293838. doi:10.1097/OGX.0b013e3181932a37.
Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric. 2012-04,. 15 Suppl 1: 18–25. PMID 22432812. S2CID 17700754. doi:10.3109/13697137.2012.669584.
Cline JM, Wood CE. The Mammary Glands of Macaques. Toxicol Pathol. 2008-12, 36 (7): 134s–141s. PMC 3070964 . PMID 21475638. doi:10.1177/0192623308327411.
Pasqualini JR. Progestins and breast cancer. Gynecol. Endocrinol. 2007,. 23 Suppl 1: 32–41. PMID 17943537. S2CID 46634314. doi:10.1080/09513590701585003.
Pasqualini JR. Breast cancer and steroid metabolizing enzymes: the role of progestogens. Maturitas. 2009,. 65 Suppl 1: S17–21. PMID 19962254. doi:10.1016/j.maturitas.2009.11.006.
Schindler AE. Dydrogesterone and other progestins in benign breast disease: an overview. Arch. Gynecol. Obstet. 2011-02, 283 (2): 369–71. PMID 20383772. S2CID 9125889. doi:10.1007/s00404-010-1456-7.
Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C. Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol. Endocrinol. 2001-12,. 15 Suppl 6: 37–43. PMID 12227885. S2CID 27589741. doi:10.1080/gye.15.s6.37.43.
Ruan X, Mueck AO. Systemic progesterone therapy--oral, vaginal, injections and even transdermal?. Maturitas. 2014-11, 79 (3): 248–55. PMID 25113944. doi:10.1016/j.maturitas.2014.07.009.
Bińkowska, Małgorzata; Woroń, Jarosław. Progestogens in menopausal hormone therapy. Menopausal Review. 2015, 14 (2): 134–143. ISSN 1643-8876. PMC 4498031 . PMID 26327902. doi:10.5114/pm.2015.52154.
Foss GL. Disturbances of lactation. Clin Obstet Gynecol. 1958-03, 1 (1): 245–54. PMID 13573669. S2CID 42825519. doi:10.1097/00003081-195803000-00021. 在实验上，我已经能够诱导一名男性异装癖者的泌乳，该男性异装癖者的睾丸在几年前已被切除，其乳房在很长一段时间内使用芪雌酚和乙炔雌酮，发育已良好[9]。1955年7月9日，皮下植入600 mg雌二醇，每周注射50 mg孕酮，持续四个月。下个月每天注射10 mg二丙酸雌二醇和50 mg孕酮。这些注射又持续了一个月，将孕酮增加到每天100 mg。然后停用两种激素，逐日增加剂量注射催乳素和生长激素，持续四天；同时，患者每天使用吸乳器四次，每次5分钟。在此期间，乳腺静脉明显增大，在第六天和第七天收集到了1到2 mg乳状液体。（Experimentally I have been able to induce lactogenesis in a male transvestite whose testes had been removed some years before and whose breasts had been well developed over a long period with stilbestrol and ethisterone.9 In July, 1955, 600 mg. of estradiol was implanted subcutaneously and weekly injections of 50 mg. of progesterone were given for four months. For the next month daily injections of 10 mg. estradiol dipropionate and 50 mg. progesterone were given. These injections were continued for another month, increasing progesterone to 100 mg. daily. Both hormones were then withdrawn, and daily injections of increasing doses of prolactin and somatotropin were given for four days; at the same time, the patient used a breast bump four times daily for 5 minutes on both sides. During this time the mammary veins were visibly enlarged and on the sixth and seventh days 1 to 2 cc. of milky fluid was collected.）
Kanhai RC, Hage JJ, van Diest PJ, Bloemena E, Mulder JW. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. The American Journal of Surgical Pathology. 2000-01, 24 (1): 74–80. PMID 10632490. doi:10.1097/00000478-200001000-00009.
Lawrence, Anne A. Transgender Health Concerns. The Health of Sexual Minorities. 2007: 473–505. ISBN 978-0-387-28871-0. doi:10.1007/978-0-387-31334-4_19.
Worsley R, Santoro N, Miller KK, Parish SJ, Davis SR. Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgens--Findings from the Fourth International Consultation on Sexual Medicine. J Sex Med. 2016-03, 13 (3): 283–90. PMID 26944460. doi:10.1016/j.jsxm.2015.12.014.
Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007, 15 (5): 427–44 [2022-01-14]. PMID 17924777. doi:10.1037/1064-1297.15.5.427. （原始内容存档于2022-06-01）.
Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G. Allopregnanolone and mood disorders. Prog. Neurobiol. 2014, 113: 88–94. PMID 23978486. S2CID 207407084. doi:10.1016/j.pneurobio.2013.07.005.
Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. The Journal of Clinical Endocrinology and Metabolism. 2003-08, 88 (8): 3467–73. PMID 12915619. doi:10.1210/jc.2002-021967 .
Davey DA. Menopausal hormone therapy: a better and safer future. Climacteric. 2018-03, 21 (5): 454–461. PMID 29526116. S2CID 3850275. doi:10.1080/13697137.2018.1439915.
Raj R, Korja M, Koroknay-Pál P, Niemelä M. Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: A report of two cases and a brief literature review. Surg Neurol Int. 2018, 9: 109. PMC 5991277 . PMID 29930875. doi:10.4103/sni.sni_22_18.
Nota NM, Wiepjes CM, de Blok CJ, Gooren LJ, Peerdeman SM, Kreukels BP, den Heijer M. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018-07, 141 (7): 2047–2054. PMID 29688280. S2CID 19934721. doi:10.1093/brain/awy108 .
Kuhl H, Schneider HP. Progesterone--promoter or inhibitor of breast cancer. Climacteric. 2013-08,. 16 Suppl 1: 54–68. PMID 23336704. S2CID 20808536. doi:10.3109/13697137.2013.768806.
de Ziegler D, Fanchin R. Progesterone and progestins: applications in gynecology. Steroids. 2000, 65 (10–11): 671–9. PMID 11108875. S2CID 5867301. doi:10.1016/S0039-128X(00)00123-9.
Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML, Bertino JS. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J Clin Pharmacol. 2005, 45 (6): 614–9. PMID 15901742. S2CID 28399314. doi:10.1177/0091270005276621.
Tollan A, Oian P, Kjeldsen SE, Eide I, Maltau JM. Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men. Gynecol. Obstet. Invest. 1993, 36 (4): 234–8. PMID 8300009. doi:10.1159/000292636.
Unfer, Vittorio; di Renzo, Gian; Gerli, Sandro; Casini, Maria. The Use of Progesterone in Clinical Practice: Evaluation of its Efficacy in Diverse Indications Using Different Routes of Administration. Current Drug Therapy. 2006, 1 (2): 211–219. ISSN 1574-8855. doi:10.2174/157488506776930923.
Brady BM, Anderson RA, Kinniburgh D, Baird DT. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. Clin. Endocrinol. (Oxf). 2003, 58 (4): 506–12. PMID 12641635. S2CID 12567639. doi:10.1046/j.1365-2265.2003.01751.x.
Paynter MJ. Medication and Facilitation of Transgender Women's Lactation. J Hum Lact. 2019-03, 35 (2): 239–243. PMID 30840524. S2CID 73466659. doi:10.1177/0890334419829729.
Telis, Leon; Baum, Stephanie; Singer, Tomer; Berookhim, Boback M. Fertility Issues in Transgender Care. Transgender Medicine. Contemporary Endocrinology. 2019: 197–212. ISBN 978-3-030-05682-7. ISSN 2523-3785. S2CID 151135327. doi:10.1007/978-3-030-05683-4_11.
Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med. 2010-09, 7 (9): 2996–3010. PMID 20626600. doi:10.1111/j.1743-6109.2010.01902.x.
Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003-02, 61 (2 Suppl 1): 32–8. PMID 12667885. doi:10.1016/S0090-4295(02)02397-X.
Higano CS. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2012-10, 30 (30): 3720–5. PMID 23008326. doi:10.1200/JCO.2012.41.8509.
Fisher, Alessandra Daphne; Maggi, Mario. Endocrine Treatment of Transsexual Male-to-Female Persons. Management of Gender Dysphoria. 2015: 83–91. ISBN 978-88-470-5695-4. doi:10.1007/978-88-470-5696-1_10.
Radix, Asa E. Medical Transition for Transgender Individuals. Lesbian, Gay, Bisexual, and Transgender Healthcare. 2016: 351–361. ISBN 978-3-319-19751-7. doi:10.1007/978-3-319-19752-4_19.
de, Blok Christel; Klaver, Maartje; Nota, Nienke; Dekker, Marieke; den, Heijer Martin. Breast development in male-to-female transgender patients after one year cross-sex hormonal treatment. Endocrine Abstracts. 2016. ISSN 1479-6848. doi:10.1530/endoabs.41.GP146.
de Blok CJ, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, Schreiner T, T'Sjoen G, den Heijer M. Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study. J. Clin. Endocrinol. Metab. 2018-02, 103 (2): 532–538. PMID 29165635. S2CID 3716975. doi:10.1210/jc.2017-01927 .
Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. Journal of Clinical Endocrinology and Metabolism. 2000-08, 85 (8): 2913–21. PMID 10946903. doi:10.1210/jc.85.8.2913 .
Randall VA, Hibberts NA, Thornton MJ, Hamada K, Merrick AE, Kato S, Jenner TJ, De Oliveira I, Messenger AG. The hair follicle: a paradoxical androgen target organ. Horm. Res. 2000, 54 (5–6): 243–50. PMID 11595812. S2CID 42826314. doi:10.1159/000053266.
Kiely PM, Carney LG, Smith G. Menstrual cycle variations of corneal topography and thickness (PDF). American Journal of Optometry and Physiological Optics. 1983-10, 60 (10): 822–9 [2022-01-14]. PMID 6650653. S2CID 43222063. doi:10.1097/00006324-198310000-00003. （原始内容 (PDF)存档于2022-03-17）.
Gurwood AS, Gurwood I, Gubman DT, Brzezicki LJ. Idiosyncratic ocular symptoms associated with the estradiol transdermal estrogen replacement patch system. Optometry and Vision Science. 1995-01, 72 (1): 29–33. PMID 7731653. doi:10.1097/00006324-199501000-00006.
Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. The Journal of Clinical Endocrinology and Metabolism. 2000-12, 85 (12): 4874–82. PMID 11134156. doi:10.1210/jcem.85.12.7072 .
Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Annals of the New York Academy of Sciences. 2002-06, 966 (1): 211–22. Bibcode:2002NYASA.966..211S. PMID 12114274. S2CID 22281698. doi:10.1111/j.1749-6632.2002.tb04217.x.
Sullivan BD, Evans JE. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. Archives of Ophthalmology. 2002-12, 120 (12): 1689–1699. PMID 12470144. doi:10.1001/archopht.120.12.1689 .
Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?. Cornea. 2003-08, 22 (6): 516–21. PMID 12883343. S2CID 29374194. doi:10.1097/00003226-200308000-00006.
Oprea L, Tiberghien A, Creuzot-Garcher C, Baudouin C. Influence des hormones sur le film lacrymal [Hormonal regulatory influence in tear film]. Journal Français d'Ophtalmologie. 2004-10, 27 (8): 933–41. PMID 15547478. doi:10.1016/S0181-5512(04)96241-9 （法语）.
van der Loos, Maria Atc; Hellinga, Ilse; Vlot, Mariska C.; Klink, Daniel T.; den Heijer, Martin; Wiepjes, Chantal M. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. 2021-05, 36 (5) [2023-12-04]. ISSN 1523-4681. PMC 8247856 . PMID 33507568. doi:10.1002/jbmr.4262. （原始内容存档于2023-03-29）.
Nguyen, Hillary B.; Chavez, Alexis M.; Lipner, Emily; Hantsoo, Liisa; Kornfield, Sara L.; Davies, Robert D.; Epperson, C. Neill. Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition. Current Psychiatry Reports. 2018, 20 (12): 110. ISSN 1523-3812. PMC 6354936 . PMID 30306351. doi:10.1007/s11920-018-0973-0.
Garcia, Maurice; Zaliznyak, Michael. Mp45-20 Effects of Feminizing Hormone Therapy on Sexual Function of Transgender Women. The Journal of Urology. 2020, 203 (Supplement 4): e672. S2CID 218946871. doi:10.1097/JU.0000000000000900.020.
Klein C., Gorzalka B.B. Sexual functioning in transsexuals following hormone therapy and genital surgery: A review. Journal of Sexual Medicine. 2009, 6 (11): 2922–2939. PMID 20092545. doi:10.1111/j.1743-6109.2009.01370.x.
Smith, Elke Stefanie; Junger, Jessica; Derntl, Birgit; Habel, Ute. The transsexual brain – A review of findings on the neural basis of transsexualism. Neuroscience & Biobehavioral Reviews. 2015, 59: 251–266. ISSN 0149-7634. PMID 26429593. S2CID 23913935. doi:10.1016/j.neubiorev.2015.09.008.
Guillamon, Antonio; Junque, Carme; Gómez-Gil, Esther. A Review of the Status of Brain Structure Research in Transsexualism. Archives of Sexual Behavior. 2016, 45 (7): 1615–1648. ISSN 0004-0002. PMC 4987404 . PMID 27255307. doi:10.1007/s10508-016-0768-5.
Mueller, Sven C.; De Cuypere, Griet; T’Sjoen, Guy. Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective. American Journal of Psychiatry. 2017, 174 (12): 1155–1162 [2022-01-14]. ISSN 0002-953X. PMID 29050504. doi:10.1176/appi.ajp.2017.17060626. hdl:1854/LU-8542009. （原始内容存档于2022-04-21）.
Nguyen HB, Loughead J, Lipner E, Hantsoo L, Kornfield SL, Epperson CN. What has sex got to do with it? The role of hormones in the transgender brain. Neuropsychopharmacology. 2019-01, 44 (1): 22–37. PMC 6235900 . PMID 30082887. doi:10.1038/s41386-018-0140-7.
Kilpatrick, Lisa A.; Holmberg, Mats; Manzouri, Amirhosein; Savic, Ivanka. Cross sex hormone treatment is linked with a reversal of cerebral patterns associated with gender dysphoria to the baseline of cisgender controls. European Journal of Neuroscience. 2019, 50 (8): 3269–3281. ISSN 0953-816X. PMC 7329231 . PMID 30991464. doi:10.1111/ejn.14420.
Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, Carlström K. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate. 1988, 13 (3): 257–61. PMID 3211807. S2CID 20686808. doi:10.1002/pros.2990130308.
von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R. Estrogen therapy and liver function--metabolic effects of oral and parenteral administration. Prostate. 1989, 14 (4): 389–95. PMID 2664738. S2CID 21510744. doi:10.1002/pros.2990140410.
Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metab. Clin. Exp. 1989-09, 38 (9): 869–73. PMID 2528051. doi:10.1016/0026-0495(89)90233-3.
Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur. Urol. 1990, 17 (2): 161–5. PMID 2178941. doi:10.1159/000464026.
Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol. 1990-03, 65 (3): 282–5. PMID 2110842. doi:10.1111/j.1464-410X.1990.tb14728.x.
Aro J. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate. 1991, 18 (2): 131–7. PMID 2006119. S2CID 27915767. doi:10.1002/pros.2990180205.
Henriksson P, Stege R. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer. Int J Technol Assess Health Care. 1991, 7 (2): 220–5. PMID 1907600. doi:10.1017/S0266462300005110.
Henriksson P. Estrogen in patients with prostatic cancer. An assessment of the risks and benefits. Drug Saf. 1991, 6 (1): 47–53. PMID 2029353. S2CID 39861824. doi:10.2165/00002018-199106010-00005.
Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb. Haemost. 1992-10, 68 (4): 392–5. PMID 1333098. doi:10.1055/s-0038-1646283.
Henriksson P, Carlström K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, Altersgård-Brorsson AK, Nordle O, Stege R. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate. 1999-07, 40 (2): 76–82. PMID 10386467. doi:10.1002/(SICI)1097-0045(19990701)40:2<76::AID-PROS2>3.0.CO;2-Q.
Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology. 2000-03, 55 (3): 328–33. PMID 10699602. doi:10.1016/S0090-4295(99)00580-4.
Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand. J. Urol. Nephrol. 2002, 36 (6): 405–13. PMID 12623503. S2CID 2799580. doi:10.1080/003655902762467549.
Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003-08, 362 (9382): 428–32. PMID 12927428. S2CID 45789951. doi:10.1016/S0140-6736(03)14066-4.
Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005-11, 112 (22): 3495–500. PMID 16301339. S2CID 13587974. doi:10.1161/CIRCULATIONAHA.105.565556 .
Basurto L, Saucedo R, Zárate A, Martínez C, Gaminio E, Reyes E, Hernandez M. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Gynecol. Obstet. Invest. 2006, 61 (2): 61–4. PMID 16192735. S2CID 38375159. doi:10.1159/000088603.
Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2006-07, 26 (7): 1660–6. PMID 16645152. S2CID 12778600. doi:10.1161/01.ATV.0000224325.96659.53 .
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand. J. Urol. Nephrol. 2008, 42 (3): 220–9. PMID 18432528. S2CID 38638336. doi:10.1080/00365590801943274.
Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008-05, 336 (7655): 1227–31. PMC 2405857 . PMID 18495631. doi:10.1136/bmj.39555.441944.BE.
Rosendale N, Goldman S, Ortiz GM, Haber LA. Acute Clinical Care for Transgender Patients: A Review. JAMA Intern Med. 2018-11, 178 (11): 1535–1543. PMID 30178031. S2CID 52146607. doi:10.1001/jamainternmed.2018.4179.
Speed V, Roberts LN, Patel JP, Arya R. Venous thromboembolism and women's health. Br. J. Haematol. 2018-11, 183 (3): 346–363. PMID 30334572. S2CID 52985304. doi:10.1111/bjh.15608 .
Khan J, Schmidt RL, Spittal MJ, Goldstein Z, Smock KJ, Greene DN. Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis. Clin. Chem. 2019-01, 65 (1): 57–66. PMID 30602475. doi:10.1373/clinchem.2018.288316 .
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015-08, 12 (8): 464–74. PMC 4624298 . PMID 26076949. doi:10.1038/nrcardio.2015.83.
Houlberg, Magda. Endocrinology, Hormone Replacement Therapy (HRT), and Aging. Transgender and Gender Nonconforming Health and Aging. 2019: 21–35. ISBN 978-3-319-95030-3. S2CID 81674566. doi:10.1007/978-3-319-95031-0_2.
Arnold JD, Sarkodie EP, Coleman ME, Goldstein DA. Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol. J Sex Med. 2016-11, 13 (11): 1773–1777. PMID 27671969. doi:10.1016/j.jsxm.2016.09.001.
Streed CG, Harfouch O, Marvel F, Blumenthal RS, Martin SS, Mukherjee M. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann. Intern. Med. 2017-08, 167 (4): 256–267. PMID 28738421. S2CID 207538881. doi:10.7326/M17-0577.
Eismann J, Heng YJ, Fleischmann-Rose K, Tobias AM, Phillips J, Wulf GM, Kansal KJ. Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature. Clin. Breast Cancer. 2019-02, 19 (1): e12–e19. PMC 7083129 . PMID 30527351. doi:10.1016/j.clbc.2018.11.007.
Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013-12, 10 (12): 3129–34. PMID 24010586. doi:10.1111/jsm.12319.
Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res. Treat. 2015-01, 149 (1): 191–8. PMID 25428790. S2CID 10935304. doi:10.1007/s10549-014-3213-2.
de Blok, Christel J M; Wiepjes, Chantal M; Nota, Nienke M; van Engelen, Klaartje; Adank, Muriel A; Dreijerink, Koen M A; Barbé, Ellis; Konings, Inge R H M; den Heijer, Martin. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019, 365: l1652. ISSN 0959-8138. PMC 6515308 . PMID 31088823. doi:10.1136/bmj.l1652.
Iwamoto, Sean J.; Defreyne, Justine; Rothman, Micol S.; Van Schuylenbergh, Judith; Van de Bruaene, Laurens; Motmans, Joz; T’Sjoen, Guy. Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism. 2019, 10: 204201881987116. ISSN 2042-0188. PMC 6719479 . PMID 31516689. doi:10.1177/2042018819871166.
Hartley RL, Stone JP, Temple-Oberle C. Breast cancer in transgender patients: A systematic review. Part 1: Male to female. Eur J Surg Oncol. 2018-10, 44 (10): 1455–1462. PMID 30087072. S2CID 51936024. doi:10.1016/j.ejso.2018.06.035.
Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B. Gynecomastia: Clinical evaluation and management. Indian J Endocrinol Metab. 2014, 18 (2): 150–8. PMC 3987263 . PMID 24741509. doi:10.4103/2230-8210.129104.
Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ. 2008, 336 (7646): 709–13. PMC 2276281 . PMID 18369226. doi:10.1136/bmj.39511.493391.BE.
Hughes IA, Werner R, Bunch T, Hiort O. Androgen insensitivity syndrome. Semin. Reprod. Med. 2012, 30 (5): 432–42. PMID 23044881. doi:10.1055/s-0032-1324728. ^{[失效連結]}
Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008, 9 (3): 239–46. PMID 18282803. doi:10.1016/S1470-2045(08)70033-0.
Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014, 46 (10): 1156–60. PMID 24329588. S2CID 1445627. doi:10.1111/and.12208.
Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013, 7 (7–8): E544–6. PMC 3758950 . PMID 24032068. doi:10.5489/cuaj.175.
McFarlane T, Zajac JD, Cheung AS. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review. Clin. Endocrinol. (Oxf). 2018-12, 89 (6): 700–711. PMID 30107028. S2CID 52003943. doi:10.1111/cen.13835 .
McFarlane, Thomas; Zajac, Jeffrey D.; Cheung, Ada S. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review. Clinical Endocrinology. 2018, 89 (6): 700–711. ISSN 0300-0664. PMID 30107028. S2CID 52003943. doi:10.1111/cen.13835 .
Nota, Nienke M; Wiepjes, Chantal M; de Blok, Christel J M; Gooren, Louis J G; Peerdeman, Saskia M; Kreukels, Baudewijntje P C; den Heijer, Martin. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018, 141 (7): 2047–2054. ISSN 0006-8950. PMID 29688280. S2CID 19934721. doi:10.1093/brain/awy108 .
Mahfouda, Simone; Moore, Julia K; Siafarikas, Aris; Hewitt, Timothy; Ganti, Uma; Lin, Ashleigh; Zepf, Florian Daniel. Gender-affirming hormones and surgery in transgender children and adolescents. The Lancet Diabetes & Endocrinology. 2019, 7 (6): 484–498. ISSN 2213-8587. PMID 30528161. S2CID 54478571. doi:10.1016/S2213-8587(18)30305-X.
Bisson, Jason R.; Chan, Kelly J.; Safer, Joshua D. Prolactin levels do not rise among transgender women treated with estradiol and spironolactone. Endocrine Practice. 2018, 24 (7): 646–651. ISSN 1530-891X. PMID 29708436. S2CID 14022275. doi:10.4158/EP-2018-0101.
Hamburger C, Sturup GK, Dahl-Iversen E. Transvestism; hormonal, psychiatric, and surgical treatment. J Am Med Assoc. 1953-05, 152 (5): 391–6. PMID 13044539. doi:10.1001/jama.1953.03690050015006.
Bullough VL. Transsexualism in history. Arch Sex Behav. 1975-09, 4 (5): 561–71. PMID 1103789. S2CID 36577490. doi:10.1007/bf01542134.
Gooren, Louis; Asscheman, Henk. Sex Reassignment: Endocrinological Interventions in Adults with Gender Dysphoria. Gender Dysphoria and Disorders of Sex Development. Focus on Sexuality Research. 2014: 277–297. ISBN 978-1-4614-7440-1. ISSN 2195-2264. doi:10.1007/978-1-4614-7441-8_14.
Benjamin H. Clinical aspects of transsexualism in the male and female. Am J Psychother. 1964-07, 18 (3): 458–69. PMID 14173773. doi:10.1176/appi.psychotherapy.1964.18.3.458.
Benjamin, Harry. Transvestism and Transsexualism in the male and female1. Journal of Sex Research. 1967, 3 (2): 107–127. ISSN 0022-4499. doi:10.1080/00224496709550519.
Schaefer LC, Wheeler CC. Harry Benjamin's first ten cases (1938-1953): a clinical historical note. Arch Sex Behav. 1995-02, 24 (1): 73–93. PMID 7733806. S2CID 31571764. doi:10.1007/bf01541990.
Edgerton MT, Knorr NJ, Callison JR. The surgical treatment of transsexual patients. Limitations and indications. Plast. Reconstr. Surg. 1970-01, 45 (1): 38–46. PMID 4902840. S2CID 27318408. doi:10.1097/00006534-197001000-00006.
Ekins, Richard. Science, Politics and Clinical Intervention: Harry Benjamin, Transsexualism and the Problem of Heteronormativity. Sexualities. 2016, 8 (3): 306–328. ISSN 1363-4607. S2CID 143544267. doi:10.1177/1363460705049578.
Meyer, Walter J.; Walker, Paul A.; Suplee, Zelda R. A survey of transsexual hormonal treatment in twenty gender‐treatment centers. The Journal of Sex Research. 1981, 17 (4): 344–349. ISSN 0022-4499. doi:10.1080/00224498109551125.
Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, Tangpricha V, Montori VM. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2009-09, 94 (9): 3132–54. PMID 19509099. doi:10.1210/jc.2009-0345 .
Moore, Eva; Wisniewski, Amy; Dobs, Adrian. Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects. The Journal of Clinical Endocrinology & Metabolism. 2003, 88 (8): 3467–3473. ISSN 0021-972X. PMID 12915619. doi:10.1210/jc.2002-021967 .
Steinbeck, A. W. Of Homosexuality: The Current State of Knowledge. Journal of Christian Education. 1977, os–20 (2): 58–82. ISSN 0021-9657. S2CID 149168765. doi:10.1177/002196577702000204.
Zingg, E.; König, M.; Cornu, F.; Wildholz, A.; Blaser, A. Transsexualismus: Erfahrungen mit der operativen Korrektur bei männlichen Transsexuellen [Transsexualism: Experience with surgical correction in male transsexuals]. Aktuelle Urologie. 1980, 11 (2): 67–77. ISSN 0001-7868. doi:10.1055/s-2008-1062961.
Dahl, Marshall; Feldman, Jamie L.; Goldberg, Joshua M.; Jaberi, Afshin. Physical Aspects of Transgender Endocrine Therapy. International Journal of Transgenderism. 2006, 9 (3–4): 111–134. ISSN 1553-2739. S2CID 146232471. doi:10.1300/J485v09n03_06.
Gooren LJ, van der Veen EA, van Kessel H, Harmsen-Louman W, Wiegel AR. Androgens in the feedback regulation of gonadotropin secretion in men: effects of administration of dihydrotestosterone to eugonadal and agonadal subjects and of spironolactone to eugonadal subjects. Andrologia. 1984, 16 (4): 289–98. PMID 6433746. S2CID 32546312. doi:10.1111/j.1439-0272.1984.tb00286.x.

doncasterccg.nhs.uk (Global: low place; Chinese: low place)

medicinesmanagement.doncasterccg.nhs.uk

Barnsley, Rotherham; Sheffield Clinical Commissioning Groups. Prescribing Guidelines: Trans woman medication (PDF) (报告). NHS. 12 October 2017 [2022-01-15]. （原始内容 (PDF)存档于2021-09-20）.

elibrary.ru (Global: 1,940^th place; Chinese: low place)

Kozlov GI, Mel'nichenko GA, Golubeva IV. Sluchai laktorei u bol'nogo muzhskogo pola s transseksualizmom [Case of galactorrhea in a transsexual male patient]. Probl Endokrinol (Mosk). 1985, 31 (1): 37–8 [2022-01-14]. ISSN 0375-9660. PMID 4039061. （原始内容存档于2022-04-21）（俄语）. [...]进行了外生殖器去势和女性化整形手术[...]手术后一段时间，患者对生活重新产生了兴趣。经过手术和荷尔蒙矫正后，患者不可抗拒地发展出母性本能。未婚，患者获准领养孩子，模拟怀孕，带着儿子从妇产医院出院。从“出生”后的第一天开始，溢乳急剧增加，出现自发流出乳汁，伴溢乳（+++）。婴儿一直母乳喂养到6个月大。[...]我们的信息是文献中第二例有关男性易性症患者溢乳的描述。R.[Flückiger]等人于1983年首次描述了这种类型(6)。这一观察结果证明了泌乳发育机制与一个人的遗传性别相独立，并且对男性发生药物性溢乳的可能性感到担忧。（[...] castration and feminizing plastic surgery of the external genitalia was performed [...] Some time after the operation, the patient developed a renewed interest in life. After the surgical and hormonal correction, the patient irresistibly developed maternal instincts. Unmarried, the patient obtained permission for the adoption of a child, simulated pregnancy, and was discharged from the maternity hospital with a son. From the first days after the “birth”, galactorrhea sharply increased, and spontaneous outflow of milk appeared, with galactorrhea (+++). The baby was breastfed up to 6 months of age. [...] Our message is the second in the world literature describing galactorrhea in a male patient with transsexualism. The first description of this kind was made in 1983 by R. [Flückiger] et al. (6). This observation demonstrates the independence of the mechanism of lactation development from one’s genetic sex and is alarming with regard to the possibility of drug-induced galactorrhea development in men.）

europeanreview.org (Global: low place; Chinese: low place)

Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A. Flutamide-induced hepatotoxicity: ethical and scientific issues (PDF). Eur Rev Med Pharmacol Sci. 2017-03, 21 (1 Suppl): 69–77 [2022-01-14]. PMID 28379593. （原始内容 (PDF)存档于2020-11-12）.

fda.gov (Global: 447^th place; Chinese: 581^st place)

accessdata.fda.gov

Orilissa (elagolix) FDA Label (PDF). 2018-07-24 [2018-07-31]. （原始内容 (PDF)存档于2021-10-21）.

fda.gov

Chang, Stephen, Bicalutamide BPCA Drug Use Review in the Pediatric Population (PDF), U.S. Department of Health and Human Service, 2010-03-10 [2016-07-20], （原始内容存档 (PDF)于2016-10-24）

fenwayhealth.org (Global: low place; Chinese: low place)

Cavanaugh, Timothy. Cross-Sex Hormone Therapy (PDF) (报告). Fenway Institute. [9 May 2019]. （原始内容 (PDF)存档于2022-05-16）.

gires.org.uk (Global: low place; Chinese: low place)

存档副本 (PDF). [2022-01-15]. （原始内容 (PDF)存档于2022-05-16）.

handle.net (Global: 102^nd place; Chinese: 492^nd place)

hdl.handle.net

Mueller, Sven C.; De Cuypere, Griet; T’Sjoen, Guy. Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective. American Journal of Psychiatry. 2017, 174 (12): 1155–1162 [2022-01-14]. ISSN 0002-953X. PMID 29050504. doi:10.1176/appi.ajp.2017.17060626. hdl:1854/LU-8542009. （原始内容存档于2022-04-21）.

harvard.edu (Global: 18^th place; Chinese: 57^th place)

ui.adsabs.harvard.edu

Schneider HP. Androgens and antiandrogens. Ann. N. Y. Acad. Sci. 2003-11, 997 (1): 292–306. Bibcode:2003NYASA.997..292S. PMID 14644837. S2CID 8400556. doi:10.1196/annals.1290.033.
Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Annals of the New York Academy of Sciences. 2002-06, 966 (1): 211–22. Bibcode:2002NYASA.966..211S. PMID 12114274. S2CID 22281698. doi:10.1111/j.1749-6632.2002.tb04217.x.

hormonebalance.org (Global: low place; Chinese: low place)

Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2022-01-07]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始内容 (PDF)存档于2016-08-22）.
Dimitrakakis C. Androgens and breast cancer in men and women (PDF). Endocrinol. Metab. Clin. North Am. 2011-09, 40 (3): 533–47, viii [2022-01-14]. PMID 21889719. doi:10.1016/j.ecl.2011.05.007. （原始内容 (PDF)存档于2022-04-21）.

independent.co.uk (Global: 36^th place; Chinese: 153^rd place)

Newman, Rosalind; Jeory, Ted. Fears of 'DIY transitioning' as hormone drugs sold to transgender women without checks. The Independent. 2016-11-16 [2018-12-29]. （原始内容存档于2021-04-14）.

internetmedicin.se (Global: low place; Chinese: low place)

Arver DS. Transsexualism, könsdysfori. 2015 [2018-11-12]. （原始内容存档于2019-03-29）.

ippf.org (Global: low place; Chinese: low place)

IMAP Statement on hormone therapy for transgender people (PDF) (报告). International Planned Parenthood Federation. October 2015 [2022-01-15]. （原始内容 (PDF)存档于2021-12-06）.

jaapl.org (Global: 8,749^th place; Chinese: low place)

Kravitz HM, Haywood TW, Kelly J, Liles S, Cavanaugh JL. Medroxyprogesterone and paraphiles: do testosterone levels matter?. Bull Am Acad Psychiatry Law. 1996, 24 (1): 73–83 [2022-01-14]. PMID 8891323. （原始内容存档于2018-08-16）.

karger.com (Global: 4,489^th place; Chinese: 2,957^th place)

Neyman, A; Fuqua, JS; Eugster, EA. Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents. Hormone Research in Paediatrics. 2017-12, 88: 1–628 [2022-01-14]. PMID 28968603. doi:10.1159/000481424 . （原始内容存档于2022-04-21）.

kup.at (Global: low place; Chinese: low place)

Nieschlag E. Clinical trials in male hormonal contraception (PDF). Contraception. 2010-11, 82 (5): 457–70 [2022-01-14]. PMID 20933120. doi:10.1016/j.contraception.2010.03.020. （原始内容 (PDF)存档于2020-12-05）.
Kuhl H. Pharmacology of Progestogens (PDF). Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 2011, 8 (1): 157–177 [2022-01-14]. （原始内容 (PDF)存档于2016-10-11）.

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Wesp LM, Deutsch MB. Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons. Psychiatr. Clin. North Am. 2017-03, 40 (1): 99–111. PMID 28159148. doi:10.1016/j.psc.2016.10.006.
Murad, Mohammad Hassan; Elamin, Mohamed B.; Garcia, Magaly Zumaeta; Mullan, Rebecca J.; Murad, Ayman; Erwin, Patricia J.; Montori, Victor M. Hormonal therapy and sex reassignment: A systematic review and meta-analysis of quality of life and psychosocial outcomes. Clinical Endocrinology. 2010, 72 (2): 214–231. PMID 19473181. S2CID 19590739. doi:10.1111/j.1365-2265.2009.03625.x.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Wesp LM, Deutsch MB. Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons. Psychiatr. Clin. North Am. 2017-03, 40 (1): 99–111. PMID 28159148. doi:10.1016/j.psc.2016.10.006.
Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016-12, 5 (6): 877–884. PMC 5182227 . PMID 28078219. doi:10.21037/tau.2016.09.04.
Randolph JF. Gender-Affirming Hormone Therapy for Transgender Females. Clin Obstet Gynecol. 2018-12, 61 (4): 705–721. PMID 30256230. doi:10.1097/GRF.0000000000000396.
Nakatsuka M. Endocrine treatment of transsexuals: assessment of cardiovascular risk factors. Expert Rev Endocrinol Metab. 2010-05, 5 (3): 319–322. PMID 30861686. S2CID 73253356. doi:10.1586/eem.10.18.
Gooren LJ. Clinical practice. Care of transsexual persons. N. Engl. J. Med. 2011-03, 364 (13): 1251–7. PMID 21449788. doi:10.1056/NEJMcp1008161.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017-04, 5 (4): 291–300. PMC 5366074 . PMID 27916515. doi:10.1016/S2213-8587(16)30319-9.
Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J. Clin. Endocrinol. Metab. 2008-01, 93 (1): 19–25. PMID 17986639. doi:10.1210/jc.2007-1809.
Meriggiola MC, Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin. Endocrinol. (Oxf). 2015-11, 83 (5): 607–15. PMID 25692882. S2CID 39706760. doi:10.1111/cen.12754.
Costa EM, Mendonca BB. Clinical management of transsexual subjects. Arq Bras Endocrinol Metabol. 2014-03, 58 (2): 188–96. PMID 24830596. doi:10.1590/0004-2730000003091.
Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. The Journal of Clinical Endocrinology and Metabolism. 2003-08, 88 (8): 3467–73. PMID 12915619. doi:10.1210/jc.2002-021967.
Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations. J. Clin. Endocrinol. Metab. 2014-12, 99 (12): 4379–89. PMID 25140398. doi:10.1210/jc.2014-1919.
Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance. Ann. Endocrinol. (Paris). 2016-02, 77 (1): 14–21. PMID 26830952. doi:10.1016/j.ando.2015.12.001.
Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Lim HH, Jang YH, Choi GY, Lee JJ, Lee ES. Gender affirmative care of transgender people: a single center's experience in Korea. Obstet Gynecol Sci. 2019-01, 62 (1): 46–55. PMC 6333764 . PMID 30671393. doi:10.5468/ogs.2019.62.1.46. When we prescribed estradiol, we preferred sublingual estradiol valerate instead of the oral form for feminizing HT since prior researchers have reported the effectiveness of sublingual administration in maintaining high blood estradiol concentration and low E1/E2 ratio [13].
Majumder, Anirban; Chatterjee, Sudip; Maji, Debasis; Roychaudhuri, Soumyabrata; Ghosh, Sujoy; Selvan, Chitra; George, Belinda; Kalra, Pramila; Maisnam, Indira; Sanyal, Debmalya. IDEA group consensus statement on medical management of adult gender incongruent individuals seeking gender reaffirmation as female. Indian Journal of Endocrinology and Metabolism. 2020, 24 (2): 128. ISSN 2230-8210. PMID 32699777. S2CID 218596936. doi:10.4103/ijem.IJEM_593_19.
Reisman T, Goldstein Z. Case Report: Induced Lactation in a Transgender Woman. Transgend Health. 2018, 3 (1): 24–26. PMC 5779241 . PMID 29372185. doi:10.1089/trgh.2017.0044.
Henderson A. Domperidone. Discovering new choices for lactating mothers. Awhonn Lifelines. 2003, 7 (1): 54–60. PMID 12674062. doi:10.1177/1091592303251726.
Stege R, Gunnarsson PO, Johansson CJ, Olsson P, Pousette A, Carlström K. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients. Prostate. 1996, 28 (5): 307–10. PMID 8610057. doi:10.1002/(SICI)1097-0045(199605)28:5<307::AID-PROS6>3.0.CO;2-8.
Leinung MC, Feustel PJ, Joseph J. Hormonal Treatment of Transgender Women with Oral Estradiol. Transgend Health. 2018, 3 (1): 74–81. PMC 5944393 . PMID 29756046. doi:10.1089/trgh.2017.0035.
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2022-01-07]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始内容 (PDF)存档于2016-08-22）.
Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016-12, 5 (6): 877–884. PMC 5182227 . PMID 28078219. doi:10.21037/tau.2016.09.04.
Lauritzen C. Clinical use of oestrogens and progestogens. Maturitas. 1990-09, 12 (3): 199–214. PMID 2215269. doi:10.1016/0378-5122(90)90004-P.
Lauritzen C. Die Behandlung der klimakterischen Beschwerden durch vaginale, rektale und transdermale Ostrogensubstitution [Treatment of disorders of the climacteric by vaginal, rectal and transdermal estrogen substitution]. Gynakologe. 1986-12, 19 (4): 248–53. ISSN 0017-5994. PMID 3817597 （德语）.
Irwig MS. Cardiovascular health in transgender people. Rev Endocr Metab Disord. 2018-09, 19 (3): 243–251. PMID 30073551. S2CID 51908458. doi:10.1007/s11154-018-9454-3.
Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, Hunkeler E, Lash TL, Millman A, Quinn VP, Robinson B, Roblin D, Silverberg MJ, Safer J, Slovis J, Tangpricha V, Goodman M. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Ann. Intern. Med. 2018-08, 169 (4): 205–213. PMC 6636681 . PMID 29987313. doi:10.7326/M17-2785.
Ockrim J, Lalani EN, Abel P. Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nat Clin Pract Oncol. 2006-10, 3 (10): 552–63. PMID 17019433. S2CID 6847203. doi:10.1038/ncponc0602.
Lycette JL, Bland LB, Garzotto M, Beer TM. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?. Clin Genitourin Cancer. 2006-12, 5 (3): 198–205. PMID 17239273. doi:10.3816/CGC.2006.n.037.
Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017-04, 5 (4): 291–300. PMC 5366074 . PMID 27916515. doi:10.1016/S2213-8587(16)30319-9.
Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A. Single drug polyestradiol phosphate therapy in prostatic cancer. Am. J. Clin. Oncol. 1988,. 11 Suppl 2: S101–3. PMID 3242384. S2CID 32650111. doi:10.1097/00000421-198801102-00024.
Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer--forward to the past?. J. Urol. 2003-05, 169 (5): 1735–7. PMID 12686820. doi:10.1097/01.ju.0000061024.75334.40.
Liang JJ, Jolly D, Chan KJ, Safer JD. Testosterone Levels Achieved by Medically Treated Transgender Women in a United States Endocrinology Clinic Cohort. Endocr Pract. 2018-02, 24 (2): 135–142. PMID 29144822. doi:10.4158/EP-2017-0116.
Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J. Clin. Endocrinol. Metab. 2008-01, 93 (1): 19–25. PMID 17986639. doi:10.1210/jc.2007-1809 .
Haupt, Claudia; Henke, Miriam; Kutschmar, Alexia; Hauser, Birgit; Baldinger, Sandra; Schreiber, Gerhard. Antiandrogens or estradiol treatments or both during hormone replacement therapy in transitioning transgender women. Cochrane Database of Systematic Reviews. 2018, 2018 (10): CD013138. ISSN 1465-1858. PMC 6517060 . doi:10.1002/14651858.CD013138.
Vermeulen A. Longacting steroid preparations. Acta Clin Belg. 1975, 30 (1): 48–55. PMID 1231448. doi:10.1080/17843286.1975.11716973.
Rauramo L, Punnonen R, Kaihola LH, Grönroos M. Serum oestrone, oestradiol and oestriol concentrations in castrated women during intramuscular oestradiol valerate and oestradiolbenzoate-oestradiolphenylpropionate therapy. Maturitas. 1980-01, 2 (1): 53–8. PMID 7402086. doi:10.1016/0378-5122(80)90060-2.
Lieberman R. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology. 2001, 58 (2 Suppl 1): 83–90. PMID 11502457. doi:10.1016/s0090-4295(01)01247-x. There are several classes of antiandrogens including (1) antigonadotropins (eg, LHRH agonists/antagonists, synthetic estrogens [diethylstilbestrol]); (2) nonsteroidal androgen-receptor antagonists (eg, flutamide, bicalutamide, nilutamide); (3) steroidal agents with mixed actions (eg, cyproterone acetate); (4) adrenal androgen inhibitors (eg, ketoconazole, hydrocortisone); (5) steroidal agents that inhibit androgen biosynthesis (eg, 5α-reductase inhibitors (type II) and dual-acting 5α-reductase inhibitors); [...]
Dimitrakakis C. Androgens and breast cancer in men and women (PDF). Endocrinol. Metab. Clin. North Am. 2011-09, 40 (3): 533–47, viii [2022-01-14]. PMID 21889719. doi:10.1016/j.ecl.2011.05.007. （原始内容 (PDF)存档于2022-04-21）.
Schneider HP. Androgens and antiandrogens. Ann. N. Y. Acad. Sci. 2003-11, 997 (1): 292–306. Bibcode:2003NYASA.997..292S. PMID 14644837. S2CID 8400556. doi:10.1196/annals.1290.033.
Tiefenbacher K, Daxenbichler G. The Role of Androgens in Normal and Malignant Breast Tissue. Breast Care (Basel). 2008, 3 (5): 325–331. PMC 2931104 . PMID 20824027. doi:10.1159/000158055.
Gibson DA, Saunders PK, McEwan IJ. Androgens and androgen receptor: Above and beyond. Mol. Cell. Endocrinol. 2018-04, 465: 1–3. PMID 29481861. S2CID 3702165. doi:10.1016/j.mce.2018.02.013.
de Lignières B, Silberstein S. Pharmacodynamics of oestrogens and progestogens. Cephalalgia. 2000-04, 20 (3): 200–7. PMID 10997774. S2CID 40392817. doi:10.1046/j.1468-2982.2000.00042.x.
Neumann F. The physiological action of progesterone and the pharmacological effects of progestogens--a short review. Postgraduate Medical Journal. 1978,. 54 Suppl 2: 11–24. PMID 368741.
Schmidt TH, Shinkai K. Evidence-based approach to cutaneous hyperandrogenism in women. J. Am. Acad. Dermatol. 2015-10, 73 (4): 672–90. PMID 26138647. doi:10.1016/j.jaad.2015.05.026.
Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem. 2000, 7 (2): 211–47. PMID 10637363. doi:10.2174/0929867003375371.
Angus L, Leemaqz S, Ooi O, Cundill P, Silberstein N, Locke P, Zajac JD, Cheung AS. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocr Connect. 2019-07, 8 (7): 935–940. PMC 6612061 . PMID 31234145. doi:10.1530/EC-19-0272.
Kolkhof P, Bärfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 2017-07, 234 (1): T125–T140. PMC 5488394 . PMID 28634268. doi:10.1530/JOE-16-0600.
McMullen GR, Van Herle AJ. Hirsutism and the effectiveness of spironolactone in its management. J. Endocrinol. Invest. 1993-12, 16 (11): 925–32. PMID 8144871. S2CID 42231952. doi:10.1007/BF03348960.
Loriaux, D. Lynn. Spironolactone and endocrine dysfunction. Annals of Internal Medicine. 1976-11, 85 (5): 630–6. PMID 984618. doi:10.7326/0003-4819-85-5-630.
Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993, 13 (1): 37–45. PMID 8094898. doi:10.1002/j.1875-9114.1993.tb02688.x (不活跃 2021-10-31).
Shaw JC. Spironolactone in dermatologic therapy. J. Am. Acad. Dermatol. 1991-02, 24 (2 Pt 1): 236–43. PMID 1826112. doi:10.1016/0190-9622(91)70034-Y.
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. Am J Clin Dermatol. 2017, 18 (2): 169–191. PMC 5360829 . PMID 28155090. doi:10.1007/s40257-016-0245-x.
Doggrell SA, Brown L. The spironolactone renaissance. Expert Opin Investig Drugs. 2001-05, 10 (5): 943–54. PMID 11322868. S2CID 39820875. doi:10.1517/13543784.10.5.943.
Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J. Urol. 1986-09, 136 (3): 624–31. PMID 2942707. doi:10.1016/S0022-5347(17)44996-2.
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int. J. Cardiol. 2015, 200: 25–9. PMID 26404748. doi:10.1016/j.ijcard.2015.05.127.
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004, 351 (6): 543–51. PMID 15295047. doi:10.1056/NEJMoa040135.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 2016, 74 (5): 945–73.e33. PMID 26897386. doi:10.1016/j.jaad.2015.12.037 .
Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol. 2015, 151 (9): 941–4. PMID 25796182. doi:10.1001/jamadermatol.2015.34 .
Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp. Clin. Endocrinol. 1994, 102 (1): 1–32. PMID 8005205. doi:10.1055/s-0029-1211261.
Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003, 63 (5): 463–92. PMID 12600226. S2CID 28436828. doi:10.2165/00003495-200363050-00003.
Koch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, Lübke K, Mehring M, Römmler A, Schwartz U, Hammerstein J. Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers. Contraception. 1976, 14 (2): 117–35. PMID 949890. doi:10.1016/0010-7824(76)90081-0.
Wang C, Yeung KK. Use of low-dosage oral cyproterone acetate as a male contraceptive. Contraception. 1980, 21 (3): 245–72. PMID 6771091. doi:10.1016/0010-7824(80)90005-0.
Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Contraception. 1980-04, 21 (4): 393–413. PMID 6771095. doi:10.1016/s0010-7824(80)80017-5.
Knuth UA, Hano R, Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J. Clin. Endocrinol. Metab. 1984, 59 (5): 963–9. PMID 6237116. doi:10.1210/jcem-59-5-963.
Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol. 1980, 52 (3): 208–15. PMID 7000222. doi:10.1111/j.1464-410x.1980.tb02961.x.
Meyer G, Mayer M, Mondorf A, Fluegel AK, Herrmann E, Bojunga J. Safety and rapid efficacy of guideline-based gender affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. Eur. J. Endocrinol. 2019-11, 182 (2): 149–156. PMID 31751300. S2CID 208229129. doi:10.1530/EJE-19-0463.
Pucci E, Petraglia F. Treatment of androgen excess in females: yesterday, today and tomorrow. Gynecol. Endocrinol. 1997-12, 11 (6): 411–33. PMID 9476091. doi:10.3109/09513599709152569.
Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol. Int. 2004, 73 (4): 289–95. PMID 15604569. S2CID 24799765. doi:10.1159/000081585.
Kravitz HM, Haywood TW, Kelly J, Liles S, Cavanaugh JL. Medroxyprogesterone and paraphiles: do testosterone levels matter?. Bull Am Acad Psychiatry Law. 1996, 24 (1): 73–83 [2022-01-14]. PMID 8891323. （原始内容存档于2018-08-16）.
Novak E, Hendrix JW, Chen TT, Seckman CE, Royer GL, Pochi PE. Sebum production and plasma testosterone levels in man after high-dose medroxyprogesterone acetate treatment and androgen administration. Acta Endocrinol. 1980-10, 95 (2): 265–70. PMID 6449127. doi:10.1530/acta.0.0950265.
Kirschner MA, Schneider G. Suppression of the pituitary-Leydig cell axis and sebum production in normal men by medroxyprogesterone acetate (provera). Acta Endocrinol. 1972-02, 69 (2): 385–93. PMID 5066846. doi:10.1530/acta.0.0690385.
Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol. Endocrinol. 1999-03, 13 (3): 440–54. PMID 10077001. doi:10.1210/mend.13.3.0255 .
Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003-08, 68 (2): 75–87. PMID 12954518. doi:10.1016/S0010-7824(03)00136-7.
Nieschlag E. Clinical trials in male hormonal contraception (PDF). Contraception. 2010-11, 82 (5): 457–70 [2022-01-14]. PMID 20933120. doi:10.1016/j.contraception.2010.03.020. （原始内容 (PDF)存档于2020-12-05）.
Nieschlag E, Zitzmann M, Kamischke A. Use of progestins in male contraception. Steroids. 2003-11, 68 (10–13): 965–72. PMID 14667989. S2CID 22458746. doi:10.1016/S0039-128X(03)00135-1.
Wu FC, Balasubramanian R, Mulders TM, Coelingh-Bennink HJ. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J. Clin. Endocrinol. Metab. 1999-01, 84 (1): 112–22. PMID 9920070. doi:10.1210/jcem.84.1.5412 .
Kumamoto Y, Yamaguchi Y, Sato Y, Suzuki R, Tanda H, Kato S, Mori K, Matsumoto H, Maki A, Kadono M. [Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part I: Nocturnal penile tumescence monitoring]. Hinyokika Kiyo. 1990-02, 36 (2): 213–26. PMID 1693037 （日语）.
Geller J, Albert J, Geller S. Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue. The Prostate. 1982, 3 (1): 11–5. PMID 6176985. S2CID 23541558. doi:10.1002/pros.2990030103.
Sander S, Nissen-Meyer R, Aakvaag A. On gestagen treatment of advanced prostatic carcinoma. Scand. J. Urol. Nephrol. 1978, 12 (2): 119–21. PMID 694436. doi:10.3109/00365597809179977.
Melamed AJ. Current concepts in the treatment of prostate cancer. Drug Intell Clin Pharm. 1987-03, 21 (3): 247–54. PMID 3552544. S2CID 7482144. doi:10.1177/106002808702100302. [醋酸甲羟孕酮]使血浆睾酮水平暂时降低至略高于去势男性的水平。当以40 mg tid的剂量使用时，与0.5–1.5 mg/d的雌二醇联合使用，可协同抑制垂体促性腺激素，并将血浆睾酮维持在去势水平长达一年。（[Megestrol acetate] produces a transient reduction in plasma testosterone to levels somewhat higher than those in castrated men. When used in a dose of 40 mg tid, in combination with estradiol 0.5–1.5 mg/d, it acts synergistically to suppress pituitary gonadotropins and maintain plasma testosterone at castration levels for periods up to one year.）
Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A. Flutamide-induced hepatotoxicity: ethical and scientific issues (PDF). Eur Rev Med Pharmacol Sci. 2017-03, 21 (1 Suppl): 69–77 [2022-01-14]. PMID 28379593. （原始内容 (PDF)存档于2020-11-12）.
Erem C. Update on idiopathic hirsutism: diagnosis and treatment. Acta Clin Belg. 2013, 68 (4): 268–74. PMID 24455796. S2CID 39120534. doi:10.2143/ACB.3267.
Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 2018-03, 103 (3): 824–838. PMID 29211888. S2CID 3784055. doi:10.1210/jc.2017-01186 .
Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997-01, 49 (1): 71–8. PMID 9000189. doi:10.1016/S0090-4295(96)00325-1.
Neyman, A; Fuqua, JS; Eugster, EA. Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents. Hormone Research in Paediatrics. 2017-12, 88: 1–628 [2022-01-14]. PMID 28968603. doi:10.1159/000481424 . （原始内容存档于2022-04-21）.
Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens. J. Urol. 2018-05, 200 (5): 956–966. PMID 29730201. S2CID 19162538. doi:10.1016/j.juro.2018.04.083.
Ito Y, Sadar MD. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Res Rep Urol. 2018, 10: 23–32. PMC 5818862 . PMID 29497605. doi:10.2147/RRU.S157116.
Ricci F, Buzzatti G, Rubagotti A, Boccardo F. Safety of antiandrogen therapy for treating prostate cancer. Expert Opin Drug Saf. 2014-11, 13 (11): 1483–99. PMID 25270521. S2CID 207488100. doi:10.1517/14740338.2014.966686.
Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology. 1996-01, 47 (1A Suppl): 70–9; discussion 80–4. PMID 8560681. doi:10.1016/S0090-4295(96)80012-4.
Vogelzang NJ. Enzalutamide--a major advance in the treatment of metastatic prostate cancer. N. Engl. J. Med. 2012-09, 367 (13): 1256–7. PMID 23013078. doi:10.1056/NEJMe1209041.
Gao Y, Maurer T, Mirmirani P. Understanding and Addressing Hair Disorders in Transgender Individuals. Am J Clin Dermatol. 2018-01, 19 (4): 517–527. PMID 29352423. S2CID 6467968. doi:10.1007/s40257-018-0343-z. 非甾体抗雄激素包括氟他胺、尼鲁米特和比卡鲁胺，它们不会降低雄激素水平，可能对想要保持性欲和生育能力的个体有利[9]。（Non-steroidal antiandrogens include flutamide, nilutamide, and bicalutamide, which do not lower androgen levels and may be favorable for individuals who want to preserve sex drive and fertility [9].）
Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International. 2001-01, 87 (1): 47–56. PMID 11121992. S2CID 28215804. doi:10.1046/j.1464-410x.2001.00988.x .
Morgante, E; Gradini, R; Realacci, M; Sale, P; D'eramo, G; Perrone, G A; Cardillo, M R; Petrangeli, E; Russo, Ma; Di Silverio, F. Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study. Histopathology. 2001, 38 (3): 195–201. ISSN 0309-0167. PMID 11260298. S2CID 36892099. doi:10.1046/j.1365-2559.2001.01077.x.
Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J. Urol. 1995-12, 154 (6): 1991–8. PMID 7500443. doi:10.1016/S0022-5347(01)66670-9.
Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007-02, 3 (2): 157–67. PMID 17237842. S2CID 19745821. doi:10.1038/ncpendmet0399.
Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015-01, 11 (1): 19–28. PMID 25581052. S2CID 7516507. doi:10.2217/whe.14.68 .
Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogues. N. Engl. J. Med. 1991-01, 324 (2): 93–103. PMID 1984190. doi:10.1056/NEJM199101103240205.
Krakowsky Y, Morgentaler A. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. Eur Urol Focus. 2017-07, 5 (1): 81–89. PMID 28753828. S2CID 10011200. doi:10.1016/j.euf.2017.06.008.
Thompson IM. Flare Associated with LHRH-Agonist Therapy. Rev Urol. 2001,. 3 Suppl 3: S10–4. PMC 1476081 . PMID 16986003.
Scaletscky R, Smith JA. Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?. Drug Saf. 1993-04, 8 (4): 265–70. PMID 8481213. S2CID 36964191. doi:10.2165/00002018-199308040-00001.
Reilly DR, Delva NJ, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Can J Psychiatry. 2000-08, 45 (6): 559–63. PMID 10986575. S2CID 27710792. doi:10.1177/070674370004500608 . [...]在第一次注射亮丙瑞林之前进行雌激素或抗雄激素治疗可能会降低[治疗开始时由睾酮“爆发”引起的症状风险]（16）。（[...] estrogen or antiandrogen treatment prior to the first leuprolide injection may reduce [the risk of symptoms caused by the testosterone "flare" at the initiation of treatment] (16).）
Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp. Clin. Endocrinol. Diabetes. 2005-12, 113 (10): 586–92. PMID 16320157. doi:10.1055/s-2005-865900.
T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of Transgender Medicine. Endocrine Reviews. 2018-10, 40 (1): 97–117 [2022-01-14]. PMID 30307546. doi:10.1210/er.2018-00011 . （原始内容存档于2022-04-21）.
Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocr. Rev. 2017-06, 38 (3): 220–254. PMC 6459338 . PMID 28472278. doi:10.1210/er.2016-1067.
Marchetti PM, Barth JH. Clinical biochemistry of dihydrotestosterone. Ann. Clin. Biochem. 2013-03, 50 (Pt 2): 95–107. PMID 23431485. S2CID 8325257. doi:10.1258/acb.2012.012159.
Marks LS. 5α-reductase: history and clinical importance. Rev Urol. 2004,. 6 Suppl 9: S11–21. PMC 1472916 . PMID 16985920.
Jin Y, Penning TM. Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract. Res. Clin. Endocrinol. Metab. 2001, 15 (1): 79–94. PMID 11469812. doi:10.1053/beem.2001.0120.
Horton R. Dihydrotestosterone is a peripheral paracrine hormone. J. Androl. 1992, 13 (1): 23–7. PMID 1551803. doi:10.1002/j.1939-4640.1992.tb01621.x.
Wilson JD. Role of dihydrotestosterone in androgen action. Prostate Suppl. 1996, 6 (S6): 88–92. PMID 8630237. doi:10.1002/(SICI)1097-0045(1996)6+<88::AID-PROS17>3.0.CO;2-N.
Okeigwe I, Kuohung W. 5-Alpha reductase deficiency: a 40-year retrospective review. Curr Opin Endocrinol Diabetes Obes. 2014-12, 21 (6): 483–7. PMID 25321150. S2CID 1093345. doi:10.1097/MED.0000000000000116.
Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol. Cell. Endocrinol. 2002-12, 198 (1–2): 51–9. PMID 12573814. S2CID 54356569. doi:10.1016/S0303-7207(02)00368-4.
Liang, Jennifer J.; Rasmusson, Ann M. Overview of the Molecular Steps in Steroidogenesis of the GABAergic Neurosteroids Allopregnanolone and Pregnanolone. Chronic Stress. 2018, 2: 247054701881855. ISSN 2470-5470. PMC 7219929 . PMID 32440589. doi:10.1177/2470547018818555.
Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014-06, 55 (6): 367–79. PMC 4064044 . PMID 24955220. doi:10.4111/kju.2014.55.6.367.
Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 2000-04, 37 (4): 367–80. PMID 10765065. S2CID 25793400. doi:10.1159/000020181.
Yamana K, Labrie F, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010-08, 2 (3): 293–9. PMID 25961201. S2CID 28841145. doi:10.1515/HMBCI.2010.035.
Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2018-08, 7 (1): 95–114. PMID 30098986. S2CID 51968365. doi:10.1016/j.sxmr.2018.06.002.
Azzouni F, Mohler J. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis. 2012-09, 15 (3): 222–30. PMID 22333687. S2CID 205537645. doi:10.1038/pcan.2012.1 .
Yim E, Nole KL, Tosti A. 5α-Reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2014-12, 21 (6): 493–8. PMID 25268732. S2CID 30008068. doi:10.1097/MED.0000000000000112.
Arif T, Dorjay K, Adil M, Sami M. Dutasteride in Androgenetic Alopecia: An Update. Curr Clin Pharmacol. 2017, 12 (1): 31–35. PMID 28294070. doi:10.2174/1574884712666170310111125.
Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010-06, 44 (6): 1090–7. PMID 20442354. S2CID 207263793. doi:10.1345/aph.1M591.
Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014-07, 15 (3): 217–30. PMID 24848508. S2CID 31245042. doi:10.1007/s40257-014-0077-5.
Reddy DS, Estes WA. Clinical Potential of Neurosteroids for CNS Disorders. Trends Pharmacol. Sci. 2016-07, 37 (7): 543–561. PMC 5310676 . PMID 27156439. doi:10.1016/j.tips.2016.04.003.
Martinez PE, Rubinow DR, Nieman LK, Koziol DE, Morrow AL, Schiller CE, Cintron D, Thompson KD, Khine KK, Schmidt PJ. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. Neuropsychopharmacology. 2016-03, 41 (4): 1093–102. PMC 4748434 . PMID 26272051. doi:10.1038/npp.2015.246.
Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012-01, 32 (1): 54–66. PMID 22392828. S2CID 12853220. doi:10.1002/PHAR.1006.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. J Clin Aesthet Dermatol. 2016-07, 9 (7): 56–62. PMC 5023004 . PMID 27672412.
Trost L, Saitz TR, Hellstrom WJ. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. Sex Med Rev. 2013-05, 1 (1): 24–41. PMID 27784557. doi:10.1002/smrj.3.
Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. J Sex Med. 2016-09, 13 (9): 1297–1310. PMID 27475241. doi:10.1016/j.jsxm.2016.07.006.
Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018-05, 28 (3): 288–293 [2022-01-14]. PMID 29528971. S2CID 4587434. doi:10.1097/MOU.0000000000000497. （原始内容存档于2022-04-21）.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011-03, 8 (3): 872–84. PMID 21176115. doi:10.1111/j.1743-6109.2010.02157.x.
Malde S, Cartwright R, Tikkinen KA. What's New in Epidemiology?. Eur Urol Focus. 2018-01, 4 (1): 11–13. PMID 29449167. doi:10.1016/j.euf.2018.02.003.
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?. Rev Endocr Metab Disord. 2015-09, 16 (3): 177–98. PMID 26296373. S2CID 25002351. doi:10.1007/s11154-015-9319-y.
Trüeb RM. Discriminating in favour of or against men with increased risk of finasteride-related side effects?. Exp. Dermatol. 2017-06, 26 (6): 527–528. PMID 27489125. S2CID 36236057. doi:10.1111/exd.13155 . [...]建议在为男性到女性的跨性别者开具口服非那雄胺的处方时要谨慎，因为该药物与诱发抑郁、焦虑和自杀意念有关，这些症状在性别不安患者中尤为常见，他们已经处于高风险中[9]。（[...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.[9]）
Macias, Hector; Hinck, Lindsay. Mammary gland development. Wiley Interdisciplinary Reviews: Developmental Biology. 2012, 1 (4): 533–557. ISSN 1759-7684. PMC 3404495 . PMID 22844349. doi:10.1002/wdev.35.
Wierckx K, Gooren L, T'Sjoen G. Clinical review: Breast development in trans women receiving cross-sex hormones. J Sex Med. 2014, 11 (5): 1240–7. PMID 24618412. doi:10.1111/jsm.12487.
Cox DB, Kent JC, Casey TM, Owens RA, Hartmann PE. Breast growth and the urinary excretion of lactose during human pregnancy and early lactation: endocrine relationships. Exp. Physiol. 1999-03, 84 (2): 421–34. PMID 10226182. doi:10.1017/S0958067099018072 .
Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects?. Trends Endocrinol. Metab. 2004-08, 15 (6): 277–85. PMID 15358281. S2CID 35891204. doi:10.1016/j.tem.2004.06.006.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Kronawitter D, Gooren LJ, Zollver H, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. Eur. J. Endocrinol. 2009-08, 161 (2): 363–8. PMID 19497984. doi:10.1530/EJE-09-0265 .
Majumder A, Sanyal D. Outcome and preferences in male-to-female subjects with gender dysphoria: Experience from Eastern India. Indian J Endocrinol Metab. 2017, 21 (1): 21–25. PMC 5240066 . PMID 28217493. doi:10.4103/2230-8210.196000.
Meyer WJ, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Archives of Sexual Behavior. 1986-04, 15 (2): 121–38. PMID 3013122. S2CID 42786642. doi:10.1007/bf01542220.
Morris JM. The syndrome of testicular feminization in male pseudohermaphrodites. Am. J. Obstet. Gynecol. 1953-06, 65 (6): 1192–1211. PMID 13057950. doi:10.1016/0002-9378(53)90359-7.
Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocrine-Related Cancer. 2006, 13 (2): 279–92. PMID 16728564. doi:10.1677/erc.1.00729 . 脂肪细胞占人体乳房的大部分，而上皮细胞仅占人体乳房体积的约10%。（Adipocytes make up the bulk of the human breast, with epithelial cells accounting for only approximately 10% of human breast volume.）
Howard BA, Gusterson BA. Human breast development. Journal of Mammary Gland Biology and Neoplasia. 2000, 5 (2): 119–37. PMID 11149569. S2CID 10819224. doi:10.1023/A:1026487120779. 在基质中，纤维和脂肪组织的数量增加，成人非哺乳期乳房由80%或更多的基质组成。（In the stroma, there is an increase in the amount of fibrous and fatty tissue, with the adult nonlactating breast consisting of 80% or more of stroma.）
Hagisawa S, Shimura N, Arisaka O. Effect of excess estrogen on breast and external genitalia development in growth hormone deficiency. Journal of Pediatric and Adolescent Gynecology. 2012, 25 (3): e61–3. PMID 22206682. doi:10.1016/j.jpag.2011.11.005. 雌激素刺激乳头的发育，从乳腺导管分叉到小管形成阶段的过程，及脂肪基质生长至构成乳房质量的约85%。（Estrogen stimulates growth of the nipples, progression of mammary duct branching to the stage at which ductiles are formed, and fatty stromal growth until it constitutes about 85% of the mass of the breast.）
Farage MA, Neill S, MacLean AB. Physiological changes associated with the menstrual cycle: a review. Obstet Gynecol Surv. 2009, 64 (1): 58–72. PMID 19099613. S2CID 22293838. doi:10.1097/OGX.0b013e3181932a37.
Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric. 2012-04,. 15 Suppl 1: 18–25. PMID 22432812. S2CID 17700754. doi:10.3109/13697137.2012.669584.
Cline JM, Wood CE. The Mammary Glands of Macaques. Toxicol Pathol. 2008-12, 36 (7): 134s–141s. PMC 3070964 . PMID 21475638. doi:10.1177/0192623308327411.
Pasqualini JR. Progestins and breast cancer. Gynecol. Endocrinol. 2007,. 23 Suppl 1: 32–41. PMID 17943537. S2CID 46634314. doi:10.1080/09513590701585003.
Pasqualini JR. Breast cancer and steroid metabolizing enzymes: the role of progestogens. Maturitas. 2009,. 65 Suppl 1: S17–21. PMID 19962254. doi:10.1016/j.maturitas.2009.11.006.
Schindler AE. Dydrogesterone and other progestins in benign breast disease: an overview. Arch. Gynecol. Obstet. 2011-02, 283 (2): 369–71. PMID 20383772. S2CID 9125889. doi:10.1007/s00404-010-1456-7.
Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C. Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol. Endocrinol. 2001-12,. 15 Suppl 6: 37–43. PMID 12227885. S2CID 27589741. doi:10.1080/gye.15.s6.37.43.
Ruan X, Mueck AO. Systemic progesterone therapy--oral, vaginal, injections and even transdermal?. Maturitas. 2014-11, 79 (3): 248–55. PMID 25113944. doi:10.1016/j.maturitas.2014.07.009.
Bińkowska, Małgorzata; Woroń, Jarosław. Progestogens in menopausal hormone therapy. Menopausal Review. 2015, 14 (2): 134–143. ISSN 1643-8876. PMC 4498031 . PMID 26327902. doi:10.5114/pm.2015.52154.
Foss GL. Disturbances of lactation. Clin Obstet Gynecol. 1958-03, 1 (1): 245–54. PMID 13573669. S2CID 42825519. doi:10.1097/00003081-195803000-00021. 在实验上，我已经能够诱导一名男性异装癖者的泌乳，该男性异装癖者的睾丸在几年前已被切除，其乳房在很长一段时间内使用芪雌酚和乙炔雌酮，发育已良好[9]。1955年7月9日，皮下植入600 mg雌二醇，每周注射50 mg孕酮，持续四个月。下个月每天注射10 mg二丙酸雌二醇和50 mg孕酮。这些注射又持续了一个月，将孕酮增加到每天100 mg。然后停用两种激素，逐日增加剂量注射催乳素和生长激素，持续四天；同时，患者每天使用吸乳器四次，每次5分钟。在此期间，乳腺静脉明显增大，在第六天和第七天收集到了1到2 mg乳状液体。（Experimentally I have been able to induce lactogenesis in a male transvestite whose testes had been removed some years before and whose breasts had been well developed over a long period with stilbestrol and ethisterone.9 In July, 1955, 600 mg. of estradiol was implanted subcutaneously and weekly injections of 50 mg. of progesterone were given for four months. For the next month daily injections of 10 mg. estradiol dipropionate and 50 mg. progesterone were given. These injections were continued for another month, increasing progesterone to 100 mg. daily. Both hormones were then withdrawn, and daily injections of increasing doses of prolactin and somatotropin were given for four days; at the same time, the patient used a breast bump four times daily for 5 minutes on both sides. During this time the mammary veins were visibly enlarged and on the sixth and seventh days 1 to 2 cc. of milky fluid was collected.）
Kanhai RC, Hage JJ, van Diest PJ, Bloemena E, Mulder JW. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. The American Journal of Surgical Pathology. 2000-01, 24 (1): 74–80. PMID 10632490. doi:10.1097/00000478-200001000-00009.
Worsley R, Santoro N, Miller KK, Parish SJ, Davis SR. Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgens--Findings from the Fourth International Consultation on Sexual Medicine. J Sex Med. 2016-03, 13 (3): 283–90. PMID 26944460. doi:10.1016/j.jsxm.2015.12.014.
Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000-10, 62 (8): 1839–46, 1849–50 [2022-01-14]. PMID 11057840. （原始内容存档于2022-04-21）.
Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007, 15 (5): 427–44 [2022-01-14]. PMID 17924777. doi:10.1037/1064-1297.15.5.427. （原始内容存档于2022-06-01）.
Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G. Allopregnanolone and mood disorders. Prog. Neurobiol. 2014, 113: 88–94. PMID 23978486. S2CID 207407084. doi:10.1016/j.pneurobio.2013.07.005.
Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. The Journal of Clinical Endocrinology and Metabolism. 2003-08, 88 (8): 3467–73. PMID 12915619. doi:10.1210/jc.2002-021967 .
Davey DA. Menopausal hormone therapy: a better and safer future. Climacteric. 2018-03, 21 (5): 454–461. PMID 29526116. S2CID 3850275. doi:10.1080/13697137.2018.1439915.
Raj R, Korja M, Koroknay-Pál P, Niemelä M. Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: A report of two cases and a brief literature review. Surg Neurol Int. 2018, 9: 109. PMC 5991277 . PMID 29930875. doi:10.4103/sni.sni_22_18.
Nota NM, Wiepjes CM, de Blok CJ, Gooren LJ, Peerdeman SM, Kreukels BP, den Heijer M. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018-07, 141 (7): 2047–2054. PMID 29688280. S2CID 19934721. doi:10.1093/brain/awy108 .
Kuhl H, Schneider HP. Progesterone--promoter or inhibitor of breast cancer. Climacteric. 2013-08,. 16 Suppl 1: 54–68. PMID 23336704. S2CID 20808536. doi:10.3109/13697137.2013.768806.
de Ziegler D, Fanchin R. Progesterone and progestins: applications in gynecology. Steroids. 2000, 65 (10–11): 671–9. PMID 11108875. S2CID 5867301. doi:10.1016/S0039-128X(00)00123-9.
Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML, Bertino JS. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J Clin Pharmacol. 2005, 45 (6): 614–9. PMID 15901742. S2CID 28399314. doi:10.1177/0091270005276621.
Tollan A, Oian P, Kjeldsen SE, Eide I, Maltau JM. Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men. Gynecol. Obstet. Invest. 1993, 36 (4): 234–8. PMID 8300009. doi:10.1159/000292636.
Brady BM, Anderson RA, Kinniburgh D, Baird DT. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. Clin. Endocrinol. (Oxf). 2003, 58 (4): 506–12. PMID 12641635. S2CID 12567639. doi:10.1046/j.1365-2265.2003.01751.x.
Paynter MJ. Medication and Facilitation of Transgender Women's Lactation. J Hum Lact. 2019-03, 35 (2): 239–243. PMID 30840524. S2CID 73466659. doi:10.1177/0890334419829729.
Kozlov GI, Mel'nichenko GA, Golubeva IV. Sluchai laktorei u bol'nogo muzhskogo pola s transseksualizmom [Case of galactorrhea in a transsexual male patient]. Probl Endokrinol (Mosk). 1985, 31 (1): 37–8 [2022-01-14]. ISSN 0375-9660. PMID 4039061. （原始内容存档于2022-04-21）（俄语）. [...]进行了外生殖器去势和女性化整形手术[...]手术后一段时间，患者对生活重新产生了兴趣。经过手术和荷尔蒙矫正后，患者不可抗拒地发展出母性本能。未婚，患者获准领养孩子，模拟怀孕，带着儿子从妇产医院出院。从“出生”后的第一天开始，溢乳急剧增加，出现自发流出乳汁，伴溢乳（+++）。婴儿一直母乳喂养到6个月大。[...]我们的信息是文献中第二例有关男性易性症患者溢乳的描述。R.[Flückiger]等人于1983年首次描述了这种类型(6)。这一观察结果证明了泌乳发育机制与一个人的遗传性别相独立，并且对男性发生药物性溢乳的可能性感到担忧。（[...] castration and feminizing plastic surgery of the external genitalia was performed [...] Some time after the operation, the patient developed a renewed interest in life. After the surgical and hormonal correction, the patient irresistibly developed maternal instincts. Unmarried, the patient obtained permission for the adoption of a child, simulated pregnancy, and was discharged from the maternity hospital with a son. From the first days after the “birth”, galactorrhea sharply increased, and spontaneous outflow of milk appeared, with galactorrhea (+++). The baby was breastfed up to 6 months of age. [...] Our message is the second in the world literature describing galactorrhea in a male patient with transsexualism. The first description of this kind was made in 1983 by R. [Flückiger] et al. (6). This observation demonstrates the independence of the mechanism of lactation development from one’s genetic sex and is alarming with regard to the possibility of drug-induced galactorrhea development in men.）
Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med. 2010-09, 7 (9): 2996–3010. PMID 20626600. doi:10.1111/j.1743-6109.2010.01902.x.
Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003-02, 61 (2 Suppl 1): 32–8. PMID 12667885. doi:10.1016/S0090-4295(02)02397-X.
Higano CS. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2012-10, 30 (30): 3720–5. PMID 23008326. doi:10.1200/JCO.2012.41.8509.
de Blok CJ, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, Schreiner T, T'Sjoen G, den Heijer M. Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study. J. Clin. Endocrinol. Metab. 2018-02, 103 (2): 532–538. PMID 29165635. S2CID 3716975. doi:10.1210/jc.2017-01927 .
Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. Journal of Clinical Endocrinology and Metabolism. 2000-08, 85 (8): 2913–21. PMID 10946903. doi:10.1210/jc.85.8.2913 .
Randall VA, Hibberts NA, Thornton MJ, Hamada K, Merrick AE, Kato S, Jenner TJ, De Oliveira I, Messenger AG. The hair follicle: a paradoxical androgen target organ. Horm. Res. 2000, 54 (5–6): 243–50. PMID 11595812. S2CID 42826314. doi:10.1159/000053266.
Leach NE, Wallis NE, Lothringer LL, Olson JA. Corneal hydration changes during the normal menstrual cycle--a preliminary study. The Journal of Reproductive Medicine. 1971-05, 6 (5): 201–4. PMID 5094729.
Kiely PM, Carney LG, Smith G. Menstrual cycle variations of corneal topography and thickness (PDF). American Journal of Optometry and Physiological Optics. 1983-10, 60 (10): 822–9 [2022-01-14]. PMID 6650653. S2CID 43222063. doi:10.1097/00006324-198310000-00003. （原始内容 (PDF)存档于2022-03-17）.
Gurwood AS, Gurwood I, Gubman DT, Brzezicki LJ. Idiosyncratic ocular symptoms associated with the estradiol transdermal estrogen replacement patch system. Optometry and Vision Science. 1995-01, 72 (1): 29–33. PMID 7731653. doi:10.1097/00006324-199501000-00006.
Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. The Journal of Clinical Endocrinology and Metabolism. 2000-12, 85 (12): 4874–82. PMID 11134156. doi:10.1210/jcem.85.12.7072 .
Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Annals of the New York Academy of Sciences. 2002-06, 966 (1): 211–22. Bibcode:2002NYASA.966..211S. PMID 12114274. S2CID 22281698. doi:10.1111/j.1749-6632.2002.tb04217.x.
Sullivan BD, Evans JE. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. Archives of Ophthalmology. 2002-12, 120 (12): 1689–1699. PMID 12470144. doi:10.1001/archopht.120.12.1689 .
Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?. Cornea. 2003-08, 22 (6): 516–21. PMID 12883343. S2CID 29374194. doi:10.1097/00003226-200308000-00006.
Oprea L, Tiberghien A, Creuzot-Garcher C, Baudouin C. Influence des hormones sur le film lacrymal [Hormonal regulatory influence in tear film]. Journal Français d'Ophtalmologie. 2004-10, 27 (8): 933–41. PMID 15547478. doi:10.1016/S0181-5512(04)96241-9 （法语）.
van der Loos, Maria Atc; Hellinga, Ilse; Vlot, Mariska C.; Klink, Daniel T.; den Heijer, Martin; Wiepjes, Chantal M. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. 2021-05, 36 (5) [2023-12-04]. ISSN 1523-4681. PMC 8247856 . PMID 33507568. doi:10.1002/jbmr.4262. （原始内容存档于2023-03-29）.
Nguyen, Hillary B.; Chavez, Alexis M.; Lipner, Emily; Hantsoo, Liisa; Kornfield, Sara L.; Davies, Robert D.; Epperson, C. Neill. Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition. Current Psychiatry Reports. 2018, 20 (12): 110. ISSN 1523-3812. PMC 6354936 . PMID 30306351. doi:10.1007/s11920-018-0973-0.
Klein C., Gorzalka B.B. Sexual functioning in transsexuals following hormone therapy and genital surgery: A review. Journal of Sexual Medicine. 2009, 6 (11): 2922–2939. PMID 20092545. doi:10.1111/j.1743-6109.2009.01370.x.
Smith, Elke Stefanie; Junger, Jessica; Derntl, Birgit; Habel, Ute. The transsexual brain – A review of findings on the neural basis of transsexualism. Neuroscience & Biobehavioral Reviews. 2015, 59: 251–266. ISSN 0149-7634. PMID 26429593. S2CID 23913935. doi:10.1016/j.neubiorev.2015.09.008.
Guillamon, Antonio; Junque, Carme; Gómez-Gil, Esther. A Review of the Status of Brain Structure Research in Transsexualism. Archives of Sexual Behavior. 2016, 45 (7): 1615–1648. ISSN 0004-0002. PMC 4987404 . PMID 27255307. doi:10.1007/s10508-016-0768-5.
Mueller, Sven C.; De Cuypere, Griet; T’Sjoen, Guy. Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective. American Journal of Psychiatry. 2017, 174 (12): 1155–1162 [2022-01-14]. ISSN 0002-953X. PMID 29050504. doi:10.1176/appi.ajp.2017.17060626. hdl:1854/LU-8542009. （原始内容存档于2022-04-21）.
Nguyen HB, Loughead J, Lipner E, Hantsoo L, Kornfield SL, Epperson CN. What has sex got to do with it? The role of hormones in the transgender brain. Neuropsychopharmacology. 2019-01, 44 (1): 22–37. PMC 6235900 . PMID 30082887. doi:10.1038/s41386-018-0140-7.
Kilpatrick, Lisa A.; Holmberg, Mats; Manzouri, Amirhosein; Savic, Ivanka. Cross sex hormone treatment is linked with a reversal of cerebral patterns associated with gender dysphoria to the baseline of cisgender controls. European Journal of Neuroscience. 2019, 50 (8): 3269–3281. ISSN 0953-816X. PMC 7329231 . PMID 30991464. doi:10.1111/ejn.14420.
Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, Carlström K. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate. 1988, 13 (3): 257–61. PMID 3211807. S2CID 20686808. doi:10.1002/pros.2990130308.
von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R. Estrogen therapy and liver function--metabolic effects of oral and parenteral administration. Prostate. 1989, 14 (4): 389–95. PMID 2664738. S2CID 21510744. doi:10.1002/pros.2990140410.
Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metab. Clin. Exp. 1989-09, 38 (9): 869–73. PMID 2528051. doi:10.1016/0026-0495(89)90233-3.
Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur. Urol. 1990, 17 (2): 161–5. PMID 2178941. doi:10.1159/000464026.
Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol. 1990-03, 65 (3): 282–5. PMID 2110842. doi:10.1111/j.1464-410X.1990.tb14728.x.
Aro J. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate. 1991, 18 (2): 131–7. PMID 2006119. S2CID 27915767. doi:10.1002/pros.2990180205.
Henriksson P, Stege R. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer. Int J Technol Assess Health Care. 1991, 7 (2): 220–5. PMID 1907600. doi:10.1017/S0266462300005110.
Henriksson P. Estrogen in patients with prostatic cancer. An assessment of the risks and benefits. Drug Saf. 1991, 6 (1): 47–53. PMID 2029353. S2CID 39861824. doi:10.2165/00002018-199106010-00005.
Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb. Haemost. 1992-10, 68 (4): 392–5. PMID 1333098. doi:10.1055/s-0038-1646283.
Stege R, Sander S. Endokrin behandling av prostatacancer. En renessanse for parenteralt østrogen [Endocrine treatment of prostatic cancer. A renaissance for parenteral estrogen]. Tidsskr. Nor. Laegeforen. 1993-03, 113 (7): 833–5. PMID 8480286 （挪威语）.
Stege R, Carlström K, Hedlund PO, Pousette A, von Schoultz B, Henriksson P. Intramuskuläres Depotöstrogen (Estradurin) in der Behandlung von Patienten mit Prostatakarzinom. Historische Aspekte, Wirkungsmechanismus, Resultate und aktueller klinischer Stand [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status]. Urologe A. 1995-09, 34 (5): 398–403. ISSN 0340-2592. PMID 7483157 （德语）.
Henriksson P, Carlström K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, Altersgård-Brorsson AK, Nordle O, Stege R. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate. 1999-07, 40 (2): 76–82. PMID 10386467. doi:10.1002/(SICI)1097-0045(19990701)40:2<76::AID-PROS2>3.0.CO;2-Q.
Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology. 2000-03, 55 (3): 328–33. PMID 10699602. doi:10.1016/S0090-4295(99)00580-4.
Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand. J. Urol. Nephrol. 2002, 36 (6): 405–13. PMID 12623503. S2CID 2799580. doi:10.1080/003655902762467549.
Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003-08, 362 (9382): 428–32. PMID 12927428. S2CID 45789951. doi:10.1016/S0140-6736(03)14066-4.
Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005-11, 112 (22): 3495–500. PMID 16301339. S2CID 13587974. doi:10.1161/CIRCULATIONAHA.105.565556 .
Basurto L, Saucedo R, Zárate A, Martínez C, Gaminio E, Reyes E, Hernandez M. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Gynecol. Obstet. Invest. 2006, 61 (2): 61–4. PMID 16192735. S2CID 38375159. doi:10.1159/000088603.
Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2006-07, 26 (7): 1660–6. PMID 16645152. S2CID 12778600. doi:10.1161/01.ATV.0000224325.96659.53 .
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand. J. Urol. Nephrol. 2008, 42 (3): 220–9. PMID 18432528. S2CID 38638336. doi:10.1080/00365590801943274.
Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008-05, 336 (7655): 1227–31. PMC 2405857 . PMID 18495631. doi:10.1136/bmj.39555.441944.BE.
Rosendale N, Goldman S, Ortiz GM, Haber LA. Acute Clinical Care for Transgender Patients: A Review. JAMA Intern Med. 2018-11, 178 (11): 1535–1543. PMID 30178031. S2CID 52146607. doi:10.1001/jamainternmed.2018.4179.
Speed V, Roberts LN, Patel JP, Arya R. Venous thromboembolism and women's health. Br. J. Haematol. 2018-11, 183 (3): 346–363. PMID 30334572. S2CID 52985304. doi:10.1111/bjh.15608 .
Khan J, Schmidt RL, Spittal MJ, Goldstein Z, Smock KJ, Greene DN. Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis. Clin. Chem. 2019-01, 65 (1): 57–66. PMID 30602475. doi:10.1373/clinchem.2018.288316 .
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015-08, 12 (8): 464–74. PMC 4624298 . PMID 26076949. doi:10.1038/nrcardio.2015.83.
Arnold JD, Sarkodie EP, Coleman ME, Goldstein DA. Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol. J Sex Med. 2016-11, 13 (11): 1773–1777. PMID 27671969. doi:10.1016/j.jsxm.2016.09.001.
Streed CG, Harfouch O, Marvel F, Blumenthal RS, Martin SS, Mukherjee M. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann. Intern. Med. 2017-08, 167 (4): 256–267. PMID 28738421. S2CID 207538881. doi:10.7326/M17-0577.
Eismann J, Heng YJ, Fleischmann-Rose K, Tobias AM, Phillips J, Wulf GM, Kansal KJ. Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature. Clin. Breast Cancer. 2019-02, 19 (1): e12–e19. PMC 7083129 . PMID 30527351. doi:10.1016/j.clbc.2018.11.007.
Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013-12, 10 (12): 3129–34. PMID 24010586. doi:10.1111/jsm.12319.
Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res. Treat. 2015-01, 149 (1): 191–8. PMID 25428790. S2CID 10935304. doi:10.1007/s10549-014-3213-2.
de Blok, Christel J M; Wiepjes, Chantal M; Nota, Nienke M; van Engelen, Klaartje; Adank, Muriel A; Dreijerink, Koen M A; Barbé, Ellis; Konings, Inge R H M; den Heijer, Martin. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019, 365: l1652. ISSN 0959-8138. PMC 6515308 . PMID 31088823. doi:10.1136/bmj.l1652.
Iwamoto, Sean J.; Defreyne, Justine; Rothman, Micol S.; Van Schuylenbergh, Judith; Van de Bruaene, Laurens; Motmans, Joz; T’Sjoen, Guy. Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism. 2019, 10: 204201881987116. ISSN 2042-0188. PMC 6719479 . PMID 31516689. doi:10.1177/2042018819871166.
Hartley RL, Stone JP, Temple-Oberle C. Breast cancer in transgender patients: A systematic review. Part 1: Male to female. Eur J Surg Oncol. 2018-10, 44 (10): 1455–1462. PMID 30087072. S2CID 51936024. doi:10.1016/j.ejso.2018.06.035.
Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B. Gynecomastia: Clinical evaluation and management. Indian J Endocrinol Metab. 2014, 18 (2): 150–8. PMC 3987263 . PMID 24741509. doi:10.4103/2230-8210.129104.
Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ. 2008, 336 (7646): 709–13. PMC 2276281 . PMID 18369226. doi:10.1136/bmj.39511.493391.BE.
Hughes IA, Werner R, Bunch T, Hiort O. Androgen insensitivity syndrome. Semin. Reprod. Med. 2012, 30 (5): 432–42. PMID 23044881. doi:10.1055/s-0032-1324728. ^{[失效連結]}
Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008, 9 (3): 239–46. PMID 18282803. doi:10.1016/S1470-2045(08)70033-0.
Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014, 46 (10): 1156–60. PMID 24329588. S2CID 1445627. doi:10.1111/and.12208.
Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013, 7 (7–8): E544–6. PMC 3758950 . PMID 24032068. doi:10.5489/cuaj.175.
McFarlane T, Zajac JD, Cheung AS. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review. Clin. Endocrinol. (Oxf). 2018-12, 89 (6): 700–711. PMID 30107028. S2CID 52003943. doi:10.1111/cen.13835 .
McFarlane, Thomas; Zajac, Jeffrey D.; Cheung, Ada S. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review. Clinical Endocrinology. 2018, 89 (6): 700–711. ISSN 0300-0664. PMID 30107028. S2CID 52003943. doi:10.1111/cen.13835 .
Nota, Nienke M; Wiepjes, Chantal M; de Blok, Christel J M; Gooren, Louis J G; Peerdeman, Saskia M; Kreukels, Baudewijntje P C; den Heijer, Martin. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018, 141 (7): 2047–2054. ISSN 0006-8950. PMID 29688280. S2CID 19934721. doi:10.1093/brain/awy108 .
Mahfouda, Simone; Moore, Julia K; Siafarikas, Aris; Hewitt, Timothy; Ganti, Uma; Lin, Ashleigh; Zepf, Florian Daniel. Gender-affirming hormones and surgery in transgender children and adolescents. The Lancet Diabetes & Endocrinology. 2019, 7 (6): 484–498. ISSN 2213-8587. PMID 30528161. S2CID 54478571. doi:10.1016/S2213-8587(18)30305-X.
Bisson, Jason R.; Chan, Kelly J.; Safer, Joshua D. Prolactin levels do not rise among transgender women treated with estradiol and spironolactone. Endocrine Practice. 2018, 24 (7): 646–651. ISSN 1530-891X. PMID 29708436. S2CID 14022275. doi:10.4158/EP-2018-0101.
Hamburger C, Sturup GK, Dahl-Iversen E. Transvestism; hormonal, psychiatric, and surgical treatment. J Am Med Assoc. 1953-05, 152 (5): 391–6. PMID 13044539. doi:10.1001/jama.1953.03690050015006.
Bullough VL. Transsexualism in history. Arch Sex Behav. 1975-09, 4 (5): 561–71. PMID 1103789. S2CID 36577490. doi:10.1007/bf01542134.
Benjamin H. Clinical aspects of transsexualism in the male and female. Am J Psychother. 1964-07, 18 (3): 458–69. PMID 14173773. doi:10.1176/appi.psychotherapy.1964.18.3.458.
Schaefer LC, Wheeler CC. Harry Benjamin's first ten cases (1938-1953): a clinical historical note. Arch Sex Behav. 1995-02, 24 (1): 73–93. PMID 7733806. S2CID 31571764. doi:10.1007/bf01541990.
Edgerton MT, Knorr NJ, Callison JR. The surgical treatment of transsexual patients. Limitations and indications. Plast. Reconstr. Surg. 1970-01, 45 (1): 38–46. PMID 4902840. S2CID 27318408. doi:10.1097/00006534-197001000-00006.
Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, Tangpricha V, Montori VM. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2009-09, 94 (9): 3132–54. PMID 19509099. doi:10.1210/jc.2009-0345 .
Moore, Eva; Wisniewski, Amy; Dobs, Adrian. Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects. The Journal of Clinical Endocrinology & Metabolism. 2003, 88 (8): 3467–3473. ISSN 0021-972X. PMID 12915619. doi:10.1210/jc.2002-021967 .
Gooren LJ, van der Veen EA, van Kessel H, Harmsen-Louman W, Wiegel AR. Androgens in the feedback regulation of gonadotropin secretion in men: effects of administration of dihydrotestosterone to eugonadal and agonadal subjects and of spironolactone to eugonadal subjects. Andrologia. 1984, 16 (4): 289–98. PMID 6433746. S2CID 32546312. doi:10.1111/j.1439-0272.1984.tb00286.x.

pubmed.ncbi.nlm.nih.gov

van der Loos, Maria Atc; Hellinga, Ilse; Vlot, Mariska C.; Klink, Daniel T.; den Heijer, Martin; Wiepjes, Chantal M. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. 2021-05, 36 (5) [2023-12-04]. ISSN 1523-4681. PMC 8247856 . PMID 33507568. doi:10.1002/jbmr.4262. （原始内容存档于2023-03-29）.

nottingham.ac.uk (Global: 4,422^nd place; Chinese: 8,845^th place)

eprints.nottingham.ac.uk

T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of Transgender Medicine. Endocrine Reviews. 2018-10, 40 (1): 97–117 [2022-01-14]. PMID 30307546. doi:10.1210/er.2018-00011 . （原始内容存档于2022-04-21）.

oup.com (Global: 485^th place; Chinese: 489^th place)

academic.oup.com

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.

phsa.ca (Global: low place; Chinese: low place)

Dahl, M; Feldman, JL; Goldberg, J; Jaberi, A. Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines (PDF). Vancouver Coastal Health. 2015 [2018-09-15]. （原始内容 (PDF)存档于2018-08-16）.

qut.edu.au (Global: 8,570^th place; Chinese: 8,998^th place)

eprints.qut.edu.au

Kiely PM, Carney LG, Smith G. Menstrual cycle variations of corneal topography and thickness (PDF). American Journal of Optometry and Physiological Optics. 1983-10, 60 (10): 822–9 [2022-01-14]. PMID 6650653. S2CID 43222063. doi:10.1097/00006324-198310000-00003. （原始内容 (PDF)存档于2022-03-17）.

rcpsych.ac.uk (Global: low place; Chinese: low place)

Wylie, Kevan; Barrett, James; Besser, Mike; Bouman, Walter Pierre; Bridgman, Michelle; Clayton, Angela; Green, Richard; Hamilton, Mark; Hines, Melissa; Ivbijaro, Gabriel; Khoosal, Deenesh; Lawrence, Alex; Lenihan, Penny; Loewenthal, Del; Ralph, David; Reed, Terry; Stevens, John; Terry, Tim; Thom, Ben; Thornton, Jane; Walsh, Dominic; Ward, David; Coleman, Eli; Di Ceglie, Domenico; Martin, Emma; McGarry, Philip; Messenger, Andrew; Reid, Russell; Sethi, Su; Sutcliffe, Paul; Wilson, Daniel; Carr, Susan; Davies, Dai; Dean, Tracey; Ellis, Michelle; Ferguson, Brian; Skinner, Darren; Williams, Vicky; Brechin, Susan; Lucey, Jim; Rathbone, Maxine. Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria (PDF). Sexual and Relationship Therapy. 2014, 29 (2): 154–214 [2021-10-15]. ISSN 1468-1994. S2CID 144632597. doi:10.1080/14681994.2014.883353. （原始内容 (PDF)存档于2018-09-02）.

reddit.com (Global: 1,082^nd place; Chinese: 1,131^st place)

r/TransDIY. Reddit. [2018-12-29]. （原始内容存档于2022-05-18）.
r/MtFHRT. Reddit. [2018-12-29]. （原始内容存档于2020-11-25）.

researchgate.net (Global: 120^th place; Chinese: 337^th place)

Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007, 15 (5): 427–44 [2022-01-14]. PMID 17924777. doi:10.1037/1064-1297.15.5.427. （原始内容存档于2022-06-01）.

scholar.google.com (Global: 1,697^th place; Chinese: 3,337^th place)

Foss, GL. Abnormalities of form and function of the human breast. Journal of Endocrinology. 1956-01, 14 (1): R6–R9 [2022-01-14]. （原始内容存档于2022-01-14）. 基于催乳理论，并受到Lyons、Li、Johnson&Cole[1955]在雄性大鼠中成功产生泌乳的激励，尝试在男性异装癖者中启动催乳。六年前，该患者接受了雌激素治疗。然后切除睾丸和阴茎，并通过整形手术构建人造阴道。该患者在1954年9月植入了500 mg雌二醇，在1955年7月植入了600 mg。然后每天注射二丙酸雌二醇和孕酮，持续6周，使乳房发育更加快速。停止该治疗后立即每天注射催乳素22·9 mg，连续3天无效。每天服用雌二醇和孕酮的第二个月后，联合注射催乳素和生长激素，持续4天，并通过吸乳器进行抽吸，每天4次。在第4天和第5天，从右侧乳头挤出几滴初乳。（Based on the theories of lactogenesis and stimulated by the success of Lyons, Li, Johnson & Cole [1955], who succeeded in producing lactation in male rats, an attempt was made to initiate lactogenesis in a male transvestist. Six years ago this patient had been given oestrogens. Both testes and penis were then removed and an artificial vagina was constructed by plastic surgery. The patient was implanted with 500 mg oestradiol in September 1954, and 600 mg in July 1955. The breasts were then developed more intensively with daily injections of oestradiol dipropionate and progesterone for 6 weeks. Immediately following withdrawal of this treatment, prolactin 22·9 mg was injected daily for 3 days without effect. After a second month on oestradiol and progesterone daily, combined injections of prolactin and somatotrophin were given for 4 days and suction was applied by a breast pump-four times daily. On the 4th and 5th days a few drops of colostrum were expressed from the right nipple.）
van Kesteren, Paul J. M. Recent Advanced in Gender Dysphoria, Gender Identity Disorder: Towards a Uniform Treatment Approach. Conference of the Royal Society of Medicine, Sexual Health and Reproductive Medicine Section. London, United Kingdom. 2002-04-16 [2022-01-14]. （原始内容存档于2022-04-19）.
Green, R., & Money, J. (1969). Transsexualism and Sex Reassignment. Johns Hopkins University Press. https://scholar.google.com/scholar?cluster=8048451400842332421 （页面存档备份，存于互联网档案馆） https://books.google.com/books?id=pdBrAAAAMAAJ （页面存档备份，存于互联网档案馆）
Benjamin, H., & Ihlenfeld, C. L. (1970). The Nature and Treatment of Transsexualism. Medical Opinion and Review, 6(11), 24–35. "Fortunately, the first medical textbook in this field, Transsexualism and Sex Reassignment, edited by Richard Green and John Money (Johns Hopkins Press, Baltimore, 1969), is now available." https://scholar.google.com/scholar?cluster=4496539582926153095 （页面存档备份，存于互联网档案馆）

semanticscholar.org (Global: 11^th place; Chinese: 332^nd place)

api.semanticscholar.org

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Murad, Mohammad Hassan; Elamin, Mohamed B.; Garcia, Magaly Zumaeta; Mullan, Rebecca J.; Murad, Ayman; Erwin, Patricia J.; Montori, Victor M. Hormonal therapy and sex reassignment: A systematic review and meta-analysis of quality of life and psychosocial outcomes. Clinical Endocrinology. 2010, 72 (2): 214–231. PMID 19473181. S2CID 19590739. doi:10.1111/j.1365-2265.2009.03625.x.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Wylie, Kevan; Barrett, James; Besser, Mike; Bouman, Walter Pierre; Bridgman, Michelle; Clayton, Angela; Green, Richard; Hamilton, Mark; Hines, Melissa; Ivbijaro, Gabriel; Khoosal, Deenesh; Lawrence, Alex; Lenihan, Penny; Loewenthal, Del; Ralph, David; Reed, Terry; Stevens, John; Terry, Tim; Thom, Ben; Thornton, Jane; Walsh, Dominic; Ward, David; Coleman, Eli; Di Ceglie, Domenico; Martin, Emma; McGarry, Philip; Messenger, Andrew; Reid, Russell; Sethi, Su; Sutcliffe, Paul; Wilson, Daniel; Carr, Susan; Davies, Dai; Dean, Tracey; Ellis, Michelle; Ferguson, Brian; Skinner, Darren; Williams, Vicky; Brechin, Susan; Lucey, Jim; Rathbone, Maxine. Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria (PDF). Sexual and Relationship Therapy. 2014, 29 (2): 154–214 [2021-10-15]. ISSN 1468-1994. S2CID 144632597. doi:10.1080/14681994.2014.883353. （原始内容 (PDF)存档于2018-09-02）.
Nakatsuka M. Endocrine treatment of transsexuals: assessment of cardiovascular risk factors. Expert Rev Endocrinol Metab. 2010-05, 5 (3): 319–322. PMID 30861686. S2CID 73253356. doi:10.1586/eem.10.18.
Winkler-Crepaz, K.; Müller, A.; Böttcher, B.; Wildt, L. Hormonbehandlung bei Transgenderpatienten [Hormone treatment of transgender patients]. Gynäkologische Endokrinologie. 2017, 15 (1): 39–42. ISSN 1610-2894. S2CID 12270365. doi:10.1007/s10304-016-0116-9.
Urdl, W. Behandlungsgrundsätze bei Transsexualität [Therapeutic principles in transsexualism]. Gynäkologische Endokrinologie. 2009, 7 (3): 153–160. ISSN 1610-2894. S2CID 8001811. doi:10.1007/s10304-009-0314-9.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Coxon, Jonny; Seal, Leighton. Hormone management of trans women. Trends in Urology & Men's Health. 2018, 9 (6): 10–14. ISSN 2044-3730. S2CID 222189278. doi:10.1002/tre.663.
Meriggiola MC, Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin. Endocrinol. (Oxf). 2015-11, 83 (5): 607–15. PMID 25692882. S2CID 39706760. doi:10.1111/cen.12754.
Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Majumder, Anirban; Chatterjee, Sudip; Maji, Debasis; Roychaudhuri, Soumyabrata; Ghosh, Sujoy; Selvan, Chitra; George, Belinda; Kalra, Pramila; Maisnam, Indira; Sanyal, Debmalya. IDEA group consensus statement on medical management of adult gender incongruent individuals seeking gender reaffirmation as female. Indian Journal of Endocrinology and Metabolism. 2020, 24 (2): 128. ISSN 2230-8210. PMID 32699777. S2CID 218596936. doi:10.4103/ijem.IJEM_593_19.
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2022-01-07]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始内容 (PDF)存档于2016-08-22）.
Irwig MS. Cardiovascular health in transgender people. Rev Endocr Metab Disord. 2018-09, 19 (3): 243–251. PMID 30073551. S2CID 51908458. doi:10.1007/s11154-018-9454-3.
Ockrim J, Lalani EN, Abel P. Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nat Clin Pract Oncol. 2006-10, 3 (10): 552–63. PMID 17019433. S2CID 6847203. doi:10.1038/ncponc0602.
Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A. Single drug polyestradiol phosphate therapy in prostatic cancer. Am. J. Clin. Oncol. 1988,. 11 Suppl 2: S101–3. PMID 3242384. S2CID 32650111. doi:10.1097/00000421-198801102-00024.
Wylie, Kevan Richard; Fung, Robert; Boshier, Claudia; Rotchell, Margaret. Recommendations of endocrine treatment for patients with gender dysphoria. Sexual and Relationship Therapy. 2009, 24 (2): 175–187. ISSN 1468-1994. S2CID 20471537. doi:10.1080/14681990903023306.
Schneider HP. Androgens and antiandrogens. Ann. N. Y. Acad. Sci. 2003-11, 997 (1): 292–306. Bibcode:2003NYASA.997..292S. PMID 14644837. S2CID 8400556. doi:10.1196/annals.1290.033.
Gibson DA, Saunders PK, McEwan IJ. Androgens and androgen receptor: Above and beyond. Mol. Cell. Endocrinol. 2018-04, 465: 1–3. PMID 29481861. S2CID 3702165. doi:10.1016/j.mce.2018.02.013.
de Lignières B, Silberstein S. Pharmacodynamics of oestrogens and progestogens. Cephalalgia. 2000-04, 20 (3): 200–7. PMID 10997774. S2CID 40392817. doi:10.1046/j.1468-2982.2000.00042.x.
McMullen GR, Van Herle AJ. Hirsutism and the effectiveness of spironolactone in its management. J. Endocrinol. Invest. 1993-12, 16 (11): 925–32. PMID 8144871. S2CID 42231952. doi:10.1007/BF03348960.
Doggrell SA, Brown L. The spironolactone renaissance. Expert Opin Investig Drugs. 2001-05, 10 (5): 943–54. PMID 11322868. S2CID 39820875. doi:10.1517/13543784.10.5.943.
Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003, 63 (5): 463–92. PMID 12600226. S2CID 28436828. doi:10.2165/00003495-200363050-00003.
Fung, Raymond; Hellstern-Layefsky, Miriam; Lega, Iliana. Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?. International Journal of Transgenderism. 2017, 18 (2): 123–128. ISSN 1553-2739. S2CID 79095497. doi:10.1080/15532739.2017.1290566.
Meyer G, Mayer M, Mondorf A, Fluegel AK, Herrmann E, Bojunga J. Safety and rapid efficacy of guideline-based gender affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. Eur. J. Endocrinol. 2019-11, 182 (2): 149–156. PMID 31751300. S2CID 208229129. doi:10.1530/EJE-19-0463.
Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol. Int. 2004, 73 (4): 289–95. PMID 15604569. S2CID 24799765. doi:10.1159/000081585.
Nieschlag E, Zitzmann M, Kamischke A. Use of progestins in male contraception. Steroids. 2003-11, 68 (10–13): 965–72. PMID 14667989. S2CID 22458746. doi:10.1016/S0039-128X(03)00135-1.
Geller J, Albert J, Geller S. Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue. The Prostate. 1982, 3 (1): 11–5. PMID 6176985. S2CID 23541558. doi:10.1002/pros.2990030103.
Wenderoth, U. K.; Jacobi, G. H. Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. World Journal of Urology. 1983, 1 (1): 40–48. ISSN 0724-4983. S2CID 23447326. doi:10.1007/BF00326861.
Melamed AJ. Current concepts in the treatment of prostate cancer. Drug Intell Clin Pharm. 1987-03, 21 (3): 247–54. PMID 3552544. S2CID 7482144. doi:10.1177/106002808702100302. [醋酸甲羟孕酮]使血浆睾酮水平暂时降低至略高于去势男性的水平。当以40 mg tid的剂量使用时，与0.5–1.5 mg/d的雌二醇联合使用，可协同抑制垂体促性腺激素，并将血浆睾酮维持在去势水平长达一年。（[Megestrol acetate] produces a transient reduction in plasma testosterone to levels somewhat higher than those in castrated men. When used in a dose of 40 mg tid, in combination with estradiol 0.5–1.5 mg/d, it acts synergistically to suppress pituitary gonadotropins and maintain plasma testosterone at castration levels for periods up to one year.）
Erem C. Update on idiopathic hirsutism: diagnosis and treatment. Acta Clin Belg. 2013, 68 (4): 268–74. PMID 24455796. S2CID 39120534. doi:10.2143/ACB.3267.
Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 2018-03, 103 (3): 824–838. PMID 29211888. S2CID 3784055. doi:10.1210/jc.2017-01186 .
Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens. J. Urol. 2018-05, 200 (5): 956–966. PMID 29730201. S2CID 19162538. doi:10.1016/j.juro.2018.04.083.
Ricci F, Buzzatti G, Rubagotti A, Boccardo F. Safety of antiandrogen therapy for treating prostate cancer. Expert Opin Drug Saf. 2014-11, 13 (11): 1483–99. PMID 25270521. S2CID 207488100. doi:10.1517/14740338.2014.966686.
Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect. Case Reports in Gastroenterology. 2018, 12 (2): 266–270. ISSN 1662-0631. S2CID 81661015. doi:10.1159/000485175 .
Gao Y, Maurer T, Mirmirani P. Understanding and Addressing Hair Disorders in Transgender Individuals. Am J Clin Dermatol. 2018-01, 19 (4): 517–527. PMID 29352423. S2CID 6467968. doi:10.1007/s40257-018-0343-z. 非甾体抗雄激素包括氟他胺、尼鲁米特和比卡鲁胺，它们不会降低雄激素水平，可能对想要保持性欲和生育能力的个体有利[9]。（Non-steroidal antiandrogens include flutamide, nilutamide, and bicalutamide, which do not lower androgen levels and may be favorable for individuals who want to preserve sex drive and fertility [9].）
Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International. 2001-01, 87 (1): 47–56. PMID 11121992. S2CID 28215804. doi:10.1046/j.1464-410x.2001.00988.x .
Morgante, E; Gradini, R; Realacci, M; Sale, P; D'eramo, G; Perrone, G A; Cardillo, M R; Petrangeli, E; Russo, Ma; Di Silverio, F. Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study. Histopathology. 2001, 38 (3): 195–201. ISSN 0309-0167. PMID 11260298. S2CID 36892099. doi:10.1046/j.1365-2559.2001.01077.x.
Jones, C. A.; Reiter, L.; Greenblatt, E. Fertility preservation in transgender patients. International Journal of Transgenderism. 2016, 17 (2): 76–82. ISSN 1553-2739. S2CID 58849546. doi:10.1080/15532739.2016.1153992. 传统上，建议患者在开始异性激素治疗之前冷冻保存精子，因为随着时间的推移，高剂量雌激素治疗可能会降低精子活力（Lubbert等，1992）。然而，由于研究有限，雌激素治疗导致的生育力下降仍有争议。（Traditionally, patients have been advised to cryopreserve sperm prior to starting cross-sex hormone therapy as there is a potential for a decline in sperm motility with high-dose estrogen therapy over time (Lubbert et al., 1992). However, this decline in fertility due to estrogen therapy is controversial due to limited studies.）
Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007-02, 3 (2): 157–67. PMID 17237842. S2CID 19745821. doi:10.1038/ncpendmet0399.
Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015-01, 11 (1): 19–28. PMID 25581052. S2CID 7516507. doi:10.2217/whe.14.68 .
Krakowsky Y, Morgentaler A. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. Eur Urol Focus. 2017-07, 5 (1): 81–89. PMID 28753828. S2CID 10011200. doi:10.1016/j.euf.2017.06.008.
Scaletscky R, Smith JA. Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?. Drug Saf. 1993-04, 8 (4): 265–70. PMID 8481213. S2CID 36964191. doi:10.2165/00002018-199308040-00001.
Reilly DR, Delva NJ, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Can J Psychiatry. 2000-08, 45 (6): 559–63. PMID 10986575. S2CID 27710792. doi:10.1177/070674370004500608 . [...]在第一次注射亮丙瑞林之前进行雌激素或抗雄激素治疗可能会降低[治疗开始时由睾酮“爆发”引起的症状风险]（16）。（[...] estrogen or antiandrogen treatment prior to the first leuprolide injection may reduce [the risk of symptoms caused by the testosterone "flare" at the initiation of treatment] (16).）
Marchetti PM, Barth JH. Clinical biochemistry of dihydrotestosterone. Ann. Clin. Biochem. 2013-03, 50 (Pt 2): 95–107. PMID 23431485. S2CID 8325257. doi:10.1258/acb.2012.012159.
Okeigwe I, Kuohung W. 5-Alpha reductase deficiency: a 40-year retrospective review. Curr Opin Endocrinol Diabetes Obes. 2014-12, 21 (6): 483–7. PMID 25321150. S2CID 1093345. doi:10.1097/MED.0000000000000116.
Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol. Cell. Endocrinol. 2002-12, 198 (1–2): 51–9. PMID 12573814. S2CID 54356569. doi:10.1016/S0303-7207(02)00368-4.
Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 2000-04, 37 (4): 367–80. PMID 10765065. S2CID 25793400. doi:10.1159/000020181.
Yamana K, Labrie F, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010-08, 2 (3): 293–9. PMID 25961201. S2CID 28841145. doi:10.1515/HMBCI.2010.035.
Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2018-08, 7 (1): 95–114. PMID 30098986. S2CID 51968365. doi:10.1016/j.sxmr.2018.06.002.
Azzouni F, Mohler J. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis. 2012-09, 15 (3): 222–30. PMID 22333687. S2CID 205537645. doi:10.1038/pcan.2012.1 .
Yim E, Nole KL, Tosti A. 5α-Reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2014-12, 21 (6): 493–8. PMID 25268732. S2CID 30008068. doi:10.1097/MED.0000000000000112.
Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010-06, 44 (6): 1090–7. PMID 20442354. S2CID 207263793. doi:10.1345/aph.1M591.
Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014-07, 15 (3): 217–30. PMID 24848508. S2CID 31245042. doi:10.1007/s40257-014-0077-5.
Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012-01, 32 (1): 54–66. PMID 22392828. S2CID 12853220. doi:10.1002/PHAR.1006.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin. Endocrinol. (Oxf). 2003-10, 59 (4): 409–18. PMID 14510900. S2CID 24493388. doi:10.1046/j.1365-2265.2003.01821.x.
Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018-05, 28 (3): 288–293 [2022-01-14]. PMID 29528971. S2CID 4587434. doi:10.1097/MOU.0000000000000497. （原始内容存档于2022-04-21）.
Traish, Abdulmaged M. The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. Current Sexual Health Reports. 2018, 10 (3): 88–103. ISSN 1548-3584. S2CID 81560714. doi:10.1007/s11930-018-0161-6.
Kuhl, Herbert; Wiegratz, Inka. Das Post-Finasterid-Syndrom [The Post-Finasteride Syndrome]. Gynäkologische Endokrinologie. 2017, 15 (2): 153–163. ISSN 1610-2894. S2CID 207071180. doi:10.1007/s10304-017-0126-2.
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?. Rev Endocr Metab Disord. 2015-09, 16 (3): 177–98. PMID 26296373. S2CID 25002351. doi:10.1007/s11154-015-9319-y.
Trüeb RM. Discriminating in favour of or against men with increased risk of finasteride-related side effects?. Exp. Dermatol. 2017-06, 26 (6): 527–528. PMID 27489125. S2CID 36236057. doi:10.1111/exd.13155 . [...]建议在为男性到女性的跨性别者开具口服非那雄胺的处方时要谨慎，因为该药物与诱发抑郁、焦虑和自杀意念有关，这些症状在性别不安患者中尤为常见，他们已经处于高风险中[9]。（[...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.[9]）
Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects?. Trends Endocrinol. Metab. 2004-08, 15 (6): 277–85. PMID 15358281. S2CID 35891204. doi:10.1016/j.tem.2004.06.006.
Fabris B, Bernardi S, Trombetta C. Cross-sex hormone therapy for gender dysphoria. J. Endocrinol. Invest. 2015-03, 38 (3): 269–82. PMID 25403429. S2CID 207503049. doi:10.1007/s40618-014-0186-2.
Meyer WJ, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Archives of Sexual Behavior. 1986-04, 15 (2): 121–38. PMID 3013122. S2CID 42786642. doi:10.1007/bf01542220.
Howard BA, Gusterson BA. Human breast development. Journal of Mammary Gland Biology and Neoplasia. 2000, 5 (2): 119–37. PMID 11149569. S2CID 10819224. doi:10.1023/A:1026487120779. 在基质中，纤维和脂肪组织的数量增加，成人非哺乳期乳房由80%或更多的基质组成。（In the stroma, there is an increase in the amount of fibrous and fatty tissue, with the adult nonlactating breast consisting of 80% or more of stroma.）
Farage MA, Neill S, MacLean AB. Physiological changes associated with the menstrual cycle: a review. Obstet Gynecol Surv. 2009, 64 (1): 58–72. PMID 19099613. S2CID 22293838. doi:10.1097/OGX.0b013e3181932a37.
Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric. 2012-04,. 15 Suppl 1: 18–25. PMID 22432812. S2CID 17700754. doi:10.3109/13697137.2012.669584.
Pasqualini JR. Progestins and breast cancer. Gynecol. Endocrinol. 2007,. 23 Suppl 1: 32–41. PMID 17943537. S2CID 46634314. doi:10.1080/09513590701585003.
Schindler AE. Dydrogesterone and other progestins in benign breast disease: an overview. Arch. Gynecol. Obstet. 2011-02, 283 (2): 369–71. PMID 20383772. S2CID 9125889. doi:10.1007/s00404-010-1456-7.
Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C. Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol. Endocrinol. 2001-12,. 15 Suppl 6: 37–43. PMID 12227885. S2CID 27589741. doi:10.1080/gye.15.s6.37.43.
Foss GL. Disturbances of lactation. Clin Obstet Gynecol. 1958-03, 1 (1): 245–54. PMID 13573669. S2CID 42825519. doi:10.1097/00003081-195803000-00021. 在实验上，我已经能够诱导一名男性异装癖者的泌乳，该男性异装癖者的睾丸在几年前已被切除，其乳房在很长一段时间内使用芪雌酚和乙炔雌酮，发育已良好[9]。1955年7月9日，皮下植入600 mg雌二醇，每周注射50 mg孕酮，持续四个月。下个月每天注射10 mg二丙酸雌二醇和50 mg孕酮。这些注射又持续了一个月，将孕酮增加到每天100 mg。然后停用两种激素，逐日增加剂量注射催乳素和生长激素，持续四天；同时，患者每天使用吸乳器四次，每次5分钟。在此期间，乳腺静脉明显增大，在第六天和第七天收集到了1到2 mg乳状液体。（Experimentally I have been able to induce lactogenesis in a male transvestite whose testes had been removed some years before and whose breasts had been well developed over a long period with stilbestrol and ethisterone.9 In July, 1955, 600 mg. of estradiol was implanted subcutaneously and weekly injections of 50 mg. of progesterone were given for four months. For the next month daily injections of 10 mg. estradiol dipropionate and 50 mg. progesterone were given. These injections were continued for another month, increasing progesterone to 100 mg. daily. Both hormones were then withdrawn, and daily injections of increasing doses of prolactin and somatotropin were given for four days; at the same time, the patient used a breast bump four times daily for 5 minutes on both sides. During this time the mammary veins were visibly enlarged and on the sixth and seventh days 1 to 2 cc. of milky fluid was collected.）
Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G. Allopregnanolone and mood disorders. Prog. Neurobiol. 2014, 113: 88–94. PMID 23978486. S2CID 207407084. doi:10.1016/j.pneurobio.2013.07.005.
Davey DA. Menopausal hormone therapy: a better and safer future. Climacteric. 2018-03, 21 (5): 454–461. PMID 29526116. S2CID 3850275. doi:10.1080/13697137.2018.1439915.
Nota NM, Wiepjes CM, de Blok CJ, Gooren LJ, Peerdeman SM, Kreukels BP, den Heijer M. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018-07, 141 (7): 2047–2054. PMID 29688280. S2CID 19934721. doi:10.1093/brain/awy108 .
Kuhl H, Schneider HP. Progesterone--promoter or inhibitor of breast cancer. Climacteric. 2013-08,. 16 Suppl 1: 54–68. PMID 23336704. S2CID 20808536. doi:10.3109/13697137.2013.768806.
de Ziegler D, Fanchin R. Progesterone and progestins: applications in gynecology. Steroids. 2000, 65 (10–11): 671–9. PMID 11108875. S2CID 5867301. doi:10.1016/S0039-128X(00)00123-9.
Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML, Bertino JS. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J Clin Pharmacol. 2005, 45 (6): 614–9. PMID 15901742. S2CID 28399314. doi:10.1177/0091270005276621.
Brady BM, Anderson RA, Kinniburgh D, Baird DT. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. Clin. Endocrinol. (Oxf). 2003, 58 (4): 506–12. PMID 12641635. S2CID 12567639. doi:10.1046/j.1365-2265.2003.01751.x.
Paynter MJ. Medication and Facilitation of Transgender Women's Lactation. J Hum Lact. 2019-03, 35 (2): 239–243. PMID 30840524. S2CID 73466659. doi:10.1177/0890334419829729.
Telis, Leon; Baum, Stephanie; Singer, Tomer; Berookhim, Boback M. Fertility Issues in Transgender Care. Transgender Medicine. Contemporary Endocrinology. 2019: 197–212. ISBN 978-3-030-05682-7. ISSN 2523-3785. S2CID 151135327. doi:10.1007/978-3-030-05683-4_11.
de Blok CJ, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, Schreiner T, T'Sjoen G, den Heijer M. Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study. J. Clin. Endocrinol. Metab. 2018-02, 103 (2): 532–538. PMID 29165635. S2CID 3716975. doi:10.1210/jc.2017-01927 .
Randall VA, Hibberts NA, Thornton MJ, Hamada K, Merrick AE, Kato S, Jenner TJ, De Oliveira I, Messenger AG. The hair follicle: a paradoxical androgen target organ. Horm. Res. 2000, 54 (5–6): 243–50. PMID 11595812. S2CID 42826314. doi:10.1159/000053266.
Kiely PM, Carney LG, Smith G. Menstrual cycle variations of corneal topography and thickness (PDF). American Journal of Optometry and Physiological Optics. 1983-10, 60 (10): 822–9 [2022-01-14]. PMID 6650653. S2CID 43222063. doi:10.1097/00006324-198310000-00003. （原始内容 (PDF)存档于2022-03-17）.
Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Annals of the New York Academy of Sciences. 2002-06, 966 (1): 211–22. Bibcode:2002NYASA.966..211S. PMID 12114274. S2CID 22281698. doi:10.1111/j.1749-6632.2002.tb04217.x.
Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?. Cornea. 2003-08, 22 (6): 516–21. PMID 12883343. S2CID 29374194. doi:10.1097/00003226-200308000-00006.
Garcia, Maurice; Zaliznyak, Michael. Mp45-20 Effects of Feminizing Hormone Therapy on Sexual Function of Transgender Women. The Journal of Urology. 2020, 203 (Supplement 4): e672. S2CID 218946871. doi:10.1097/JU.0000000000000900.020.
Smith, Elke Stefanie; Junger, Jessica; Derntl, Birgit; Habel, Ute. The transsexual brain – A review of findings on the neural basis of transsexualism. Neuroscience & Biobehavioral Reviews. 2015, 59: 251–266. ISSN 0149-7634. PMID 26429593. S2CID 23913935. doi:10.1016/j.neubiorev.2015.09.008.
Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, Carlström K. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate. 1988, 13 (3): 257–61. PMID 3211807. S2CID 20686808. doi:10.1002/pros.2990130308.
von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R. Estrogen therapy and liver function--metabolic effects of oral and parenteral administration. Prostate. 1989, 14 (4): 389–95. PMID 2664738. S2CID 21510744. doi:10.1002/pros.2990140410.
Aro J. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate. 1991, 18 (2): 131–7. PMID 2006119. S2CID 27915767. doi:10.1002/pros.2990180205.
Henriksson P. Estrogen in patients with prostatic cancer. An assessment of the risks and benefits. Drug Saf. 1991, 6 (1): 47–53. PMID 2029353. S2CID 39861824. doi:10.2165/00002018-199106010-00005.
Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand. J. Urol. Nephrol. 2002, 36 (6): 405–13. PMID 12623503. S2CID 2799580. doi:10.1080/003655902762467549.
Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003-08, 362 (9382): 428–32. PMID 12927428. S2CID 45789951. doi:10.1016/S0140-6736(03)14066-4.
Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005-11, 112 (22): 3495–500. PMID 16301339. S2CID 13587974. doi:10.1161/CIRCULATIONAHA.105.565556 .
Basurto L, Saucedo R, Zárate A, Martínez C, Gaminio E, Reyes E, Hernandez M. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Gynecol. Obstet. Invest. 2006, 61 (2): 61–4. PMID 16192735. S2CID 38375159. doi:10.1159/000088603.
Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2006-07, 26 (7): 1660–6. PMID 16645152. S2CID 12778600. doi:10.1161/01.ATV.0000224325.96659.53 .
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand. J. Urol. Nephrol. 2008, 42 (3): 220–9. PMID 18432528. S2CID 38638336. doi:10.1080/00365590801943274.
Rosendale N, Goldman S, Ortiz GM, Haber LA. Acute Clinical Care for Transgender Patients: A Review. JAMA Intern Med. 2018-11, 178 (11): 1535–1543. PMID 30178031. S2CID 52146607. doi:10.1001/jamainternmed.2018.4179.
Speed V, Roberts LN, Patel JP, Arya R. Venous thromboembolism and women's health. Br. J. Haematol. 2018-11, 183 (3): 346–363. PMID 30334572. S2CID 52985304. doi:10.1111/bjh.15608 .
Houlberg, Magda. Endocrinology, Hormone Replacement Therapy (HRT), and Aging. Transgender and Gender Nonconforming Health and Aging. 2019: 21–35. ISBN 978-3-319-95030-3. S2CID 81674566. doi:10.1007/978-3-319-95031-0_2.
Streed CG, Harfouch O, Marvel F, Blumenthal RS, Martin SS, Mukherjee M. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann. Intern. Med. 2017-08, 167 (4): 256–267. PMID 28738421. S2CID 207538881. doi:10.7326/M17-0577.
Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res. Treat. 2015-01, 149 (1): 191–8. PMID 25428790. S2CID 10935304. doi:10.1007/s10549-014-3213-2.
Hartley RL, Stone JP, Temple-Oberle C. Breast cancer in transgender patients: A systematic review. Part 1: Male to female. Eur J Surg Oncol. 2018-10, 44 (10): 1455–1462. PMID 30087072. S2CID 51936024. doi:10.1016/j.ejso.2018.06.035.
Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014, 46 (10): 1156–60. PMID 24329588. S2CID 1445627. doi:10.1111/and.12208.
McFarlane T, Zajac JD, Cheung AS. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review. Clin. Endocrinol. (Oxf). 2018-12, 89 (6): 700–711. PMID 30107028. S2CID 52003943. doi:10.1111/cen.13835 .
McFarlane, Thomas; Zajac, Jeffrey D.; Cheung, Ada S. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review. Clinical Endocrinology. 2018, 89 (6): 700–711. ISSN 0300-0664. PMID 30107028. S2CID 52003943. doi:10.1111/cen.13835 .
Nota, Nienke M; Wiepjes, Chantal M; de Blok, Christel J M; Gooren, Louis J G; Peerdeman, Saskia M; Kreukels, Baudewijntje P C; den Heijer, Martin. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018, 141 (7): 2047–2054. ISSN 0006-8950. PMID 29688280. S2CID 19934721. doi:10.1093/brain/awy108 .
Mahfouda, Simone; Moore, Julia K; Siafarikas, Aris; Hewitt, Timothy; Ganti, Uma; Lin, Ashleigh; Zepf, Florian Daniel. Gender-affirming hormones and surgery in transgender children and adolescents. The Lancet Diabetes & Endocrinology. 2019, 7 (6): 484–498. ISSN 2213-8587. PMID 30528161. S2CID 54478571. doi:10.1016/S2213-8587(18)30305-X.
Bisson, Jason R.; Chan, Kelly J.; Safer, Joshua D. Prolactin levels do not rise among transgender women treated with estradiol and spironolactone. Endocrine Practice. 2018, 24 (7): 646–651. ISSN 1530-891X. PMID 29708436. S2CID 14022275. doi:10.4158/EP-2018-0101.
Bullough VL. Transsexualism in history. Arch Sex Behav. 1975-09, 4 (5): 561–71. PMID 1103789. S2CID 36577490. doi:10.1007/bf01542134.
Schaefer LC, Wheeler CC. Harry Benjamin's first ten cases (1938-1953): a clinical historical note. Arch Sex Behav. 1995-02, 24 (1): 73–93. PMID 7733806. S2CID 31571764. doi:10.1007/bf01541990.
Edgerton MT, Knorr NJ, Callison JR. The surgical treatment of transsexual patients. Limitations and indications. Plast. Reconstr. Surg. 1970-01, 45 (1): 38–46. PMID 4902840. S2CID 27318408. doi:10.1097/00006534-197001000-00006.
Ekins, Richard. Science, Politics and Clinical Intervention: Harry Benjamin, Transsexualism and the Problem of Heteronormativity. Sexualities. 2016, 8 (3): 306–328. ISSN 1363-4607. S2CID 143544267. doi:10.1177/1363460705049578.
Steinbeck, A. W. Of Homosexuality: The Current State of Knowledge. Journal of Christian Education. 1977, os–20 (2): 58–82. ISSN 0021-9657. S2CID 149168765. doi:10.1177/002196577702000204.
Dahl, Marshall; Feldman, Jamie L.; Goldberg, Joshua M.; Jaberi, Afshin. Physical Aspects of Transgender Endocrine Therapy. International Journal of Transgenderism. 2006, 9 (3–4): 111–134. ISSN 1553-2739. S2CID 146232471. doi:10.1300/J485v09n03_06.
Gooren LJ, van der Veen EA, van Kessel H, Harmsen-Louman W, Wiegel AR. Androgens in the feedback regulation of gonadotropin secretion in men: effects of administration of dihydrotestosterone to eugonadal and agonadal subjects and of spironolactone to eugonadal subjects. Andrologia. 1984, 16 (4): 289–98. PMID 6433746. S2CID 32546312. doi:10.1111/j.1439-0272.1984.tb00286.x.

sherbourne.on.ca (Global: low place; Chinese: low place)

Bourns, Amy. Guidelines and Protocols for Comprehensive Primary Care for Trans Clients (PDF). Sherbourne Health Centre. 2015 [2018-08-15]. （原始内容 (PDF)存档于2020-05-10）.

sunderlandccg.nhs.uk (Global: low place; Chinese: low place)

Leighton Seal; James Barret. GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA (PDF) (报告). NHS. December 2015 [2022-01-15]. （原始内容 (PDF)存档于2021-07-03）.

theatlantic.com (Global: 228^th place; Chinese: 597^th place)

Branstetter, Gillian. Sketchy Pharmacies Are Selling Hormones to Transgender People: Burdened by cost and medical discrimination, many people are taking a do-it-yourself approach to transitioning. The Atlantic. 2016-08-31 [2018-12-29]. （原始内容存档于2021-04-15）.

transgendercare.com (Global: low place; Chinese: low place)

Asscheman H, Gooren LJ. Hormone Treatment in Transsexuals. 1992 [2008-06-13]. （原始内容存档于2012-06-03）.

ucsf.edu (Global: 5,479^th place; Chinese: 5,439^th place)

transhealth.ucsf.edu

Deutsch, Madeline. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People (PDF) 2nd. University of California, San Francisco: Center of Excellence for Transgender Health: 28. 2016-06-17 [2021-10-15]. （原始内容 (PDF)存档于2019-05-22）.

ugent.be (Global: 3,695^th place; Chinese: 6,619^th place)

biblio.ugent.be

Mueller, Sven C.; De Cuypere, Griet; T’Sjoen, Guy. Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective. American Journal of Psychiatry. 2017, 174 (12): 1155–1162 [2022-01-14]. ISSN 0002-953X. PMID 29050504. doi:10.1176/appi.ajp.2017.17060626. hdl:1854/LU-8542009. （原始内容存档于2022-04-21）.

upi.com (Global: 290^th place; Chinese: 1,067^th place)

Cone, Allen. FDA approves drug to control endometriosis pain. UPI. 2018-07-25 [2018-07-31]. （原始内容存档于2022-04-25）.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Deutsch, Madeline. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People (PDF) 2nd. University of California, San Francisco: Center of Excellence for Transgender Health: 28. 2016-06-17 [2021-10-15]. （原始内容 (PDF)存档于2019-05-22）.
Dahl, M; Feldman, JL; Goldberg, J; Jaberi, A. Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines (PDF). Vancouver Coastal Health. 2015 [2018-09-15]. （原始内容 (PDF)存档于2018-08-16）.
Bourns, Amy. Guidelines and Protocols for Comprehensive Primary Care for Trans Clients (PDF). Sherbourne Health Centre. 2015 [2018-08-15]. （原始内容 (PDF)存档于2020-05-10）.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Branstetter, Gillian. Sketchy Pharmacies Are Selling Hormones to Transgender People: Burdened by cost and medical discrimination, many people are taking a do-it-yourself approach to transitioning. The Atlantic. 2016-08-31 [2018-12-29]. （原始内容存档于2021-04-15）.
Newman, Rosalind; Jeory, Ted. Fears of 'DIY transitioning' as hormone drugs sold to transgender women without checks. The Independent. 2016-11-16 [2018-12-29]. （原始内容存档于2021-04-14）.
r/TransDIY. Reddit. [2018-12-29]. （原始内容存档于2022-05-18）.
r/MtFHRT. Reddit. [2018-12-29]. （原始内容存档于2020-11-25）.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (PDF). J. Clin. Endocrinol. Metab. 2017-11, 102 (11): 3869–3903 [2021-10-15]. PMID 28945902. S2CID 3726467. doi:10.1210/jc.2017-01658. （原始内容 (PDF)存档于2021-04-15）.
Wylie, Kevan; Barrett, James; Besser, Mike; Bouman, Walter Pierre; Bridgman, Michelle; Clayton, Angela; Green, Richard; Hamilton, Mark; Hines, Melissa; Ivbijaro, Gabriel; Khoosal, Deenesh; Lawrence, Alex; Lenihan, Penny; Loewenthal, Del; Ralph, David; Reed, Terry; Stevens, John; Terry, Tim; Thom, Ben; Thornton, Jane; Walsh, Dominic; Ward, David; Coleman, Eli; Di Ceglie, Domenico; Martin, Emma; McGarry, Philip; Messenger, Andrew; Reid, Russell; Sethi, Su; Sutcliffe, Paul; Wilson, Daniel; Carr, Susan; Davies, Dai; Dean, Tracey; Ellis, Michelle; Ferguson, Brian; Skinner, Darren; Williams, Vicky; Brechin, Susan; Lucey, Jim; Rathbone, Maxine. Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria (PDF). Sexual and Relationship Therapy. 2014, 29 (2): 154–214 [2021-10-15]. ISSN 1468-1994. S2CID 144632597. doi:10.1080/14681994.2014.883353. （原始内容 (PDF)存档于2018-09-02）.
James Barrett. Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management. CRC Press. 2017-09-29: 216– [2021-10-15]. ISBN 978-1-315-34513-0. （原始内容存档于2021-02-08）.
Carlo Trombetta; Giovanni Liguori; Michele Bertolotto. Management of Gender Dysphoria: A Multidisciplinary Approach. Springer. 2015-03-03: 85– [2021-10-15]. ISBN 978-88-470-5696-1. （原始内容存档于2022-04-25）.
Kristen Eckstrand; Jesse M. Ehrenfeld. Lesbian, Gay, Bisexual, and Transgender Healthcare: A Clinical Guide to Preventive, Primary, and Specialist Care. Springer. 2016-02-17: 357– [2021-10-15]. ISBN 978-3-319-19752-4. （原始内容存档于2022-04-25）.
Arver DS. Transsexualism, könsdysfori. 2015 [2018-11-12]. （原始内容存档于2019-03-29）.
Vincenzo Mirone. Clinical Uro-Andrology. Springer. 2015-02-12: 17– [2021-10-15]. ISBN 978-3-662-45018-5. （原始内容存档于2022-04-21）.
Gianna E. Israel. Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. 2001-03: 56– [2021-10-15]. ISBN 978-1-56639-852-7. （原始内容存档于2022-04-21）.
Orilissa (elagolix) FDA Label (PDF). 2018-07-24 [2018-07-31]. （原始内容 (PDF)存档于2021-10-21）.
William B. Shore. Adolescent Medicine, An Issue of Primary Care: Clinics in Office Practice, E-Book. Elsevier Health Sciences. 2014-08-21: 663– [2022-01-07]. ISBN 978-0-323-32340-6. （原始内容存档于2022-04-21）.
Ivy M. Alexander; Versie Johnson-Mallard; Elizabeth Kostas-Polston; Catherine Ingram Fogel, Nancy Fugate Woods. Women's Health Care in Advanced Practice Nursing, Second Edition. Springer Publishing Company. 2017-06-28: 468– [2022-01-07]. ISBN 978-0-8261-9004-8. （原始内容存档于2022-04-25）.
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2022-01-07]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始内容 (PDF)存档于2016-08-22）.
Alfred S. Wolf; H.P.G. Schneider. Östrogene in Diagnostik und Therapie. Springer-Verlag. 2013-03-12: 79, 81 [2022-01-14]. ISBN 978-3-642-75101-1. （原始内容存档于2022-04-21）.
Leinung, MC. Variable Response to Oral Estradiol Therapy in Male to Female Transgender Patients. Endocrine Reviews. 2014-06, 35 (Supplement) [2022-01-07]. doi:10.1210/endo-meetings.2014.RE.2.OR42-1 (不活跃 2021-10-31). （原始内容存档于2022-04-21）.
Carlo Trombetta; Giovanni Liguori; Michele Bertolotto. Management of Gender Dysphoria: A Multidisciplinary Approach. Springer. 2015-03-03: 85– [2021-10-15]. ISBN 978-88-470-5696-1. （原始内容存档于2022-04-25）.
Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg. Williams Textbook of Endocrinology. Elsevier Health Sciences. 2015-11-11: 714, 934 [2022-01-14]. ISBN 978-0-323-34157-8. （原始内容存档于2022-05-23）.
Sarah Boslaugh. Transgender Health Issues. ABC-CLIO. 2018-08-03: 37– [2022-01-14]. ISBN 978-1-4408-5888-8. （原始内容存档于2022-04-25）.
Jerome F. Strauss; Robert L. Barbieri; Antonio R. Gargiulo. Yen & Jaffe's Reproductive Endocrinology E-Book: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. 2017-12-23: 250– [2022-01-14]. ISBN 978-0-323-58232-2. （原始内容存档于2022-04-22）.
Dimitrakakis C. Androgens and breast cancer in men and women (PDF). Endocrinol. Metab. Clin. North Am. 2011-09, 40 (3): 533–47, viii [2022-01-14]. PMID 21889719. doi:10.1016/j.ecl.2011.05.007. （原始内容 (PDF)存档于2022-04-21）.
Loren S Schechter. Surgical Management of the Transgender Patient. Elsevier Health Sciences. 2016-09-22: 26– [2022-01-14]. ISBN 978-0-323-48408-4. （原始内容存档于2022-04-25）.
Lynne Carroll; Lauren Mizock. Clinical Issues and Affirmative Treatment with Transgender Clients, An Issue of Psychiatric Clinics of North America, E-Book. Elsevier Health Sciences. 2017-02-07: 107– [2022-01-14]. ISBN 978-0-323-51004-2. （原始内容存档于2022-04-21）.
Laura Erickson-Schroth. Trans Bodies, Trans Selves: A Resource for the Transgender Community. Oxford University Press. 2014-05-12: 258– [2022-01-14]. ISBN 978-0-19-932536-8. （原始内容存档于2022-04-25）.
J. Larry Jameson; Leslie J. De Groot. Endocrinology - E-Book: Adult and Pediatric. Elsevier Health Sciences. 2010-05-18: 2282– [2022-01-14]. ISBN 978-1-4557-1126-0. （原始内容存档于2022-04-21）.
Randi Ettner; Stan Monstrey; Eli Coleman. Principles of Transgender Medicine and Surgery. Routledge. 2016-05-20: 169–170, 216, 251 [2022-01-14]. ISBN 978-1-317-51460-2. （原始内容存档于2022-04-25）.
Jashin J. Wu. Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. 2012-10-18: 364– [2022-01-14]. ISBN 978-1-4557-3801-4. （原始内容存档于2020-08-19）. Spironolactone is an aldosterone antagonist and a relatively weak antiandrogen that blocks the AR and inhibits androgen biosynthesis.
H.J.T. Coelingh Benni; H.M. Vemer. Chronic Hyperandrogenic Anovulation. CRC Press. 1990-12-15: 152– [2022-01-14]. ISBN 978-1-85070-322-8. （原始内容存档于2020-08-19）.
Jeffrey K. Aronson. Meyler's Side Effects of Cardiovascular Drugs. Elsevier. 2009-03-02: 253–258 [2022-01-14]. ISBN 978-0-08-093289-7. （原始内容存档于2020-08-19）.
Pharmacology of the Skin II: Methods, Absorption, Metabolism and Toxicity, Drugs and Diseases. Springer Science & Business Media. 2012-12-06: 474, 489 [2022-01-14]. ISBN 978-3-642-74054-1. （原始内容存档于2022-04-30）.
Dangerous Sex Offenders: A Task Force Report of the American Psychiatric Association. American Psychiatric Pub. 1999: 112–144 [2022-01-14]. ISBN 978-0-89042-280-9. （原始内容存档于2020-08-01）.
Kravitz HM, Haywood TW, Kelly J, Liles S, Cavanaugh JL. Medroxyprogesterone and paraphiles: do testosterone levels matter?. Bull Am Acad Psychiatry Law. 1996, 24 (1): 73–83 [2022-01-14]. PMID 8891323. （原始内容存档于2018-08-16）.
Nieschlag E. Clinical trials in male hormonal contraception (PDF). Contraception. 2010-11, 82 (5): 457–70 [2022-01-14]. PMID 20933120. doi:10.1016/j.contraception.2010.03.020. （原始内容 (PDF)存档于2020-12-05）.
Hinman, Frank, Jr. Benign Prostatic Hypertrophy. Springer Science & Business Media. 1983: 259, 266, 272 [2022-01-14]. ISBN 978-1-4612-5476-8. （原始内容存档于2022-04-21）.
Wein, Alan J.; Kavoussi, Louis R.; Novick, Andrew C.; Partin, Alan W.; Peters, Craig A. Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. 2011-08-25: 2938– [2022-01-14]. ISBN 978-1-4160-6911-9. （原始内容存档于2020-12-22）.
A. Hughes; S. H. Hasan; G. W. Oertel; H. E. Voss, F. Bahner, F. Neumann, H. Steinbeck, K.-J. Gräf, J. Brotherton, H. J. Horn, R. K. Wagner. Androgens II and Antiandrogens / Androgene II und Antiandrogene. Springer Science & Business Media. 2013-11-27: 490–491 [2022-01-14]. ISBN 978-3-642-80859-3. （原始内容存档于2022-04-25）.
Thomas L. Lemke; David A. Williams. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 2008: 1286–1288 [2022-01-14]. ISBN 978-0-7817-6879-5. （原始内容存档于2017-09-08）.
Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A. Flutamide-induced hepatotoxicity: ethical and scientific issues (PDF). Eur Rev Med Pharmacol Sci. 2017-03, 21 (1 Suppl): 69–77 [2022-01-14]. PMID 28379593. （原始内容 (PDF)存档于2020-11-12）.
William D. Figg; Cindy H. Chau; Eric J. Small. Drug Management of Prostate Cancer. Springer Science & Business Media. 2010-09-14: 71–72 [2022-01-14]. ISBN 978-1-60327-829-4. （原始内容存档于2022-04-21）.
Bruce A. Chabner; Dan L. Longo. Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. 2010-11-08: 680– [2022-01-14]. ISBN 978-1-60547-431-1. （原始内容存档于2020-07-27）.
Neyman, A; Fuqua, JS; Eugster, EA. Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents. Hormone Research in Paediatrics. 2017-12, 88: 1–628 [2022-01-14]. PMID 28968603. doi:10.1159/000481424 . （原始内容存档于2022-04-21）.
Lutz Moser. Controversies in the Treatment of Prostate Cancer. Karger Medical and Scientific Publishers. 2008-01-01: 41– [2022-01-14]. ISBN 978-3-8055-8524-8. （原始内容存档于2020-07-27）.
Prostate Cancer. Demos Medical Publishing. 2011-12-20: 460, 504 [2022-01-14]. ISBN 978-1-935281-91-7. （原始内容存档于2022-04-25）.
Chang, Stephen, Bicalutamide BPCA Drug Use Review in the Pediatric Population (PDF), U.S. Department of Health and Human Service, 2010-03-10 [2016-07-20], （原始内容存档 (PDF)于2016-10-24）
J. Ramon; L.J. Denis. Prostate Cancer. Springer Science & Business Media. 2007-06-05: 256– [2022-01-14]. ISBN 978-3-540-40901-4. （原始内容存档于2020-07-27）.
Payne, Anita H.; Hardy, Matthew P. The Leydig Cell in Health and Disease. Springer Science & Business Media. 2007-10-28: 422–431 [2022-01-14]. ISBN 978-1-59745-453-7. （原始内容存档于2020-07-27）. 雌激素是下丘脑-垂体-睾丸轴的高效抑制剂（212-214）。除了它们在下丘脑和垂体水平的负反馈作用外，还可能对睾丸产生直接抑制作用（215，216）。[...][用雌激素治疗的]睾丸组织学显示曲细精管紊乱、空泡化和管腔缺失，以及精子发生的区室化。（Estrogens are highly efficient inhibitors of the hypothalamic-hypophyseal-testicular axis (212–214). Aside from their negative feedback action at the level of the hypothalamus and pituitary, direct inhibitory effects on the testis are likely (215,216). [...] The histology of the testes [with estrogen treatment] showed disorganization of the seminiferous tubules, vacuolization and absence of lumen, and compartmentalization of spermatogenesis.）
Salam, Muhammad A. Principles & Practice of Urology: A Comprehensive Text. Universal-Publishers. 2003: 684– [2022-01-14]. ISBN 978-1-58112-412-5. （原始内容存档于2020-07-27）. 雌激素主要通过下丘脑-垂体水平的负反馈来减少LH分泌和睾丸雄激素合成。[...]有趣的是，如果不间断地暴露，3年后停止雌激素治疗，血清睾酮可能会保持在去势水平长达3年。这种长期抑制被认为是雌激素对睾丸间质细胞的直接影响所致。（Estrogens act primarily through negative feedback at the hypothalamic-pituitary level to reduce LH secretion and testicular androgen synthesis. [...] Interestingly, if the treatment with estrogens is discontinued after 3 yr. of uninterrupted exposure, serum testosterone may remain at castration levels for up to another 3 yr. This prolonged suppression is thought to result from a direct effect of estrogens on the Leydig cells.）
Shlomo Melmed. Williams Textbook of Endocrinology. Elsevier Health Sciences. 2016-01-01: 154, 621, 711 [2022-01-14]. ISBN 978-0-323-29738-7. （原始内容存档于2022-04-21）.
Timothy L. Ratliff; William J. Catalona. Genitourinary Cancer: Basic and Clinical Aspects. Springer Science & Business Media. 2012-12-06: 158– [2022-01-14]. ISBN 978-1-4613-2033-3. （原始内容存档于2022-04-21）.
Jerome F. Strauss; Jerome F. Strauss, III; Robert L. Barbieri. Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. 2013-09-13: 272– [2022-01-14]. ISBN 978-1-4557-2758-2. （原始内容存档于2022-04-25）.
J. Larry Jameson; Leslie J. De Groot. Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. 2015-02-25: 2009, 2207, 2479 [2022-01-14]. ISBN 978-0-323-32195-2. （原始内容存档于2022-04-21）.
Louis J Denis; Keith Griffiths; Amir V Kaisary; Gerald P Murphy. Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. CRC Press. 1999-03-01: 308– [2022-01-14]. ISBN 978-1-85317-422-3. （原始内容存档于2021-02-08）.
Loren S Schechter; Bauback Safa. Gender Confirmation Surgery, An Issue of Clinics in Plastic Surgery, E-Book. Elsevier Health Sciences. 2018-06-23: 314– [2022-01-14]. ISBN 978-0-323-61075-9. （原始内容存档于2022-04-26）.
Emans, S. Jean; Laufer, Marc R. Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology. Lippincott Williams & Wilkins. 2012-01-05: 365–. ISBN 978-1-4511-5406-1. （原始内容存档于2016-05-16）. Therapy with GnRH analogs is expensive and requires intramuscular injections of depot formulations, the insert of a subcutaneous implant yearly, or, much less commonly, daily subcutaneous injections.
Hillard, Paula J. Adams. Practical Pediatric and Adolescent Gynecology. John Wiley & Sons. 2013-03-29: 182– [2022-01-14]. ISBN 978-1-118-53857-9. （原始内容存档于2020-07-27）. Treatment is expensive, with costs typically in the range of $10,000–$15,000 per year.
Everett E. Vokes; Harvey M. Golomb. Oncologic Therapies. Springer Science & Business Media. 2011-06-28: 493– [2022-01-14]. ISBN 978-3-642-55780-4. （原始内容存档于2022-04-21）.
T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of Transgender Medicine. Endocrine Reviews. 2018-10, 40 (1): 97–117 [2022-01-14]. PMID 30307546. doi:10.1210/er.2018-00011 . （原始内容存档于2022-04-21）.
Cone, Allen. FDA approves drug to control endometriosis pain. UPI. 2018-07-25 [2018-07-31]. （原始内容存档于2022-04-25）.
Ulrike Blume-Peytavi; David A. Whiting; Ralph M. Trüeb. Hair Growth and Disorders. Springer Science & Business Media. 2008-06-26: 182, 369 [2022-01-14]. ISBN 978-3-540-46911-7. （原始内容存档于2020-01-11）.
Jerry Shapiro; Nina Otberg. Hair Loss and Restoration, Second Edition. CRC Press. 2015-04-17: 39–40 [2022-01-14]. ISBN 978-1-4822-3199-1. （原始内容存档于2020-01-11）.
Ralph M. Trüeb; Won-Soo Lee. Male Alopecia: Guide to Successful Management. Springer Science & Business Media. 2014-02-13: 91– [2022-01-14]. ISBN 978-3-319-03233-7. （原始内容存档于2021-08-29）.
Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018-05, 28 (3): 288–293 [2022-01-14]. PMID 29528971. S2CID 4587434. doi:10.1097/MOU.0000000000000497. （原始内容存档于2022-04-21）.
Thomas L. Lemke; David A. Williams. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 2012-01-24: 1397–1399 [2022-01-14]. ISBN 978-1-60913-345-0. （原始内容存档于2021-04-15）.
Mary C. Brucker; Tekoa L. King. Pharmacology for Women's Health. Jones & Bartlett Publishers. 2015-09-08: 368– [2022-01-14]. ISBN 978-1-284-05748-5. （原始内容存档于2022-04-26）.
Ilan H. Meyer; Mary E. Northridge. The Health of Sexual Minorities: Public Health Perspectives on Lesbian, Gay, Bisexual and Transgender Populations. Springer. 2007-03-12: 476– [2022-01-14]. ISBN 978-0-387-31334-4. （原始内容存档于2022-05-06）.
Gianna E. Israel; Donald E. Tarver; Joy Diane Shaffer. Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. 2001-03-01: 58– [2022-01-14]. ISBN 978-1-56639-852-7. （原始内容存档于2022-04-25）.
Richard Ekins; Dave King. The Transgender Phenomenon. SAGE Publications. 2006-10-23: 48– [2022-01-14]. ISBN 978-1-84787-726-0. （原始内容存档于2022-04-21）.
Daniel R. Mishell; Val Davajan. Reproductive endocrinology, infertility, and contraception. F. A. Davis Co. 1979: 224 [2022-01-14]. ISBN 978-0-8036-6235-3. （原始内容存档于2022-05-02）. 有人建议在每个雌激素治疗周期的最后一周添加孕激素，以形成更圆润的乳房，而不是这些患者中出现的锥形乳房，但我们无法检测到乳房轮廓在有没有孕激素情况下的差异。（It has been suggested that progestins be added during the last week of each cycle of estrogen therapy in order to develop more rounded breasts rather than the conical breasts many of these patients develop, but we have been unable to detect any difference in breast contour with or without progestins.）
Sperling, Mark A. Pediatric Endocrinology. Elsevier Health Sciences. 2014-04-10: 598– [2022-01-14]. ISBN 978-1-4557-5973-6. （原始内容存档于2022-04-30）. 雌激素刺激乳头生长，乳腺终末导管分支发展到形成导管的阶段，脂肪基质生长至构成乳房质量的约85%。[...]初潮前后，当末端导管分支形成多个盲囊芽时，乳腺小叶出现。这些效果是由于有孕酮存在。[...]完整的小泡发育通常仅在怀孕期间，在额外的孕酮和催乳素的影响下发生。（Estrogen stimulates the nipples to grow, mammary terminal duct branching to progress to the stage at which ductules are formed, and fatty stromal growth to increase until it constitutes about 85% of the mass of the breast. [...] Lobulation appears around menarche, when multiple blind saccular buds form by branching of the terminal ducts. These effects are due to the presence of progesterone. [...] Full alveolar development normally only occurs during pregnancy under the influence of additional progesterone and prolactin.）
Lee-Ellen C. Copstead-Kirkhorn; Jacquelyn L. Banasik. Pathophysiology - E-Book. Elsevier Health Sciences. 2014-06-25: 660– [2022-01-14]. ISBN 978-0-323-29317-4. （原始内容存档于2021-04-14）. 在整个生育期，一些女性在月经开始前的每个月经周期后期都会注意到乳房肿胀。在月经周期的这个阶段，乳房组织的保水和随后的肿胀被认为是由于高水平的循环孕酮刺激了乳房的分泌细胞。（Throughout the reproductive years, some women note swelling of the breast around the latter part of each menstrual cycle before the onset of menstruation. The water retention and subsequent swelling of breast tissue during this phase of the menstrual cycle are thought to be due to high levels of circulating progesterone stimulating the secretory cells of the breast.12）
Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 889– [2022-01-14]. ISBN 978-0-7817-1750-2. （原始内容存档于2022-04-21）.
Sanjay Rajagopalan; Debabrata Mukherjee; Emile R. Mohler. Manual of Vascular Diseases. Lippincott Williams & Wilkins. 2005: 1– [2022-01-14]. ISBN 978-0-7817-4499-7. （原始内容存档于2022-04-21）.
Paul Peter Rosen. Rosen's Breast Pathology. Lippincott Williams & Wilkins. 2009: 31– [2022-01-14]. ISBN 978-0-7817-7137-5. （原始内容存档于2020-07-27）.
Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000-10, 62 (8): 1839–46, 1849–50 [2022-01-14]. PMID 11057840. （原始内容存档于2022-04-21）.
Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007, 15 (5): 427–44 [2022-01-14]. PMID 17924777. doi:10.1037/1064-1297.15.5.427. （原始内容存档于2022-06-01）.
Kuhl H. Pharmacology of Progestogens (PDF). Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 2011, 8 (1): 157–177 [2022-01-14]. （原始内容 (PDF)存档于2016-10-11）.
A. Wayne Meikle. Hormone Replacement Therapy. Springer Science & Business Media. 1999-06-01: 383, 389 [2022-01-14]. ISBN 978-1-59259-700-0. （原始内容存档于2020-08-01）.
Kozlov GI, Mel'nichenko GA, Golubeva IV. Sluchai laktorei u bol'nogo muzhskogo pola s transseksualizmom [Case of galactorrhea in a transsexual male patient]. Probl Endokrinol (Mosk). 1985, 31 (1): 37–8 [2022-01-14]. ISSN 0375-9660. PMID 4039061. （原始内容存档于2022-04-21）（俄语）. [...]进行了外生殖器去势和女性化整形手术[...]手术后一段时间，患者对生活重新产生了兴趣。经过手术和荷尔蒙矫正后，患者不可抗拒地发展出母性本能。未婚，患者获准领养孩子，模拟怀孕，带着儿子从妇产医院出院。从“出生”后的第一天开始，溢乳急剧增加，出现自发流出乳汁，伴溢乳（+++）。婴儿一直母乳喂养到6个月大。[...]我们的信息是文献中第二例有关男性易性症患者溢乳的描述。R.[Flückiger]等人于1983年首次描述了这种类型(6)。这一观察结果证明了泌乳发育机制与一个人的遗传性别相独立，并且对男性发生药物性溢乳的可能性感到担忧。（[...] castration and feminizing plastic surgery of the external genitalia was performed [...] Some time after the operation, the patient developed a renewed interest in life. After the surgical and hormonal correction, the patient irresistibly developed maternal instincts. Unmarried, the patient obtained permission for the adoption of a child, simulated pregnancy, and was discharged from the maternity hospital with a son. From the first days after the “birth”, galactorrhea sharply increased, and spontaneous outflow of milk appeared, with galactorrhea (+++). The baby was breastfed up to 6 months of age. [...] Our message is the second in the world literature describing galactorrhea in a male patient with transsexualism. The first description of this kind was made in 1983 by R. [Flückiger] et al. (6). This observation demonstrates the independence of the mechanism of lactation development from one’s genetic sex and is alarming with regard to the possibility of drug-induced galactorrhea development in men.）
Foss, GL. Abnormalities of form and function of the human breast. Journal of Endocrinology. 1956-01, 14 (1): R6–R9 [2022-01-14]. （原始内容存档于2022-01-14）. 基于催乳理论，并受到Lyons、Li、Johnson&Cole[1955]在雄性大鼠中成功产生泌乳的激励，尝试在男性异装癖者中启动催乳。六年前，该患者接受了雌激素治疗。然后切除睾丸和阴茎，并通过整形手术构建人造阴道。该患者在1954年9月植入了500 mg雌二醇，在1955年7月植入了600 mg。然后每天注射二丙酸雌二醇和孕酮，持续6周，使乳房发育更加快速。停止该治疗后立即每天注射催乳素22·9 mg，连续3天无效。每天服用雌二醇和孕酮的第二个月后，联合注射催乳素和生长激素，持续4天，并通过吸乳器进行抽吸，每天4次。在第4天和第5天，从右侧乳头挤出几滴初乳。（Based on the theories of lactogenesis and stimulated by the success of Lyons, Li, Johnson & Cole [1955], who succeeded in producing lactation in male rats, an attempt was made to initiate lactogenesis in a male transvestist. Six years ago this patient had been given oestrogens. Both testes and penis were then removed and an artificial vagina was constructed by plastic surgery. The patient was implanted with 500 mg oestradiol in September 1954, and 600 mg in July 1955. The breasts were then developed more intensively with daily injections of oestradiol dipropionate and progesterone for 6 weeks. Immediately following withdrawal of this treatment, prolactin 22·9 mg was injected daily for 3 days without effect. After a second month on oestradiol and progesterone daily, combined injections of prolactin and somatotrophin were given for 4 days and suction was applied by a breast pump-four times daily. On the 4th and 5th days a few drops of colostrum were expressed from the right nipple.）
Harold Gardiner-Hill. Modern Trends in Endocrinology. Butterworth. 1958: 192 [2022-01-14]. （原始内容存档于2022-04-21）. 最近，Foss(1956)尝试在一名被阉割的男性异装癖者中开始哺乳。给他植入了500 mg的雌二醇，10个月后，又植入了600 mg的雌二醇，随后每天注射二丙酸雌二醇和黄体酮，持续6周。停药后立即每天注射22·9 mg催乳素，连续3天，但没有效果。在每天用雌二醇和黄体酮治疗的第二个月后，他被给予催乳素和生长激素联合注射4天，每天使用吸乳器抽吸4次。在第四天和第五天，从右侧乳头挤出几滴初乳。这是现代激素知识在男性中的一个可能应用，值得进一步试验。（Recently, an attempt has been made by Foss (1956) to initiate lactation in a castrated male transvestist. He was given an implant of 500 milligrams of oestradiol, and 10 months later, a further 600 milligrams of oestradiol, followed by daily injections of oestradiol dipropionate and progesterone for 6 weeks. Immediately after withdrawal of this treatment, 22·9 milligrams of prolactin were injected daily for 3 days but without effect. After a second month of treatment with oestradiol and progesterone daily, he was given combined injections of prolactin and somatotrophin for 4 days, suction with a breast-pump being employed 4 times daily. On the fourth and fifth days a few drops of colostrum were expressed from the right nipple. There is a possible application here of modern hormone knowledge to man, and further trials would be of interest.）
Edward Flückiger; Emilio Del Pozo; Klaus von Werder. Prolactin: Physiology, Pharmacology, and Clinical Findings. Springer-Verlag. 1982: 13 [2022-01-14]. ISBN 978-3-540-11071-2. （原始内容存档于2022-04-28）. [...]对男性变性者的观察（Wyss和DelPozo未发表）表明，在人类男性中也可以类似地实现泌乳诱导。[...]（[...] An observation (Wyss and Del Pozo unpublished) in a male transsexual showed that induction of lactation can be similarly achieved in the human male. [...]）
Carla A. Pfeffer. Queering Families: The Postmodern Partnerships of Cisgender Women and Transgender Men. Oxford University Press. 2017: 19– [2022-01-14]. ISBN 978-0-19-990805-9. （原始内容存档于2022-04-21）. 仅仅2年后，温弗瑞进行的另一次采访，引发了许多观众相同的反应。在2010年的这一集中，女同性恋伙伴克里斯汀·麦金博士和丽莎·博茨抱着他们的双胞胎婴儿时喜极而泣。再一次，当人们发现美丽的克里斯汀是一位男到女变性人，曾经是一位英俊的军官克里斯时，观众的下巴都掉了下来，而丽莎使用克里斯汀在性别确认手术之前储存的精子生下了她们的亲生孩子[10]。当温弗瑞观看克里斯汀母乳喂养她们孩子的视频时，温弗瑞的下巴差点撞到地板上（这一集在网上称为“成为自己孩子父亲的妈妈”）。[...]（Just 2 years later, Winfrey would feature another interview that elicited many of the same audience reactions. In this 2010 episode, lesbian partners Dr. Christine McGinn and Lisa Bortz beamed with joy as they held their infant twins. Again, audience members' jaws dropped when it was revealed that beautiful Christine was a male-to-female transsexual who used to be a handsome military officer Chris, and that Lisa had given birth to the couple's biological children using sperm Chris banked prior to gender confirmation surgeries.10 And it was Winfrey's chin that nearly hit the floor as she watched video of Christine breastfeeding the couples' children (the episode is referred to online as "The Mom Who Fathered Her Own Children"). [...]）
Michael S. Baggish; Mickey M. Karram. Atlas of Pelvic Anatomy and Gynecologic Surgery. Elsevier Health Sciences. 2011-08-18: 1200– [2022-01-14]. ISBN 978-1-4557-1068-3. （原始内容存档于2022-04-19）.
van Kesteren, Paul J. M. Recent Advanced in Gender Dysphoria, Gender Identity Disorder: Towards a Uniform Treatment Approach. Conference of the Royal Society of Medicine, Sexual Health and Reproductive Medicine Section. London, United Kingdom. 2002-04-16 [2022-01-14]. （原始内容存档于2022-04-19）.
Kiely PM, Carney LG, Smith G. Menstrual cycle variations of corneal topography and thickness (PDF). American Journal of Optometry and Physiological Optics. 1983-10, 60 (10): 822–9 [2022-01-14]. PMID 6650653. S2CID 43222063. doi:10.1097/00006324-198310000-00003. （原始内容 (PDF)存档于2022-03-17）.
van der Loos, Maria Atc; Hellinga, Ilse; Vlot, Mariska C.; Klink, Daniel T.; den Heijer, Martin; Wiepjes, Chantal M. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. 2021-05, 36 (5) [2023-12-04]. ISSN 1523-4681. PMC 8247856 . PMID 33507568. doi:10.1002/jbmr.4262. （原始内容存档于2023-03-29）.
Peterson's Principles of Oral and Maxillofacial Surgery. PMPH-USA. 2012: 1209– [2022-01-14]. ISBN 978-1-60795-111-7. （原始内容存档于2022-04-30）.
Mueller, Sven C.; De Cuypere, Griet; T’Sjoen, Guy. Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective. American Journal of Psychiatry. 2017, 174 (12): 1155–1162 [2022-01-14]. ISSN 0002-953X. PMID 29050504. doi:10.1176/appi.ajp.2017.17060626. hdl:1854/LU-8542009. （原始内容存档于2022-04-21）.
Marc A. Fritz; Leon Speroff. Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. 2012-03-28: 753– [2022-01-15]. ISBN 978-1-4511-4847-3. （原始内容存档于2022-04-21）.
Christopher Li. Breast Cancer Epidemiology. Springer Science & Business Media. 2009-11-11: 266– [2022-01-15]. ISBN 978-1-4419-0685-4. （原始内容存档于2022-04-21）.
Stella Pelengaris; Michael Khan. The Molecular Biology of Cancer: A Bridge from Bench to Bedside. John Wiley & Sons. 2013-03-13: 586– [2022-01-15]. ISBN 978-1-118-43085-9. （原始内容存档于2022-04-21）.
Gilda Cardenosa. Breast Imaging. Lippincott Williams & Wilkins. 2004: 1– [2022-01-15]. ISBN 978-0-7817-4685-4. （原始内容存档于2022-04-21）.
Jerome F. Strauss, III; Robert L. Barbieri. Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. 2013-09-13: 236– [2022-01-15]. ISBN 978-1-4557-2758-2. （原始内容存档于2020-07-27）.
Cavanaugh, Timothy. Cross-Sex Hormone Therapy (PDF) (报告). Fenway Institute. [9 May 2019]. （原始内容 (PDF)存档于2022-05-16）.
https://web.archive.org/web/20190905231203/http://callen-lorde.org/graphics/2018/05/Callen-Lorde-TGNC-Hormone-Therapy-Protocols-2018.pdf
IMAP Statement on hormone therapy for transgender people (PDF) (报告). International Planned Parenthood Federation. October 2015 [2022-01-15]. （原始内容 (PDF)存档于2021-12-06）.
存档副本 (PDF). [2022-01-15]. （原始内容 (PDF)存档于2022-05-16）.
Barnsley, Rotherham; Sheffield Clinical Commissioning Groups. Prescribing Guidelines: Trans woman medication (PDF) (报告). NHS. 12 October 2017 [2022-01-15]. （原始内容 (PDF)存档于2021-09-20）.
Leighton Seal; James Barret. GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA (PDF) (报告). NHS. December 2015 [2022-01-15]. （原始内容 (PDF)存档于2021-07-03）.
Sunderland Clinical Commissioning Group. SHARED CARE PRESCRIBING GUIDANCE FOR Treatment of Gender Dysphoria in Transwomen (Male to Female Transsexuals) (PDF) (报告). NHS. 14 March 2017 [2022-01-15]. （原始内容 (PDF)存档于2019-03-28）.
Elizabeth Siegel Watkins. The Estrogen Elixir: A History of Hormone Replacement Therapy in America. JHU Press. 2007-04-16: 10– [2022-01-14]. ISBN 978-0-8018-8602-7. （原始内容存档于2022-04-19）.
Institute of Medicine; Board on the Health of Select Populations; Committee on Lesbian, Gay, Bisexual, and Transgender Health Issues and Research Gaps and Opportunities. The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. National Academies Press. 2011-06-24: 70– [2022-01-14]. ISBN 978-0-309-21065-2. （原始内容存档于2022-04-25）.
Dallas Denny. Current Concepts in Transgender Identity. Routledge. 2013-05-13: 15– [2022-01-14]. ISBN 978-1-134-82110-5. （原始内容存档于2022-04-25）.
Susan Stryker; Associate Professor of Gender and Women's Studies Susan Stryker; Stephen Whittle. The Transgender Studies Reader. Taylor & Francis. 2006: 363– [2022-01-14]. ISBN 978-0-415-94709-1. （原始内容存档于2022-04-21）.
Baudewijntje P.C. Kreukels; Thomas D. Steensma; Annelou L.C. de Vries. Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge. Springer Science & Business Media. 2013-07-01: 279– [2022-01-14]. ISBN 978-1-4614-7441-8. （原始内容存档于2022-04-25）.
Harry Benjamin; Gobind Behari Lal; Richard Green; Robert E. L. Masters. The Transsexual Phenomenon. Ace Publishing Company. 1966 [2022-01-14]. （原始内容存档于2022-04-21）.
Hamburger, Christian; Benjamin, Harry. Endocrine Treatment of Male and Female Transsexualism / Appendix for the Practicing Physician: Suggestions and Guidelines for the Management of Transsexuals. Money, John; Green, Richard (编). Transsexualism and Sex Reassignment. Johns Hopkins Press. 1969: 291–307 [2022-01-14]. ISBN 9780801810381. OCLC 6866559. （原始内容存档于2022-04-21）.
Abbie E. Goldberg. The SAGE Encyclopedia of LGBTQ Studies. SAGE Publications. 2016-04-13: 1211– [2022-01-14]. ISBN 978-1-4833-7132-0. （原始内容存档于2022-04-25）.
Susan Stryker; Stephen Whittle. The Transgender Studies Reader. Routledge. 2013-10-18: 45– [2022-01-14]. ISBN 978-1-135-39884-2. （原始内容存档于2022-04-21）.
International Symposia - WPATH World Professional Association for Transgender Health. [2022-01-14]. （原始内容存档于2022-04-21）.
Green, R., & Money, J. (1969). Transsexualism and Sex Reassignment. Johns Hopkins University Press. https://scholar.google.com/scholar?cluster=8048451400842332421 （页面存档备份，存于互联网档案馆） https://books.google.com/books?id=pdBrAAAAMAAJ （页面存档备份，存于互联网档案馆）
Benjamin, H., & Ihlenfeld, C. L. (1970). The Nature and Treatment of Transsexualism. Medical Opinion and Review, 6(11), 24–35. "Fortunately, the first medical textbook in this field, Transsexualism and Sex Reassignment, edited by Richard Green and John Money (Johns Hopkins Press, Baltimore, 1969), is now available." https://scholar.google.com/scholar?cluster=4496539582926153095 （页面存档备份，存于互联网档案馆）

webcitation.org (Global: 24^th place; Chinese: 29^th place)

Asscheman H, Gooren LJ. Hormone Treatment in Transsexuals. 1992 [2008-06-13]. （原始内容存档于2012-06-03）.

wikipedia.org (Global: low place; Chinese: low place)

en.wikipedia.org

专门为了诱导泌乳（英语：induction of lactation）从而实现母乳哺育。
这时候最大维持剂量不太可能造成更进一步的变化。最大效果很大程度上取决于遗传学、身体状态（英语：body habitus）、年龄和生殖腺去除的状态。通常而言，拥有完整生殖腺的年老个体可能总体上女性化程度较低。
完全去除男性胡须和体毛需要电解、激光脱毛（英语：laser hair removal），或两者都进行。暂时脱毛可以通过剃毛、脱毛器（英语：epilator）、蜡脱毛（英语：waxing）和其他方法完成。
需要进一步的研究来确定持久性，但雌激素治疗对精子质量（英语：sperm quality）的某种永久性影响是可能的，应该建议和考虑在开始治疗前选择精子保存。
报告存在争议，没有在跨性别女性中观察到的报告，但在通过雄激素剥夺疗法（英语：androgen deprivation therapy）治疗前列腺癌的男性中报告了虽然轻微但显著的阴茎变小。^[281]^[282]^[283]^[284]
为声音训练（英语：Voice therapy (transgender)）进行的言语治疗是有效的。

worldcat.org (Global: 5^th place; Chinese: 12^th place)

Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Wylie, Kevan; Barrett, James; Besser, Mike; Bouman, Walter Pierre; Bridgman, Michelle; Clayton, Angela; Green, Richard; Hamilton, Mark; Hines, Melissa; Ivbijaro, Gabriel; Khoosal, Deenesh; Lawrence, Alex; Lenihan, Penny; Loewenthal, Del; Ralph, David; Reed, Terry; Stevens, John; Terry, Tim; Thom, Ben; Thornton, Jane; Walsh, Dominic; Ward, David; Coleman, Eli; Di Ceglie, Domenico; Martin, Emma; McGarry, Philip; Messenger, Andrew; Reid, Russell; Sethi, Su; Sutcliffe, Paul; Wilson, Daniel; Carr, Susan; Davies, Dai; Dean, Tracey; Ellis, Michelle; Ferguson, Brian; Skinner, Darren; Williams, Vicky; Brechin, Susan; Lucey, Jim; Rathbone, Maxine. Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria (PDF). Sexual and Relationship Therapy. 2014, 29 (2): 154–214 [2021-10-15]. ISSN 1468-1994. S2CID 144632597. doi:10.1080/14681994.2014.883353. （原始内容 (PDF)存档于2018-09-02）.
Fishman, Sarah L.; Paliou, Maria; Poretsky, Leonid; Hembree, Wylie C. Endocrine Care of Transgender Adults. Transgender Medicine. Contemporary Endocrinology. 2019: 143–163. ISBN 978-3-030-05682-7. ISSN 2523-3785. doi:10.1007/978-3-030-05683-4_8.
Winkler-Crepaz, K.; Müller, A.; Böttcher, B.; Wildt, L. Hormonbehandlung bei Transgenderpatienten [Hormone treatment of transgender patients]. Gynäkologische Endokrinologie. 2017, 15 (1): 39–42. ISSN 1610-2894. S2CID 12270365. doi:10.1007/s10304-016-0116-9.
Urdl, W. Behandlungsgrundsätze bei Transsexualität [Therapeutic principles in transsexualism]. Gynäkologische Endokrinologie. 2009, 7 (3): 153–160. ISSN 1610-2894. S2CID 8001811. doi:10.1007/s10304-009-0314-9.
Coxon, Jonny; Seal, Leighton. Hormone management of trans women. Trends in Urology & Men's Health. 2018, 9 (6): 10–14. ISSN 2044-3730. S2CID 222189278. doi:10.1002/tre.663.
Athanasoulia-Kaspar, Anastasia P.; Stalla, Günter K. Endokrinologische Betreuung von Patienten mit Transsexualität [Endocrinological care of patients with transsexuality]. Geburtshilfe und Frauenheilkunde. 2019, 79 (7): 672–675. ISSN 0016-5751. doi:10.1055/a-0801-3319.
Asscheman, Henk; Gooren, Louis J.G. Hormone Treatment in Transsexuals. Journal of Psychology & Human Sexuality. 1993, 5 (4): 39–54. ISSN 0890-7064. doi:10.1300/J056v05n04_03.
Majumder, Anirban; Chatterjee, Sudip; Maji, Debasis; Roychaudhuri, Soumyabrata; Ghosh, Sujoy; Selvan, Chitra; George, Belinda; Kalra, Pramila; Maisnam, Indira; Sanyal, Debmalya. IDEA group consensus statement on medical management of adult gender incongruent individuals seeking gender reaffirmation as female. Indian Journal of Endocrinology and Metabolism. 2020, 24 (2): 128. ISSN 2230-8210. PMID 32699777. S2CID 218596936. doi:10.4103/ijem.IJEM_593_19.
Lauritzen C. Die Behandlung der klimakterischen Beschwerden durch vaginale, rektale und transdermale Ostrogensubstitution [Treatment of disorders of the climacteric by vaginal, rectal and transdermal estrogen substitution]. Gynakologe. 1986-12, 19 (4): 248–53. ISSN 0017-5994. PMID 3817597 （德语）.
Wylie, Kevan Richard; Fung, Robert; Boshier, Claudia; Rotchell, Margaret. Recommendations of endocrine treatment for patients with gender dysphoria. Sexual and Relationship Therapy. 2009, 24 (2): 175–187. ISSN 1468-1994. S2CID 20471537. doi:10.1080/14681990903023306.
Haupt, Claudia; Henke, Miriam; Kutschmar, Alexia; Hauser, Birgit; Baldinger, Sandra; Schreiber, Gerhard. Antiandrogens or estradiol treatments or both during hormone replacement therapy in transitioning transgender women. Cochrane Database of Systematic Reviews. 2018, 2018 (10): CD013138. ISSN 1465-1858. PMC 6517060 . doi:10.1002/14651858.CD013138.
Gava, Giulia; Seracchioli, Renato; Meriggiola, Maria Cristina. Therapy with Antiandrogens in Gender Dysphoric Natal Males. Endocrinology of the Testis and Male Reproduction. Endocrinology. 2017: 1199–1209. ISBN 978-3-319-44440-6. ISSN 2510-1927. doi:10.1007/978-3-319-44441-3_42.
Moltz, L.; Römmler, A.; Schwartz, U.; Hammerstein, J. Effects of Cyproterone Acetate (CPA) on Pituitary Gonadotrophin Release and on Androgen Secretion Before and After LH-RH Double Stimulation Tests in Men. International Journal of Andrology. 1978, 1 (s2b): 713–719. ISSN 0105-6263. doi:10.1111/j.1365-2605.1978.tb00518.x .
Fung, Raymond; Hellstern-Layefsky, Miriam; Lega, Iliana. Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?. International Journal of Transgenderism. 2017, 18 (2): 123–128. ISSN 1553-2739. S2CID 79095497. doi:10.1080/15532739.2017.1290566.
Lothstein, Leslie M. Antiandrogen treatment for sexual disorders: Guidelines for establishing a standard of care. Sexual Addiction & Compulsivity. 1996, 3 (4): 313–331. ISSN 1072-0162. doi:10.1080/10720169608400122.
Wenderoth, U. K.; Jacobi, G. H. Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. World Journal of Urology. 1983, 1 (1): 40–48. ISSN 0724-4983. S2CID 23447326. doi:10.1007/BF00326861.
Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect. Case Reports in Gastroenterology. 2018, 12 (2): 266–270. ISSN 1662-0631. S2CID 81661015. doi:10.1159/000485175 .
Morgante, E; Gradini, R; Realacci, M; Sale, P; D'eramo, G; Perrone, G A; Cardillo, M R; Petrangeli, E; Russo, Ma; Di Silverio, F. Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study. Histopathology. 2001, 38 (3): 195–201. ISSN 0309-0167. PMID 11260298. S2CID 36892099. doi:10.1046/j.1365-2559.2001.01077.x.
Jones, C. A.; Reiter, L.; Greenblatt, E. Fertility preservation in transgender patients. International Journal of Transgenderism. 2016, 17 (2): 76–82. ISSN 1553-2739. S2CID 58849546. doi:10.1080/15532739.2016.1153992. 传统上，建议患者在开始异性激素治疗之前冷冻保存精子，因为随着时间的推移，高剂量雌激素治疗可能会降低精子活力（Lubbert等，1992）。然而，由于研究有限，雌激素治疗导致的生育力下降仍有争议。（Traditionally, patients have been advised to cryopreserve sperm prior to starting cross-sex hormone therapy as there is a potential for a decline in sperm motility with high-dose estrogen therapy over time (Lubbert et al., 1992). However, this decline in fertility due to estrogen therapy is controversial due to limited studies.）
Liang, Jennifer J.; Rasmusson, Ann M. Overview of the Molecular Steps in Steroidogenesis of the GABAergic Neurosteroids Allopregnanolone and Pregnanolone. Chronic Stress. 2018, 2: 247054701881855. ISSN 2470-5470. PMC 7219929 . PMID 32440589. doi:10.1177/2470547018818555.
Traish, Abdulmaged M. The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. Current Sexual Health Reports. 2018, 10 (3): 88–103. ISSN 1548-3584. S2CID 81560714. doi:10.1007/s11930-018-0161-6.
Kuhl, Herbert; Wiegratz, Inka. Das Post-Finasterid-Syndrom [The Post-Finasteride Syndrome]. Gynäkologische Endokrinologie. 2017, 15 (2): 153–163. ISSN 1610-2894. S2CID 207071180. doi:10.1007/s10304-017-0126-2.
Macias, Hector; Hinck, Lindsay. Mammary gland development. Wiley Interdisciplinary Reviews: Developmental Biology. 2012, 1 (4): 533–557. ISSN 1759-7684. PMC 3404495 . PMID 22844349. doi:10.1002/wdev.35.
Bińkowska, Małgorzata; Woroń, Jarosław. Progestogens in menopausal hormone therapy. Menopausal Review. 2015, 14 (2): 134–143. ISSN 1643-8876. PMC 4498031 . PMID 26327902. doi:10.5114/pm.2015.52154.
Unfer, Vittorio; di Renzo, Gian; Gerli, Sandro; Casini, Maria. The Use of Progesterone in Clinical Practice: Evaluation of its Efficacy in Diverse Indications Using Different Routes of Administration. Current Drug Therapy. 2006, 1 (2): 211–219. ISSN 1574-8855. doi:10.2174/157488506776930923.
Telis, Leon; Baum, Stephanie; Singer, Tomer; Berookhim, Boback M. Fertility Issues in Transgender Care. Transgender Medicine. Contemporary Endocrinology. 2019: 197–212. ISBN 978-3-030-05682-7. ISSN 2523-3785. S2CID 151135327. doi:10.1007/978-3-030-05683-4_11.
Kozlov GI, Mel'nichenko GA, Golubeva IV. Sluchai laktorei u bol'nogo muzhskogo pola s transseksualizmom [Case of galactorrhea in a transsexual male patient]. Probl Endokrinol (Mosk). 1985, 31 (1): 37–8 [2022-01-14]. ISSN 0375-9660. PMID 4039061. （原始内容存档于2022-04-21）（俄语）. [...]进行了外生殖器去势和女性化整形手术[...]手术后一段时间，患者对生活重新产生了兴趣。经过手术和荷尔蒙矫正后，患者不可抗拒地发展出母性本能。未婚，患者获准领养孩子，模拟怀孕，带着儿子从妇产医院出院。从“出生”后的第一天开始，溢乳急剧增加，出现自发流出乳汁，伴溢乳（+++）。婴儿一直母乳喂养到6个月大。[...]我们的信息是文献中第二例有关男性易性症患者溢乳的描述。R.[Flückiger]等人于1983年首次描述了这种类型(6)。这一观察结果证明了泌乳发育机制与一个人的遗传性别相独立，并且对男性发生药物性溢乳的可能性感到担忧。（[...] castration and feminizing plastic surgery of the external genitalia was performed [...] Some time after the operation, the patient developed a renewed interest in life. After the surgical and hormonal correction, the patient irresistibly developed maternal instincts. Unmarried, the patient obtained permission for the adoption of a child, simulated pregnancy, and was discharged from the maternity hospital with a son. From the first days after the “birth”, galactorrhea sharply increased, and spontaneous outflow of milk appeared, with galactorrhea (+++). The baby was breastfed up to 6 months of age. [...] Our message is the second in the world literature describing galactorrhea in a male patient with transsexualism. The first description of this kind was made in 1983 by R. [Flückiger] et al. (6). This observation demonstrates the independence of the mechanism of lactation development from one’s genetic sex and is alarming with regard to the possibility of drug-induced galactorrhea development in men.）
de, Blok Christel; Klaver, Maartje; Nota, Nienke; Dekker, Marieke; den, Heijer Martin. Breast development in male-to-female transgender patients after one year cross-sex hormonal treatment. Endocrine Abstracts. 2016. ISSN 1479-6848. doi:10.1530/endoabs.41.GP146.
van der Loos, Maria Atc; Hellinga, Ilse; Vlot, Mariska C.; Klink, Daniel T.; den Heijer, Martin; Wiepjes, Chantal M. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. 2021-05, 36 (5) [2023-12-04]. ISSN 1523-4681. PMC 8247856 . PMID 33507568. doi:10.1002/jbmr.4262. （原始内容存档于2023-03-29）.
Nguyen, Hillary B.; Chavez, Alexis M.; Lipner, Emily; Hantsoo, Liisa; Kornfield, Sara L.; Davies, Robert D.; Epperson, C. Neill. Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition. Current Psychiatry Reports. 2018, 20 (12): 110. ISSN 1523-3812. PMC 6354936 . PMID 30306351. doi:10.1007/s11920-018-0973-0.
Smith, Elke Stefanie; Junger, Jessica; Derntl, Birgit; Habel, Ute. The transsexual brain – A review of findings on the neural basis of transsexualism. Neuroscience & Biobehavioral Reviews. 2015, 59: 251–266. ISSN 0149-7634. PMID 26429593. S2CID 23913935. doi:10.1016/j.neubiorev.2015.09.008.
Guillamon, Antonio; Junque, Carme; Gómez-Gil, Esther. A Review of the Status of Brain Structure Research in Transsexualism. Archives of Sexual Behavior. 2016, 45 (7): 1615–1648. ISSN 0004-0002. PMC 4987404 . PMID 27255307. doi:10.1007/s10508-016-0768-5.
Mueller, Sven C.; De Cuypere, Griet; T’Sjoen, Guy. Transgender Research in the 21st Century: A Selective Critical Review From a Neurocognitive Perspective. American Journal of Psychiatry. 2017, 174 (12): 1155–1162 [2022-01-14]. ISSN 0002-953X. PMID 29050504. doi:10.1176/appi.ajp.2017.17060626. hdl:1854/LU-8542009. （原始内容存档于2022-04-21）.
Kilpatrick, Lisa A.; Holmberg, Mats; Manzouri, Amirhosein; Savic, Ivanka. Cross sex hormone treatment is linked with a reversal of cerebral patterns associated with gender dysphoria to the baseline of cisgender controls. European Journal of Neuroscience. 2019, 50 (8): 3269–3281. ISSN 0953-816X. PMC 7329231 . PMID 30991464. doi:10.1111/ejn.14420.
Stege R, Carlström K, Hedlund PO, Pousette A, von Schoultz B, Henriksson P. Intramuskuläres Depotöstrogen (Estradurin) in der Behandlung von Patienten mit Prostatakarzinom. Historische Aspekte, Wirkungsmechanismus, Resultate und aktueller klinischer Stand [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status]. Urologe A. 1995-09, 34 (5): 398–403. ISSN 0340-2592. PMID 7483157 （德语）.
de Blok, Christel J M; Wiepjes, Chantal M; Nota, Nienke M; van Engelen, Klaartje; Adank, Muriel A; Dreijerink, Koen M A; Barbé, Ellis; Konings, Inge R H M; den Heijer, Martin. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019, 365: l1652. ISSN 0959-8138. PMC 6515308 . PMID 31088823. doi:10.1136/bmj.l1652.
Iwamoto, Sean J.; Defreyne, Justine; Rothman, Micol S.; Van Schuylenbergh, Judith; Van de Bruaene, Laurens; Motmans, Joz; T’Sjoen, Guy. Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism. 2019, 10: 204201881987116. ISSN 2042-0188. PMC 6719479 . PMID 31516689. doi:10.1177/2042018819871166.
McFarlane, Thomas; Zajac, Jeffrey D.; Cheung, Ada S. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review. Clinical Endocrinology. 2018, 89 (6): 700–711. ISSN 0300-0664. PMID 30107028. S2CID 52003943. doi:10.1111/cen.13835 .
Nota, Nienke M; Wiepjes, Chantal M; de Blok, Christel J M; Gooren, Louis J G; Peerdeman, Saskia M; Kreukels, Baudewijntje P C; den Heijer, Martin. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain. 2018, 141 (7): 2047–2054. ISSN 0006-8950. PMID 29688280. S2CID 19934721. doi:10.1093/brain/awy108 .
Mahfouda, Simone; Moore, Julia K; Siafarikas, Aris; Hewitt, Timothy; Ganti, Uma; Lin, Ashleigh; Zepf, Florian Daniel. Gender-affirming hormones and surgery in transgender children and adolescents. The Lancet Diabetes & Endocrinology. 2019, 7 (6): 484–498. ISSN 2213-8587. PMID 30528161. S2CID 54478571. doi:10.1016/S2213-8587(18)30305-X.
Bisson, Jason R.; Chan, Kelly J.; Safer, Joshua D. Prolactin levels do not rise among transgender women treated with estradiol and spironolactone. Endocrine Practice. 2018, 24 (7): 646–651. ISSN 1530-891X. PMID 29708436. S2CID 14022275. doi:10.4158/EP-2018-0101.
Gooren, Louis; Asscheman, Henk. Sex Reassignment: Endocrinological Interventions in Adults with Gender Dysphoria. Gender Dysphoria and Disorders of Sex Development. Focus on Sexuality Research. 2014: 277–297. ISBN 978-1-4614-7440-1. ISSN 2195-2264. doi:10.1007/978-1-4614-7441-8_14.
Benjamin, Harry. Transvestism and Transsexualism in the male and female1. Journal of Sex Research. 1967, 3 (2): 107–127. ISSN 0022-4499. doi:10.1080/00224496709550519.
Hamburger, Christian; Benjamin, Harry. Endocrine Treatment of Male and Female Transsexualism / Appendix for the Practicing Physician: Suggestions and Guidelines for the Management of Transsexuals. Money, John; Green, Richard (编). Transsexualism and Sex Reassignment. Johns Hopkins Press. 1969: 291–307 [2022-01-14]. ISBN 9780801810381. OCLC 6866559. （原始内容存档于2022-04-21）.
Ekins, Richard. Science, Politics and Clinical Intervention: Harry Benjamin, Transsexualism and the Problem of Heteronormativity. Sexualities. 2016, 8 (3): 306–328. ISSN 1363-4607. S2CID 143544267. doi:10.1177/1363460705049578.
Meyer, Walter J.; Walker, Paul A.; Suplee, Zelda R. A survey of transsexual hormonal treatment in twenty gender‐treatment centers. The Journal of Sex Research. 1981, 17 (4): 344–349. ISSN 0022-4499. doi:10.1080/00224498109551125.
Moore, Eva; Wisniewski, Amy; Dobs, Adrian. Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects. The Journal of Clinical Endocrinology & Metabolism. 2003, 88 (8): 3467–3473. ISSN 0021-972X. PMID 12915619. doi:10.1210/jc.2002-021967 .
Steinbeck, A. W. Of Homosexuality: The Current State of Knowledge. Journal of Christian Education. 1977, os–20 (2): 58–82. ISSN 0021-9657. S2CID 149168765. doi:10.1177/002196577702000204.
Zingg, E.; König, M.; Cornu, F.; Wildholz, A.; Blaser, A. Transsexualismus: Erfahrungen mit der operativen Korrektur bei männlichen Transsexuellen [Transsexualism: Experience with surgical correction in male transsexuals]. Aktuelle Urologie. 1980, 11 (2): 67–77. ISSN 0001-7868. doi:10.1055/s-2008-1062961.
Dahl, Marshall; Feldman, Jamie L.; Goldberg, Joshua M.; Jaberi, Afshin. Physical Aspects of Transgender Endocrine Therapy. International Journal of Transgenderism. 2006, 9 (3–4): 111–134. ISSN 1553-2739. S2CID 146232471. doi:10.1300/J485v09n03_06.

wpath.org (Global: low place; Chinese: low place)

Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
Coleman, E.; Bockting, W.; Botzer, M.; Cohen-Kettenis, P.; DeCuypere, G.; Feldman, J.; Fraser, L.; Green, J.; Knudson, G.; Meyer, W. J.; Monstrey, S.; Adler, R. K.; Brown, G. R.; Devor, A. H.; Ehrbar, R.; Ettner, R.; Eyler, E.; Garofalo, R.; Karasic, D. H.; Lev, A. I.; Mayer, G.; Meyer-Bahlburg, H.; Hall, B. P.; Pfaefflin, F.; Rachlin, K.; Robinson, B.; Schechter, L. S.; Tangpricha, V.; van Trotsenburg, M.; Vitale, A.; Winter, S.; Whittle, S.; Wylie, K. R.; Zucker, K. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 (PDF). International Journal of Transgenderism. 2012, 13 (4): 165–232 [2021-10-16]. ISSN 1553-2739. S2CID 39664779. doi:10.1080/15532739.2011.700873. （原始内容 (PDF)存档于2021-04-12）.
International Symposia - WPATH World Professional Association for Transgender Health. [2022-01-14]. （原始内容存档于2022-04-21）.

yonsei.ac.kr (Global: low place; Chinese: low place)

ir.ymlib.yonsei.ac.kr

Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018-05, 28 (3): 288–293 [2022-01-14]. PMID 29528971. S2CID 4587434. doi:10.1097/MOU.0000000000000497. （原始内容存档于2022-04-21）.

zenodo.org (Global: 621^st place; Chinese: 1,608^th place)

Hughes IA, Werner R, Bunch T, Hiort O. Androgen insensitivity syndrome. Semin. Reprod. Med. 2012, 30 (5): 432–42. PMID 23044881. doi:10.1055/s-0032-1324728. ^{[失效連結]}

女性化激素疗法 (Chinese Wikipedia)

aafp.org (Global: 1,916th place; Chinese: 1,764th place)

archive.org (Global: 6th place; Chinese: 4th place)

bedfordshire.nhs.uk (Global: low place; Chinese: low place)

gpref.bedfordshire.nhs.uk

books.google.com (Global: 3rd place; Chinese: 8th place)

confex.com (Global: 6,094th place; Chinese: 4,939th place)

endo.confex.com

doi.org (Global: 2nd place; Chinese: 23rd place)

doncasterccg.nhs.uk (Global: low place; Chinese: low place)

medicinesmanagement.doncasterccg.nhs.uk

elibrary.ru (Global: 1,940th place; Chinese: low place)

europeanreview.org (Global: low place; Chinese: low place)

fda.gov (Global: 447th place; Chinese: 581st place)

accessdata.fda.gov

fda.gov

fenwayhealth.org (Global: low place; Chinese: low place)

gires.org.uk (Global: low place; Chinese: low place)

handle.net (Global: 102nd place; Chinese: 492nd place)

hdl.handle.net

harvard.edu (Global: 18th place; Chinese: 57th place)

ui.adsabs.harvard.edu

hormonebalance.org (Global: low place; Chinese: low place)

independent.co.uk (Global: 36th place; Chinese: 153rd place)

internetmedicin.se (Global: low place; Chinese: low place)

ippf.org (Global: low place; Chinese: low place)

jaapl.org (Global: 8,749th place; Chinese: low place)

karger.com (Global: 4,489th place; Chinese: 2,957th place)

kup.at (Global: low place; Chinese: low place)

nih.gov (Global: 4th place; Chinese: 5th place)

ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

nottingham.ac.uk (Global: 4,422nd place; Chinese: 8,845th place)

eprints.nottingham.ac.uk

oup.com (Global: 485th place; Chinese: 489th place)

academic.oup.com

phsa.ca (Global: low place; Chinese: low place)

qut.edu.au (Global: 8,570th place; Chinese: 8,998th place)

eprints.qut.edu.au

rcpsych.ac.uk (Global: low place; Chinese: low place)

reddit.com (Global: 1,082nd place; Chinese: 1,131st place)

researchgate.net (Global: 120th place; Chinese: 337th place)

scholar.google.com (Global: 1,697th place; Chinese: 3,337th place)

semanticscholar.org (Global: 11th place; Chinese: 332nd place)

api.semanticscholar.org

sherbourne.on.ca (Global: low place; Chinese: low place)

sunderlandccg.nhs.uk (Global: low place; Chinese: low place)

theatlantic.com (Global: 228th place; Chinese: 597th place)

transgendercare.com (Global: low place; Chinese: low place)

ucsf.edu (Global: 5,479th place; Chinese: 5,439th place)

transhealth.ucsf.edu

ugent.be (Global: 3,695th place; Chinese: 6,619th place)

biblio.ugent.be

upi.com (Global: 290th place; Chinese: 1,067th place)

web.archive.org (Global: 1st place; Chinese: 1st place)

webcitation.org (Global: 24th place; Chinese: 29th place)

wikipedia.org (Global: low place; Chinese: low place)

en.wikipedia.org

worldcat.org (Global: 5th place; Chinese: 12th place)

wpath.org (Global: low place; Chinese: low place)

yonsei.ac.kr (Global: low place; Chinese: low place)

ir.ymlib.yonsei.ac.kr

zenodo.org (Global: 621st place; Chinese: 1,608th place)

aafp.org (Global: 1,916^th place; Chinese: 1,764^th place)

archive.org (Global: 6^th place; Chinese: 4^th place)

books.google.com (Global: 3^rd place; Chinese: 8^th place)

confex.com (Global: 6,094^th place; Chinese: 4,939^th place)

doi.org (Global: 2^nd place; Chinese: 23^rd place)

elibrary.ru (Global: 1,940^th place; Chinese: low place)

fda.gov (Global: 447^th place; Chinese: 581^st place)

handle.net (Global: 102^nd place; Chinese: 492^nd place)

harvard.edu (Global: 18^th place; Chinese: 57^th place)

independent.co.uk (Global: 36^th place; Chinese: 153^rd place)

jaapl.org (Global: 8,749^th place; Chinese: low place)

karger.com (Global: 4,489^th place; Chinese: 2,957^th place)

nih.gov (Global: 4^th place; Chinese: 5^th place)

nottingham.ac.uk (Global: 4,422^nd place; Chinese: 8,845^th place)

oup.com (Global: 485^th place; Chinese: 489^th place)

qut.edu.au (Global: 8,570^th place; Chinese: 8,998^th place)

reddit.com (Global: 1,082^nd place; Chinese: 1,131^st place)

researchgate.net (Global: 120^th place; Chinese: 337^th place)

scholar.google.com (Global: 1,697^th place; Chinese: 3,337^th place)

semanticscholar.org (Global: 11^th place; Chinese: 332^nd place)

theatlantic.com (Global: 228^th place; Chinese: 597^th place)

ucsf.edu (Global: 5,479^th place; Chinese: 5,439^th place)

ugent.be (Global: 3,695^th place; Chinese: 6,619^th place)

upi.com (Global: 290^th place; Chinese: 1,067^th place)

web.archive.org (Global: 1^st place; Chinese: 1^st place)

webcitation.org (Global: 24^th place; Chinese: 29^th place)

worldcat.org (Global: 5^th place; Chinese: 12^th place)

zenodo.org (Global: 621^st place; Chinese: 1,608^th place)